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This work was initially stimulated by a 79-year-old man who presented to 
hospital with a ruptured abdominal aortic aneurysm. He was in profound 
shock, was not able to be retrieved and died after 1 hour of hospital 
presentation. On assessing his available radiological imaging performed 6 
years ago, an undiagnosed 3.3cm infrarenal abdominal aortic aneurysm was 
seen.  
Potentially, his aneurysm could have been treated prior to his demise.  
 
Abdominal aortic aneurysm (AAA) is a permanent dilatation of the infrarenal 
segment of the abdominal aorta which can be fatal if the aneurysm ruptures. 
Ruptured AAA is the second leading cause of global surgical mortality, and 
prophylactic AAA repair can decrease mortality by a tenfold if surgery is 
performed as an elective procedure. While screening and repair of AAA could 
potentially reduce AAA-related mortality, selecting patients that are likely to 
benefit from repair remains a complex medical decision process which has 
been compounded by an improved life expectancy of the general population, 
minimal invasive treatment methods and the increased prevalence of AAA in 
the elderly. 
The overall aim of this thesis was to improve detection and management of 
AAA and to develop a predictive decision tool that can assist in clinical 
management. This thesis has been conducted, to shed some light into issues 
highlighted above using New Zealand and international data. The format of 
this thesis was categorized into three main domains:  First, the prevalence of 
AAA and the influence of aortic size on late survival was documented in a 
large cohort of individuals undergoing CT colonography for gastrointestinal 
symptoms in Canterbury, New Zealand; Second, a systematic review and 
meta-analysis of prognostic factors that might influence late survival 
following AAA repair were performed, and the national clinical and 
administrative AAA repair databases were interrogated to provide 
epidemiological and outcome data; Third, the factors identified from this 
review were applied into developing a discrete event-simulation model to 
predict survival following AAA repair. The model developed has been 
externally validated against existing national databases of patients 
undergoing AAA repair and it appears sufficiently accurate to predict five-
year survival. The results and conclusions presented throughout this thesis 
fill some of the gap in AAA knowledge, and such predictive decision-making 
tools might help improve AAA management.   
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"If we knew what it was we were doing, it would not be called 
research, would it?” 
Albert Einstein (14 March 1879 – 18 April 1955) 
Died of a ruptured AAA 

 
1.1 Introduction to AAA 
Infrarenal abdominal aortic aneurysm (AAA) is generally an asymptomatic 
condition that is potentially fatal if rupture occurs. The term aneurysm 
originates from the Greek word “aneurysma” meaning dilation or widening. 
The definition of AAA varies but is usually accepted when the diameter of the 
abdominal aorta reaches 3cm or greater (1). The natural history of AAA is 
gradual sac expansion until rupture (law of Laplace) causing death unless 
the aneurysm is repaired surgically or death from other causes occurs. 
Repair of ruptured AAA caries a ten-fold increase in operative mortality 
compared to elective AAA repair, which carries a 2-5% 30-day mortality.  
The aetiology of AAA can be classified into three broad categories:  
1) Degenerative (atherosclerotic) or late onset 
2) Infectious or non-infectious aortitis 
3) Connective tissue disease resulting in aneurysm formation 
Degenerative AAAs, which are associated with global atherosclerosis, are by 
far the most common and will be the primary emphasis of this thesis. 
Repair of AAA is an established evidence-based treatment that provides life-
preserving prophylaxis against death from rupture. The natural history of 
slow growth and the potential for early detection prior to rupture which 
results in reduced mortality rates make AAA a condition suitable for 
population screening to prevent death from rupture. In New Zealand, basic 
population data on AAA prevalence, management and outcomes are not well 
documented. The primary aim of this thesis was to obtain information that 
can aid in the detection of AAA and develop models that may assist in the 
clinical decision-making of AAA management.  
1.2 Abdominal Aortic Aneurysm 
1.2.1 Definition 
In order to diagnose AAAs, an accepted definition is required. The most 
commonly used clinical definition for diagnosing an AAA is an aortic 
diameter of > 3cm. However, other definitions have been proposed (2); for 
example, the Society for Vascular Surgery (SVS) defines an aneurysm as 
being 1.5 times that of the expected normal diameter (3). A consensus that 
provides a standardized definition of AAA is yet to be established and is 
likely to be adjusted to gender and body measurements. For the majority of 
clinical practical purposes, an infra-renal abdominal aortic diameter > 3cm 
is considered an AAA. 
1.2.2 Risks for developing AAA 
Population studies have consistently identified risk factors that increase the 
probability of developing AAA. These fall in two groups: 
1) Non-modifiable – sex (males), age, family history (genetics) and 
ethnicity (Caucasians compared to other ethnicities). 
2) Modifiable – smoking (current/history), hypertension, ischemic 
heart disease, peripheral vascular disease and high cholesterol.          
These risk factors are similar to those shared with other cardiovascular 
diseases with the exception of diabetes that appears to be protective against 
AAA formation (4).  
1.2.3 AAA presentation 
Patients with AAA generally present to healthcare services in one of two 
ways: Electively without symptoms often as an incidental finding, or acutely 
with abdominal pain and/or rupture, which -if occurs- may be responsible 
for sudden death. 
The most common mode of presentation for patients with AAA is as an 
incidental finding. Patient presentations with AAA steadily increased 
between the 1950s-1980s (5), associated with a wider use of radiological 
modalities and an increase in awareness of the condition and the treatment 
options available.  
The most common acute presentation is with rupture where the overall 
mortality is approximately 80%, including pre-hospital death in 30% of the 
cases and preoperative mortality of 50% as represented in Figure 1.1 (6). Of 
those patients reaching hospital and not undergoing repair, approximately 
80% die within 24 hours (7) and virtually all within one month. Preoperative 






















Figure 1.1 Presentation of ruptured AAA and proportion of patients with 
associated mortality 
Data adapted from Reimerink et al. Systematic review and meta-analysis of 
population-based mortality from ruptured abdominal aortic aneurysm (6) 
Less commonly acute non-ruptured AAA presentations may include 
abdominal pain related to the aneurysm, mass effect against adjacent 
structures, thrombosis and distal embolization. This presentation is usually 
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category is a distinctive group in that patients have an operative mortality 
that is intermediate between ruptured AAA and elective AAA repair (9).  
1.2.4 Prevalence of AAA 
AAA prevalence is an important determinant of the effectiveness of 
population screening. Historically, prevalence of AAA was obtained from 
population studies and autopsy series (10). AAA prevalence rates vary 
depending on the demographics of the population screened and the 
geographical location. A meta-analysis of the published AAA prevalence in 
men and women reported a pooled rate of 4.8% (95%CI: 4.3-5.3). Subgroup 
analysis revealed that AAA prevalence was 6.0% in males and 1.6% in 
females (11). AAA prevalence also increases with age, with an odds ratio 
increase of 5 per 5-year age-category for >55 age groups when compared to 
those younger than 55 years old (reference category) (12). 
1.2.4.1 Change in prevalence 
Epidemiological studies from Europe, Australia and New Zealand have 
suggested that AAA prevalence is changing. One study compared AAA 
episodes from national administrative datasets from New Zealand, England 
and Wales between 1991 and 2007 and showed that the age-standardized 
mortality rate and the deaths from AAA have sharply reduced in these 
regions (13). Population data from Australia has also suggested that AAA 
rupture and non-rupture incidences in all age groups have decreased in the 
last decade (14). With regards to point prevalence, a sub-group analysis from 
a meta-analysis consisting of 37 studies from Europe showed that AAA 
prevalence decreased from 6.5% (95%CI: 4.8-8.1) during 1988-1992 to 
2.8% (95%CI: 1.4-4.3) during 2011-2013 (11). 
However, it may be that AAA burden is shifting to an older age group rather 
than decreasing. Choke et al. highlighted that although the trends of 
emergency AAA repair and associated mortality have declined, elective AAA 
cases have not changed in England and Wales during 2001 to 2009. It was 
also noted that the AAA population has shifted to an older age group (15).  
The Aneurysm Global Epidemiology Study on trends in AAA mortality using 
the World Health Organization (WHO) mortality database from 19 nations 
showed that there was a decline in AAA mortality in most countries (16, 17). 
This was associated with improved cardiovascular risk modification in 
patients (17) and the decrease in smoking patterns (18). However, AAA 
mortality has increased in Austria, Denmark, Hungary and Romania. 
Factors that might have contributed to a decline in AAA prevalence and 
mortality in the last decade are a decline in tobacco use, screening studies, 
increased incidental detection and non-operative management of small AAA 
(<5cm). However, factors that might have led to an increase in reported AAA 
prevalence and mortality are an improved overall life expectancy in patients 
who are more likely to have an AAA, advancement in medical management 
and improved awareness of AAA disease by both individuals and primary 
care doctors who refer patients for management.  
In summary, the prevalence of AAA appears to be changing and the age-
standardized mortality rates of AAA are decreasing, but whether the overall 
crude burden of people with AAA has decreased is debatable. The 
remarkable changes during the last two decades require better 
understanding but may be partially explained by a decrease in cigarette 
smoking habits. 
1.2.4.2 Current international prevalence 
AAAs are more prevalent in Western countries and Australasia compared to 
Asia, Africa and South America (11) (19). For example, the prevalence of AAA 
in Europe and Asia is 5.1% (95%CI: 4.4-5.9) and 0.5% (95%CI: 0.3-0.7) 
respectively. In Sweden, results of the AAA screening programme in the 
middle region of the country revealed a prevalence of 1.7% in 22,187 men 
aged 65 years old. The prevalence increased to 2.2% when men with 
previously repaired AAA or already on AAA surveillance were included (20). 
Preliminary data from the United Kingdom (UK) National AAA screening 
Programme (NAAASP) indicates recent AAA prevalence of 1.2% in 65-year-
old men (21). This is considerably different from the 4.9% figure observed 
in the MASS trial from 1997 to 1999 (22). Population AAA screening in 
Denmark in men aged 65 to 74 years reported a prevalence of 3.3% which 
has decreased slightly during the last 15 years from 4.0% (23).  National 
screening data is likely to be confounded by the age group of men being 
invited, screening avoidance and the method in which individuals are invited 
to attend screening. Evidence that AAA prevalence is declining in such 
populations is convincing but the true magnitude of the fall is unclear. 
1.2.5 The burden of AAA on health systems 
It was first noted that AAA mortality was increasing at a rapid rate from 1951 
to 1968 until it reached a steady plateau through 1981 in the USA (24). This 
can probably be attributed to an increased clinical awareness of AAA, 
improved diagnostic methods and the subsequent treatment options that 
became available during this time. 
The Global Burden of Disease study from 2010 documented the mortality of 
235 causes of death (25). The deaths related to aortic aneurysm in 1990 and 
2010 were 1,319,000 (946,000-1,733,000) and 1,917,000 (1,403,000-
2,492,000) respectively, corresponding to a 45.4% increase. However, the 
age-standardized mortality decreased from 3.3 (2.4-4.3) to 2.9 (2.1-3.8) per 
100,000 persons.  
The crude annual AAA mortality count reported from the WHO (2010) in the 
USA, UK, Germany and Italy was 6,289, 5,251, 1,251 and 2,073 respectively 
(26). The USA population is at least four times larger than the UK and serious 
underreporting is likely occurring. In Italy and Germany where the 
population is similar to the UK, the annual mortality is two to three times 
lower. This inconsistency is likely to influence the recommendations 
reported from such organizations such as the WHO.   
1.3 Natural History of AAA 
The natural history of AAA is a gradual progressive increase in aortic 
diameter. There are well- documented risk factors linked to AAA 
development and sac expansion.  Understanding such risk associated with 
the development and expansion of AAA may aid in targeted detection of AAA 
and in clinical decision-making surrounding management and surveillance 
intervals.  
1.3.1 Risks of small AAA expansion 
The predictors of growth of individual AAA are not fully understood, 
probably due to the complex behaviour of the biology of AAA expansion.  
There is a general acceptance that most AAAs steadily increase in diameter 
with time and several studies have reported a mean expansion rate of 
approximately 2.5mm/year (27, 28). However, this figure is neither absolute 
nor linear for all patients with AAA and several factors influence the rate. 
Some AAAs have erratic or stepwise non-growth periods (29). Three general 
patterns of growth have been described: linear, accelerated and 
uncategorized growths (27).  
The best information available with regards to the natural history of AAA 
expansion and rupture comes from the RESCAN study, which is a large 
collaborative collection of >15,000 individual patient data points from 
published and unpublished datasets (8).    
The initial AAA diameter is the most important predictor of growth, which 
means that in general larger AAAs grow more rapidly than smaller AAAs 
(RESSCAN). The most important modifiable factor associated with an 
increase in AAA expansion found in the RESCAN meta-analysis was smoking. 
The “current use” of tobacco was a dominant factor affecting AAA expansion 
associated with a 0.35mm increase in growth rate per annum (8, 30). The 
only factor that has been shown to decrease expansion rates is diabetes (8). 
Pharmacological medications such as statins, beta-blockers and antiplatelet 
therapy individually do not appear to influence expansion in adjusted 
analysis (8). In another study an increase in expansion was reported in 
patients with family history of AAA compared to those patients without a 
family history (31).  
1.3.2 Risks of AAA rupture 
There is consistent agreement that AAA diameter at initial 
presentation/assessment remains the strongest predictor of rupture. After 
adjusting for baseline AAA size, the RESCAN study reported that women had 
a hazard ratio (HR) of 3.76 (95%CI: 2.58-5.47) for rupture compared to men, 
and smokers had a HR of 2.02 (95%CI: 1.33-3.06) compared to ex-smokers 
and never smokers (8). Other factors that are reported to be associated with 
an increased rupture risk are age, lower BMI and hypertension (32). 
The European and the USA Society for Vascular Surgery (SVS) guidelines 
have reported annual rupture risks to guide clinicians with management 
options (33, 34). These guidelines report slightly different predicted rupture 
risks. The estimated annual rupture risk stratified according to 10mm-AAA-
diameter categories is shown in Table 1.1. 
Table 1.1: Annual AAA rupture risk by diameter    
European Vascular Society guidelines (33) USA SVS guidelines (34) 
AAA diameter (mm) Annual rupture 
risk (%) 
AAA diameter (cm) Annual rupture 
risk (%) 
30-39 0 <4 0 
40-49 1 4-5 0.5-5 
50-59 1-11 5-6 3-15 
60-69 10-22 6-7 10-20 
>70 30-33 7-8 20-40 
  >8 30-50 
 SVS: Society of Vascular Surgery, adapted from referenced guidelines 
There is agreement in the literature that the rupture risk for small AAA 
(<5cm) is very small and regular surveillance is the safest and most cost-
effective option.  
There is limited data on the natural history of rupture in AAA >5cm in 
diameter. Collection of such information is difficult and indeed unethical, as 
the majority of such patients should undergo AAA repair, with the exception 
of those with severe co-morbidities. The rupture risk of AAA >5cm is 
confounded by the presence of multiple co-morbidities and hence a higher 
overall background mortality.  A meta-analysis attempted to quantify the 
risk of rupture of larger AAAs and it was noted that the pooled cumulative 
yearly rupture risk for AAAs of 5.5-6cm, 6.1-7cm and >7cm was 3.5%, 4.1% 
and 6.3% respectively (35). This information should be interpreted with 
caution as autopsy confirmations of the diagnosis were not obtained and 
therefore the information most probably underestimates the true rupture 
risk. 
1.4 Measurement and Detection 
Clinical examination with physical palpation of the aorta to diagnose the 
presence of an AAA is the simplest and least expensive method of diagnosing 
AAA. However, the primary limitation of this strategy is the low sensitivity 
particularly with small AAA (36). This makes it an unacceptable test for mass 
screening. The gold standard tool for detecting AAA is ultrasound (US), with 
reported sensitivity of >85% and specificity of >99% (37). An aortic US scan 
is non-invasive and is not associated with any physical risks. It is relatively 
cheaper than other radiological modalities such as CT and MRI. The 
examination can be performed accurately in less than 10 minutes. 
1.4.1 Variations in methods of measurement  
Generally, measurement errors can be caused by differences in 
methodological techniques of the same measurement (intra-observer error) 
or by measurements being performed by different individuals (inter-
observer error). Measuring aortas accurately is required to diagnose 
aneurysms since the definition of AAA is based on a measured diameter.  
Factors contributing to errors in AAA diameter measurement include: 
irregular AAA shape, aortic wall thickness, phase at cardiac cycle, 
magnification, resolution of acquired images and imaging modality used. As 
expected, each radiological modality will inherit some variations in AAA 
measurements.  
Radiological modalities such as catheter angiograms and magnetic 
resonance imaging (MRI) have a tendency to underestimate the true AAA 
diameter because these techniques rely on intra-luminal flow, therefore 
aortic wall thickness, calcium deposition and the presence of thrombus 
formation can potentially be underestimated (38). On the other hand, 
computed topography (CT) scans may overestimate the diameter of the 
aorta when the readers do not account for aortic tortuosity and angulation. 
US remains the most suitable tool for accurate AAA measurements due to the 
ability of the technologist/sonographer to correct the US probe to maintain 
a true cross-sectional view of the aorta (39). A review by Long and colleagues 
documented the wide range of different methodologies used in the existing 
AAA prevalence and surveillance literature (40). Of 10 studies that reported 
guidelines for screening of AAA using US, only three studies described 
specific details of measuring techniques.  
Caliper Position   
There is no universally accepted measurement technique for AAA. The aortic 
wall is composed of three distinct layers and their respective thicknesses can 
vary between different aortas and variations of 5mm may occur (41). There 
are three accepted methods of positioning calipers during measurement: 
Outer-to-outer (OTO), inner-to-inner (ITI) and leading edge-to-leading edge 
(LELE) (Figure 1.2). 
Figure 1.2: Different methods of measuring abdominal aortic diameters  
Copyright 2015 with permission from John Wiley and Sons  
Inner-to-inner (ITI) and outer-to-outer (OTO) aortic wall measurements 
may differ by a mean difference of 4.2mm (42). ITI measurement may be 
associated with better reproducibility (43) (useful when multiple personnel 
are performing scans), but may exclude a group of people with AAA from 
diagnosis and surveillance— a potentially hazardous omission particularly 
in younger patients with a long life-expectancy. 
The National AAA Screening Programme (NAAASP) in the UK has replicated 
the aortic measurement methodology used in the Multicentre Aneurysm 
Screening Study (MASS) which was based on the ITI, whereas the Swedish 
AAA screening program used the LELE methodology (41, 43). This difference 
in measurement must be considered when combining AAA datasets and 
comparing prevalence of AAA between studies. 
1.4.2 Detection of AAA by serendipity or screening 
AAA prevalence is one of the key parameters in determining the likely 
effectiveness of population screening. A second determinant is the 
proportion of non-screen detected AAA prior to screening or outside the 
screening recommendation— principally (incidental) findings of abdominal 
imaging for unrelated diagnostic purposes. This figure is reported to range 
from 35-46% (44). In the MASS, 277 patients in the control group had 
undergone elective AAA repair for incidentally identified AAA, compared to 
600 patients in the screened group. In the Western Australian (WA) Health 
in Men study, 54 men in the control group had an elective repair compared 
to 86 men in the screened group. With this high rate of background AAA 
detection in the WA study, AAA screening in men was not effective (45).  
In the absence of a formal AAA detection program, vascular surgery health 
care units managing AAA disease depend on radiological modalities for 
diagnosis and clinician referrals of people with AAA.  
1.5 Management of Established Asymptomatic AAA 
Once an AAA is detected and presence has been confirmed by appropriate 
radiological imaging, three management options could be considered:  
1. Non-intervention if treatment is unlikely to offer significant benefit 
due to low life expectancy or high operative risk. 
2. Surveillance until AAA reaches the size threshold for repair (5.5cm 
diameter). 
3. Repair with either open aneurysm repair (OAR) or endovascular 
aneurysm repair (EVAR). 
1.5.1 Surveillance of small AAA 
Surveillance is a well-established strategy in the management of small AAA. 
The frequency of US intervals differs depending on the size of the initial AAA. 
Serial scans are used to measure the aorta at agreed surveillance intervals 
depending on the initial AAA diameter. Stather et al. summarized the global 
AAA surveillance experience from expert representatives at an international 
meeting (46). The majority of screening strategies reduced intervals when 
AAA diameter increases (Table 1.2). However, some of the reported intervals 
from some countries are not accurate; for example, it has been reported that 
the surveillance interval in NZ for >3cm AAA is 12 months, which is not an 
accurate reflection for the majority of vascular units in NZ.  












UK SAT(30) Frequency 
intervals 
(months) 
2.5-2.9 60 - - 3-3.9 24 
3-3.4 36   4-4.5 12 
3.5-4.4 12 3-4.4 12 4.5-5 6 
4.5-5.4 6 4.5-5.5 3 >5 3 
NAAASP: National AAA screening program; SAT: small aneurysm trial 
1.5.2 AAA repair of small AAA (<5.5cm) 
In the mid-1990s, prior to the establishment of screening programs, there 
was a suggestion that patients with small AAAs (4 to 5.4cm) might benefit 
from early repair to prevent the devastating high mortality of rupture. Four 
randomised trials (two open vs. surveillance and two EVAR vs. surveillance) 
have been conducted to answer the question “if AAAs are repaired at a 
smaller size, would AAA rupture and hence overall mortality be reduced?”  
Initially two RCTs, one from the UK (UK Small Aneurysm Trial, UK SAT) and 
the other from the USA (Aneurysm Detection and Management study, 
ADAM) randomised patients into early repair vs. surveillance. Their results 
showed that there was no survival difference observed among patients who 
underwent immediate AAA repair versus surveillance. This difference was 
maintained even after 12 years of follow up (48). Approximately a decade 
later, two further EVAR trials were conducted: Comparison of surveillance 
versus Aortic Endografting for Small Aneurysm Repair (CAESAR, Italy) and 
the Positive Impact of endoVascular Options for Treating Aneurysm earLy, 
(PIVOTAL, USA) (49, 50). The argument for conducting the EVAR trials was 
that the 30-day mortality with EVAR is much lower than OAR and hence 
EVAR would be a more suitable treatment and the benefits of intervention to 
prevent rupture would be elucidated.  Both trials concluded that there was 
again no difference in overall mortality with early treatment compared to 
surveillance. A systematic review and meta-analysis of these four trials 
concluded that there were no benefits of early repair (51). In addition, the 
US and European guidelines have recommended against early repair for 
small AAA.  
1.5.3 AAA repair of large AAA (>5.5cm) 
To date, there are no known specific drug therapies that have been 
effectively shown to reduce AAA expansion (52). Therefore, repair of the 
aneurysm is the only effective treatment to exclude AAA and prevent 
rupture. The repair could be achieved with open AAA repair or by 
endovascular stent insertion. Each approach comes with its unique 
advantages and limitations. 
1.5.3.1 History 
Until the 1950s, ligation of the aneurysm was the adopted surgical treatment 
available. This remained the case until 1951 when Dubost performed the 
first successful AAA open repair with a homograft (53), and restoration of 
blood-flow continuity was achieved. It became widely noticed that non-
operated AAA had a poorer survival than operated AAA, and resection was 
recommended (54, 55). Hence, there were no trials comparing AAA repair 
versus no repair conducted in that era. During the late 1980s, independent 
reports by Volodos (56) in the Soviet Union and Parodi et al. (57) in Buenos 
Aries, Argentina, were the first to report AAA treatment using a stent graft 
for treating AAA disease. This technique later became known as 
EndoVascular Aneurysm Repair (EVAR).  
1.5.3.2 Open AAA repair 
The AAA is usually approached via either a laparotomy (transverse or 
midline incision) or using a left retroperitoneal exposure. The extent of the 
AAA is defined and control of the AAA proximally and distally is achieved 
with clamps. The aorta is then cross-clamped, the aneurysm sac is entered, 
aneurysm contents (thrombus) evacuated, and a prosthetic graft is sewn in-
situ as a tube graft if the AAA was confined to the aorta or as a bifurcated 
graft if the disease extends into the iliac or femoral arteries.  Then the aortic 
sac is used to cover the graft to isolate the foreign material from the bowel 
cavity (Figure 1.3). 
Figure 1.3 Intraoperative images of OAR 
Left: the aorta and iliac arteries are clamped and AAA sac opened. Right: a bifurcated 
Dacron graft sewn from the infra-renal aorta to the iliac arteries  
1.5.3.3 Endovascular aneurysm repair 
EVAR is an alternative minimal invasive method of excluding AAA with a 
prosthetic stent graft inserted through the femoral arteries using 
fluoroscopic guidance. The stent is positioned and deployed, and the 
presence of contrast (blood) reperfusing the AAA sac is checked. Technical 
success of the procedure can be defined as the absence of sac perfusion and 
restoration/preservation of blood flow to major organs (Figure 1.4).  If 
contrast is seen outside the stent, the term “endoleak” is given, which is 
subsequently classified into 5 types (58):  
Type 1: Flow origination from the proximal or distal seal 
Type 2: Retrograde blood vessel flow into sac 
Type 3: Structural graft failure 
Type 4: Graft fabric porosity 
Type 5: Endotension (presence of endoleak without an identifiable 
cause) 
Given that EVAR is relatively a new technology, life-long stent graft 
surveillance is still recommended to monitor the presence of endoleak, sac 
expansion and stent graft complications such as migration, dislocation or 
kinking.  Hence, endoleaks are the main drawback of EVAR and are seen by 
many as the ‘Achilles heel’ of this technology.  
Figure 1.4 Abdominal aortic aneurysm treated with EVAR 
Left: Completion Digital Subtraction Angiography during an EVAR. Right: 3D CT 
Angiogram reconstruction of EVAR at 3 months follow-up showing no endoleak  
1.5.3.4 Results of RCT comparing OAR and EVAR 
Historically, the “gold standard” and mainstream strategy for treating AAA 
was with open surgery. However, since the introduction of a minimal 
invasive option (EVAR), there have been four randomised controlled trials 
(RCTs) conducted to compare EVAR with the more open aneurysm repair 
(OAR) for the treatment of large AAA. The first trials from the UK 
(Endovascular Aneurysm Repair EVAR-1) and the Netherlands/Belgium 
(Dutch Randomised Endovascular Aneurysm Management, DREAM) were 
very comparable and reported their initial findings in 2004. EVAR-1, DREAM 
and the Open Versus Endovascular Repair (OVER) from the USA reported 
very similar findings in short- and long-term outcomes. The most recent RCT 
Aneurysme de l‘aorte abominale: Chirugie versus Endoprothese (ACE) from 
France randomised low- to moderate-risk patients to EVAR or OAR. The ACE 
investigators reported no difference in 30-day or up to 3-year mortality 
between the two modalities, but EVAR was associated with more re-
interventions. The ACE trial ended after the 3-year follow-up and no long-
term data is expected (personal communication with principal author). Two 
meta-analyses of the RCTs concluded that EVAR had significantly lower 30-
day mortality compared to OAR but long-term survival was very similar for 
both approaches. However, re-intervention rates in the EVAR group were 
significantly higher (59, 60).  Despite this, EVAR utility has reached 70-75% 
in the United States and Australia between 2010- 2011 (61, 62). Summaries 
of the trial results are presented in Table 1.3.  
Table 1.3  Short- and long-term results of four randomised controlled trials 
comparing OAR and EVAR 












    OAR EVAR OAR EVA
R 
OAR EVAR 
EVAR-1 2004 1047 UK 24 (4.7) 9 (1.7) 54 54  90  72  
DREAM 2004 345 Netherlands 
& Belgium 
8 (4.7) 2 (1.2) 69.9 68.9 81.9 70.4 
OVER 2009 881 USA 13 (3) 2 (0.5) 60 58% NR† NR‡ 
ACE 2011 299 France 1 (0.6) 2 (1.3) 86.7  86.3  85.8 76.1 
† ACE 3 years, EVAR-1 8 years, DREAM 6 years, OVER 9 years 
‡ Only reported as a combined freedom of re-intervention and death 
 
Numbers in parenthesis indicate percentages 
1.5.4 Long-term results 
Three of the randomized trials have published follow-ups longer than 5-
years. The results of a meta-analysis that included four randomised 
controlled trials (RCT) comparing open AAA repair (OAR) with endovascular 
aneurysm repair (EVAR) showed that the modality chosen for AAA repair 
does not influence survival at 4 years (OR 0.92, 95% CI: 0.75-1.12) (59). 
When the results from three propensity-score matched studies were 
included in the meta-analysis, the main conclusion did not change (HR 0.97, 
95% CI: 0.9-1.04) (63). In a selected large Medicare population which 
included 39,996 propensity-matched patients who underwent EVAR or OAR 
from 2001 to 2008, no difference in survival was observed between the types 
of repair (64).  
The crossover point between EVAR and OAR was observed in the trials 
between 2 to 4 years following repair, were EVAR “lost” the early survival 
advantage and the long-term survival was unchanged. In RCTs with an 
intention to treat analysis, the baseline selection bias is “non-existent” and 
the treatment allocated is the primary outcome. 
There is a suggestion that operative mortality has improved with time, 
particularly with the advancement in endovascular technology (64, 65), but 
even in contemporary series, overall survival does not appear to have 
changed. 
1.5.5 Cost estimates of AAA repair 
In this era where health expenditure is increasing, cost effectiveness 
analyses have become an important element when treatment options are 
compared. In order to justify a national AAA screening program advocating 
repair with one type of repair or another or balancing repair with quality of 
life gained, the economics of AAA management costs should be considered. 
This information can be divided into three components analysed in the 
following sections. 
1.5.5.1 The cost of AAA repair versus no repair 
The actual costs of conservative treatment without repair are relatively 
inexpensive compared to AAA surgical repair-related treatment costs. The 
well-established treatment management for most fit patients with AAA 
precludes a trial designed to determine cost-effectiveness of AAA repair 
versus no AAA repair. Actuarial costs have been described from the EVAR-2 
trial where patients who were deemed not physically fit to undergo OAR 
were randomised into EVAR or no repair. The costs of the EVAR were more 
expensive than the no-repair group. However, there was no statistical 
difference in survival between the two groups (66). 
1.5.5.2 Costs of treatment – OAR vs. EVAR 
The comparative costs between EVAR and OAR have been mostly derived 
from the RCTs. Since elective and emergency procedures differ significantly 
between each type of presentation, cost information will be discussed 
separately below. 
Elective setting  
Randomized trials comparing OAR and EVAR have provided some evidence 
on cost differences between each treatment approach. In the short term, 
EVAR was more expensive than OAR despite the significantly shorter 
hospital stay, less blood requirement and less intensive care unit (ICU) costs 
associated with EVAR (67). This is largely due to the upfront cost of the 
endovascular device. A meta-analysis and Markov-based modelling of the 
four trials concluded that OAR was also more cost effective than EVAR in the 
long-term in the European-based studies but not in the OVER trials (USA) 
(68).  
Acute or emergency setting  
In contrary to scheduled aneurysm repair, endovascular treatment was 
found to be associated with lower costs than open repair for emergency 
procedures in one trial (69) but not in another trial (70). Reasons for the 
contradictory findings might be related to the randomization process in 
including patients and differences in the cost of stent devices (71).  
1.5.5.3 Costs of elective versus rupture AAA repair  
Despite the higher mortality associated with ruptured AAAs, the costs of 
emergency repair are significantly higher than elective repair driven 
primarily by an increase in ICU length of stay, blood products and a higher 
complication rate. In a study using a Markov model, Patel et al showed that 
the costs incurred from a ruptured AAA (despite the associated high 
morbidity and mortality) was cost-effective as it led to an improvement in 
quality adjusted life years (QALY) compared to immediate deaths without 
any repair (72).  
A local study of 169 consecutive patients who underwent AAA repairs at 
Christchurch Hospital revealed that the costs (NZ dollars) of repairing a 
ruptured AAA were significantly more expensive than elective AAA ($38,804 
vs. $28,019, 95% CI for mean difference: $249-$21,321). This finding was 
consistent with similar studies published two decades ago (73). 
1.5.6 Long-term survival following AAA repair 
Given the association of AAA with cardiovascular risk factors, it is expected 
that life expectancy of patients with AAA would be lower than a matched 
“normal” population. A review from 2001 revealed that the 5-year crude 
estimated survival following AAA was 70% and the expected survival for 
matched population was about 80% (74). Furthermore, a meta-analysis 
published in 2015 reported that the crude observed estimated 5-year 
survival following elective AAA repair (OAR and EVAR) was 69% (95%CI: 
67-71), and this figure has not changed during the last 40 years (75) despite 
the decrease in 30-day operative mortality.  
1.5.7 Factors influencing late survival 
As operative experience accumulated during the last century, it became 
apparent to surgeons that certain groups of post-AAA-repair patients had a 
reduced survival compared to others (76). Multiple risk factors were 
associated with worse survival, including an increase in age, hypertension 
and heart disease. As more follow-up data was gathered, further predictors 
were described and differences in predictors between the types of repair 
were reported. 
However, predictors that influence survival have not been consistent among 
the studied population and the follow-up period varied. Obtaining accurate 
assessments for such predictors might provide better estimates of the 
relative influence of each predictor and its impact on survival. In Chapter 4 
of this thesis, a comprehensive review of the literature will be presented to 
provide the best estimates for each of the factors that influence late survival 
following AAA repair. 
1.5.8 AAA-related death 
Despite treatment or exclusion of AAA by repair, patients have a lifelong 
ongoing risk of AAA-related complications and death. The mechanisms of 
such complications can be broadly categorized as 1) device or graft material 
failure, 2) biological factors causing aneurysmal formation in proximal or 
distal segments that can expand, 3) erosion of the prosthetic into adjacent 
structures (i.e. duodenum) and 4) a life-long risk of prosthetic infection. 
Fortunately, such aortic complications are uncommon and by far the 
majority of deaths following AAA repair are due primarily to cardiovascular 
and oncological conditions (77). Such causes of death are also the same 
causes of death in an age-matched population without AAA disease (78). 
Despite the fact that prosthetic-graft-related complications are estimated to 
be in the range of 2-3% (79), such complications confer a high risk of 
mortality and morbidity. 
The most catastrophic scenario is a rupture of a previously-repaired AAA by 
either EVAR or OAR. The rupture rates following EVAR have been reported 
to be significantly higher than after OAR. Data from the UK EVAR 1 and 2 
trials indicate that from a total of 1,442 patients, 27 (3.2%) ruptures 
occurred in the EVAR group and 0 ruptures occurred in the OAR group after 
a mean follow-up of 57.6 months (80). A meta-analysis estimated that the 
incidence of late rupture after EVAR was 0.9% with a mean time to rupture 
of 3 years from the index procedure (81).  
1.5.9 Quality of life after repair 
The RCTs comparing EVAR and OAR as well as some observational studies 
have provided information on the relatively short-term post-operative 
period extending to 5 years. The general summary from the trials was that 
both types of repair had a similar return to baseline for lifestyle activities 
and quality of life at 1 and 2 years post repair. 5-year follow-up from the 
DREAM trial showed that patients who underwent EVAR had a worse health-
related quality of life than patients who underwent OAR (82). 
There is a paucity of long-term quality of life data following AAA repair (83), 
particularly in this era when the morbidity and mortality from both types of 
repair are declining and the proportion of octogenarians who are offered 
repair is increasing. 
1.6 Screening for AAA 
1.6.1 History of screening 
AAA screening could theoretically detect patients with aneurysms and 
prevent AAA-related complications and death (84). As AAA’s health-burden 
increased through greater detection and better-established, safer surgical 
repair, interest in large-scale AAA screening developed -especially in Europe 
and Australia- in the early 1990s. 
1.6.2 AAA screening trials 
There have been four RCTs that compared US screening for AAA with 
unscreened controls, these are summarised in Table 1.4. The first RCT was 
conducted in Chichester, UK and was the only trial that included females, but 
given the lower prevalence of AAA detected in women, they were excluded 
from future trials. A meta-analysis of the screening trials concluded that AAA 
screening reduced AAA-specific mortality (rupture) in asymptomatic men 
over the age of 65, OR 0.60 (95%CI: 047-0.78) (85) and was associated with 
a trend to decrease overall long-term mortality in men (86).   
The main conclusion from the trials was that US screening for AAA in men 
reduced death from AAA by 40%, was safe and cost effective and could be 
recommended. It was first adopted at a national level in England in 2009. 
Other countries have initiated national AAA screening programs, although 
protocols differ between countries (46).  
Table 1.4 – Summary of the four AAA RCT screening trials 
Study/ 
year 








































19,352 12,213 19,352 65- 79† 7.2% 63% 
† Expected age at midpoint of the study, M: males, F: females 
The studies were fairly similar in design but the higher prevalence seen in 
the Western Australian and Chichester studies could be due to their 
inclusion of >75 year old men, compared to the other two studies. 
There appeared to be some other benefits of screening from these studies; 
men who underwent AAA repair from the screening arm of the RCT had 
lower postoperative mortality compared to men in the control group who 
underwent AAA repair (87). This could be due to the medical treatment and 
risk-factor modification initiated during AAA surveillance. This finding also 
supports the notion that screening for AAA is beneficial. 
Outcome data outside the RCTs differed from that observed within the AAA 
screening programs. The longest reported AAA program has been running in 
Gloucestershire, UK since 1990. This program reported a decrease in AAA 
rupture during the study period thought to be related to the screening 
program (88).  On the other hand, in Malmo, Sweden, Otterhag and 
colleagues have suggested that the incidence of AAA rupture has been 
decreasing between 2004-2010 prior to the introduction of the national AAA 
program in late 2010 (89). 
Compared to other cancer screening programs, AAA screening reduces death 
by 4 per 1000 (21) (breast cancer screening reduces death by 0.7 per 1,000 
and colorectal cancer screening reduces death by 1.5 per 1,000). The number 
of people needed to be screened to save one life from death by AAA is 217 
(86). 
1.6.3 Established screening programmes 
The overall prevalence from the NAAASP in England from the first 700,000 
screened men was 1.34% and the mean uptake was 78.1% (range: 61.7-
85.8%). Interestingly, during the same study period, there were 27,421 men 
over 65 years who self-referred and their AAA prevalence was 2.8%. This 
may simply be due to AAA prevalence increasing with age, or other 
individual reasons such as having a family history of an AAA or having higher 
risk factors (90).  
In Sweden, the screening program started in one county in 2006 and was 
introduced throughout the country in 2010. The overall prevalence of AAA 
in 65-year-old men was 2.2%, including 0.5% of the eligible population with 
a known or previously repaired AAA (20).  
In the United States, following a meta-analysis of published AAA screening 
studies (91), a recommendation for screening all men and women aged 65-
75 who had ever smoked or those with a known family history of AAA was 
introduced as a package by Medicare (92). The uptake of this program has 
generally been very low (93) and outside AAA screening recommendations 
(92, 93). The prevalence of AAA from a single Veterans Affairs centre was 
relatively high at 7.2%, perhaps reflecting the impact of smoking (94).  
In Denmark, a second RCT trial- the Viborg Vascular (VIVA) has been 
completed to determine if AAA screening in this decade is still considered 
beneficial. Preliminary data suggests that the prevalence of AAA in men 
(aged 65-74 year) is 3.3% (95). The mortality outcomes for both groups have 
not been reported to date.  
1.6.4 Cost effectiveness of AAA screening 
Cost effectiveness of an AAA programme is defined as the comparison of the 
costs of the proposed screening program compared to the status quo in AAA 
clinical management. This relies on the costs encountered for this treatment 
or strategy divided by the health utility or quality of adjusted life years 
gained or lost (96). 
The following parameters are required to be met to determine the cost 
effectiveness: prevalence of AAA, mortality rates, cost associated with 
treatment and the quality of life of patients. Data from RCTs have provided 
the costs and quality of life for AAA patients that had not undergone 
screening (i.e. had their AAA diagnosed incidentally).  
There are two types of AAA screening cost-effectiveness evidence models 
discussed within the literature; 1) actual costs from prospective trials, 2) 
predictive models based on published studies that can test a range of 
estimates. Estimating costs for any screening program is a complex process 
and has to be modified to accommodate local practices and health 
expenditure. There is some disagreement regarding the cost-effectiveness of 
screening programs (97), and the method of economic modelling used can 
have limitations and impact the conclusions drawn (98).  
Contemporary national AAA screening programmes have reported lower 
AAA prevalence rates. Despite the lower prevalence of AAA being detected 
in the UK after the introduction of the NAAASP, a revised and updated cost-
effectiveness model using current data and long-term data from the MASS 
trial showed that the AAA screening programme remained hugely cost-
effective (99, 100). This finding has also been observed in Sweden where the 
prevalence of AAA was estimated to be 1.3% (101). In another cost-
effectiveness model from Sweden, screening for AAA remained cost-effective 
even with a low prevalence of 0.3, provided the background incidental AAA 
detection remains low (<30%) (44). 
1.6.5 Reasons for lack of screening 
AAA burden is not evenly distributed around the globe and mainly affects 
Caucasians in Western countries. In continents such as Africa and Asia, AAA 
disease is very uncommon and therefore AAA screening programs would 
very likely to be less beneficial and non-cost-effective. In addition, the 
screening can be costly to nations with health budget constraints.  
Another reason for the slow uptake of screening programs is related to the 
suggestion that the incidence of AAA is decreasing, therefore it is deemed 
unnecessary to implement screening. A potentially important but perhaps 
less reported reason for not implementing AAA screening is due to the costs 
to healthcare in an era where constraints to governing health authorities are 
already stretched.  
1.7 Challenges  
From the information presented to date, several challenges in the 
management of AAA have been encountered, and despite the intensive 
research in this field, many questions remain unanswered. It is important to 
note that the majority of previous studies were conducted 20-30 years ago 
and there is a need for more contemporary data to inform discussion given 
the rapid evolution in our understanding and treatment of AAA. 
1.7.1 Women and AAA disease 
The screening and management of AAA in women is a particular challenge, 
primarily because the majority of AAA research has included more men. 
Traditionally, woman have been excluded from AAA screening trials as the 
prevalence of AAA in women is 4-5 times less than men. Only one RCT 
included 4682 women invited for screening and 4600 women included in the 
control group. There were 3052 women that attended aortic screening and 
an overall prevalence of 1.3% was documented. Interestingly, the acceptance 
rates for women were lower across all age categories when compared to 
men. This study did not show a benefit for screening AAA in women (102). 
A study from Sweden that invited 6,925 women of which 5,140 accepted and 
attended an AAA screening had an overall prevalence in non-smokers of 
0.03% and 2.1% for current smokers (103). This strongly suggests that 
women who never smoke should not be included in screening programs. 
Also, women with a history of smoking have a higher incidence than men 
who have never smoked (104). 
The second challenge that arises with this gender difference is that women 
presenting with an AAA rupture present approximately 6 years older than 
men. Although women in the general population have a longer life 
expectancy than men, when AAA disease is present, this relationship 
inverses and women seem to have higher mortality following repair. In a 
meta-analysis, the pooled 30-day mortality after elective AAA repair is 
significantly higher in women following OAR and EVAR with adjusted odds 
ratios for age being 1.28 (95% CI: 1.09-1.49) and 2.41 (95% CI: 1.49-3.88) 
when compared to men (105). The influence of gender on long-term survival 
following AAA repair is still controversial.  
1.7.2 AAA in the elderly 
Life expectancy in the developed world is increasing and health services are 
observing the increased costs of delivering health care. With regards to AAA, 
prevalence increases with age in both genders. The average age of patients 
with AAA presenting to hospitals is increasing (15).   
This has also been shown from a decade of AAA presentations in Australia 
where the trend of non-rupture AAA in men over the age of 80 has increased 
(14). Elderly men >75 years old who undergo AAA repair and survive confer 
the most benefit and have lower standardized mortality ratio than the 
normal population (48).  
With a lower 30-day mortality with EVAR, some elderly patients who prior 
to the EVAR trials would have been deemed unfit for the conventional repair, 
might benefit from EVAR particularly if death caused by AAA rupture is 
prevented. 
Although an increase in age is associated with worse short-term and long-
term outcomes, the actual association (in isolation) is small compared to 
other predictors such as cardiac, respiratory or renal disease. 
1.7.3 Targeted screening 
Targeted or selected screening can be defined as focused strategies to 
increase the efficacy or yield of a screening program. The proposed AAA 
screening programs in the UK, Sweden, USA and others are considered 
targeted/selective, as men over the age of 65 years old in the UK and men or 
woman with a history of smoking 100 or more cigarettes during a lifetime 
(as part of a Medicare package) in the USA are eligible for screening. As AAA 
predominantly affects men >60 years old, there is no doubt that the 
screening is targeted to a certain degree to remain effective.  
In order to improve detection and increase the yield of AAA screening, a 
more targeted approach has been suggested. Owing to the well-established 
risk factors for AAA development, selecting patients according to age, 
smoking history and the presence of cardiovascular risk can all be factored 
into screening targeted groups. 
The drawbacks of such approaches include the fact that selecting people 
with higher risk factors who might have a lower relative survival might cause 
the overall benefits of AAA treatment not be observed. Moreover, there are 
ethical implications if fit patients are not offered screening when the chances 
of developing an AAA are still 1 to 3%.  
The prevalence of AAA increases in patients with IHD (106, 107) and in one 
study this relation was proportional to the number of coronary vessels 
involved (108). Another relatively simple and selective screening is to scan 
all patients referred to the vascular US laboratory for an AAA. This approach 
has demonstrated a strong association of AAA presence with patients who 
have significant lower extremity, carotid artery stenosis and renal artery 
stenosis (109). 
Inviting men at 65 years of age will not diagnose all men with AAA in the 
community. This is supported by data from Finland, which included 587 
patients presenting with a ruptured AAA over a 12-year period. The authors 
showed that 18.3% of patients with ruptured AAA were in fact younger than 
65 years of age. Of these, 21.4% were males less than 65 years of age and 3% 
were females (110). This indicates that within the most commonly proposed 
AAA screening program paradigm, inviting men on their 65th birthday, one 
in five affected men would potentially have an AAA rupture prior to 
screening.   
Data from the Western Australian AAA screening randomised controlled 
trial revealed that if AAA screening was targeted to the known risk factors, 
25% of patients would be missed, thereby improving the specificity of AAA 
detection, but with a trade-off in detection sensitivity (111). Another limiting 
issue within targeted screening approaches is the likely selection of older 
patients with AAA, as has been observed in the Western Australian (111) 
study and other studies (108). These examples highlight the potential issues 
that might arise if more targeted AAA screening programmes were to be 
applied. 
1.7.4 Barriers to AAA screening 
Information on AAA population screening is now available from national 
programmes. Some of the identified barriers to AAA screening in men were: 
recent immigration, low income and education levels, being single or 
divorced and having to travel long distances (112). Two studies from 
different regions in Scotland, where the reported uptake of each program 
was >85%, identified that an increase in deprivation decile was associated 
with lower attendance to AAA screening (113-115). 
1.7.5 Who to target for AAA screening? 
AAA screening has traditionally been targeted towards men at 65 years of 
age and this was the strategy used by governmental health authorities 
during the mid-1990s to the mid-2000s. Emerging evidence has revealed 
that the change in AAA epidemiology, lower preoperative mortality with 
repair and improved life expectancy should be considered rather than the 
adaptation of the same screening guidelines.  
Many developed cities have an overrepresentation of multicultural and 
ethnic societies, which could underestimate AAA prevalence, as the disease 
is less common in non-white persons. In the UK, men from the following 
ethnic backgrounds: Asian, Black and Chinese have very low prevalence of 
AAA and had higher attendance rates compared to white British males (21). 
Therefore, the number needed to be screened increases when non-White 
men are screened. This has also been seen in the USA where ethnic 
minorities had a lower prevalence of AAA. 
In addition, a family history of AAA increases the chances of having an AAA 
in both males and females (116). This group of patients has a higher 
prevalence of AAA than the general population and present at a younger age 
(117). 
1.8 New Zealand Specific AAA Data 
National health bodies are investigating the implications of an AAA screening 
program in NZ and local national data is required to assist with this process. 
Population screening to estimate the prevalence of AAA in New Zealand has 
never been conducted. However, there are indications that the disease 
burden is significant. A study of ruptured AAAs in Auckland from 1993-1997 
reported a 6.1 per 100,000 per year (118), which is in the mid- range of the 
reported incidence of ruptured AAA from a systematic review that included 
22 studies ranging between 2.9 to 14.1 per 100,000 persons per year (6). 
In New Zealand (NZ), where there are several ethnic groups including the 
indigenous people of NZ – Māori, it is important to know what the prevalence 
of AAA is as Māori have higher health disparities than NZ Europeans. With 
regards to AAA risk factors, Māori have high smoking rates particularly in 
Māori women. 
Māori in general have a higher mortality after AAA repair and present at a 
younger age than non-Māori (119). Māori women appear to have AAA 
mortality rates almost comparable to NZ European males and substantially 
greater than NZ European females (120).  The drivers of this high mortality 
have not been well documented. 
Specific research on AAA burden in NZ is limited to a few studies. Therefore, 
obtaining local national data is vastly important so a decision on the 
appropriateness of an AAA screening program can be made. In New Zealand, 
it is estimated that 236 deaths per year can be attributed to AAA (121). This 
figure does not include the number of people with ruptures that do not 
present to hospital and do not undergo emergency repair. Contemporary 
data regarding burden of AAA, workload, and annual mortality rates in NZ is 
lacking.  
Estimating prevalence of AAA in New Zealand will be the primary focus of 
Chapter 2 in this thesis. In chapter 4, interrogation and validation of the 
available NZ data on AAA will be presented.  
1.9 Academic Papers 
This doctoral thesis has been completed with the publication of ten articles, 
five of which contributed directly to chapters and the remaining five as 
supplementary or exploratory work. However, the amount of repetition was 
kept to a minimum. The summary of the five publications, author 
contribution and reference is outlined in Table 1.5. 
Permission has been granted by journal publishers to include this content 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































1.10 Structure of Thesis 
This thesis will focus on the methods of detection and management of AAA 
disease. The thesis will provide prevalence of AAA in a large selected 
population undergoing CT colonography (chapter 2). The definition and risk 
factors of developing AAA and how the aortic diameter influences survival 
will be provided in chapter 3. Data relevant to AAA treatment and outcomes 
in New Zealand will be collected and analysed to describe the burden of AAA 
in New Zealand (chapter 4). The prognostic factors that influence survival 
following AAA repair will be documented and quantified from a systematic 
review and meta-analysis of the published literature (chapter 5). Predictors 
of short- and long-term survival will be then fitted into a prognostic model 
that will inform the gains (or losses) in survival of AAA repair for an 
individual patient. This model will be validated with established databases 
(chapter 6). Finally, chapter 7 discusses and summarises the entire thesis 










“There is no disease more conducive to clinical humility than 
aneurysm of the aorta” 





Due to the fact that abdominal aortic aneurysm (AAA) rupture has an overall 
mortality exceeding 80%, elective AAA repair is one of the most effective 
surgical procedures for prevention of premature death from AAA rupture. 
This necessitates an effective method of detection, as aneurysms are usually 
asymptomatic.   
Interest in AAA screening initially started in the 1980s following a better 
understanding of the natural history of AAA and the increased mortality 
associated with non-operative management in AAA > 5cm. In addition, the 
use of ultrasound (US) scan provides a relatively cheap and safe method for 
AAA detection.  
Four studies randomised men over the age of 65-80 to an AAA US scan versus 
no scan and demonstrated a reduction in AAA-related mortality in the 
screened group. Denmark has undertaken a second randomized trial (Viborg 
Vascular screening trial, VIVA) to determine whether AAA screening is still 
beneficial in 65-74 year old men in the context of an apparent reduction in 
AAA prevalence. The medium- to long-term results are not published yet but 
a prevalence of 3.3% has been reported (95) and it is likely that screening 
will remain cost effective within Europe. 
In New Zealand (NZ), a large national randomised study is unlikely to be 
undertaken given well-established evidence provided by the international 
studies. The costs of such a trial would potentially be better used for the 
development of an AAA detection program.  However, NZ lacks even basic 
local information on AAA including prevalence. 
To provide AAA prevalence information, an observational study was 
undertaken in the Canterbury region of the South Island of NZ. 
The questions that arise from this in relation to AAA screening in NZ are: 
1) What is the prevalence of AAA in the general population? 
2) What are the predictors for AAA presence and demographics of 
patients with AAA disease? 
3) In those people with AAA, how does the life expectancy match the 
general population? 
2.2 Contribution  
In this project, I was the principal investigator for the research. I performed 
all measurements of the AAA from the CTC images stored on the Picture 
Archiving and Communication System (PACS), then collected demographical, 
clinical risk factor and outcome data on patients with AAA. I performed the 
data analysis and noted some inaccuracies in death records. An application 
to the Ministry of Health was made to obtain accurate and current survival 
statuses of the included patients.  
2.3 Publication 
Khashram M, Jones GT, Roake JA. Prevalence of Abdominal Aortic Aneurysm 
(AAA) in a Population Undergoing Computed Tomography Colonography in 
Canterbury, New Zealand. European journal of vascular and endovascular 
surgery. 2015; 50 (2):199-205 
2.4 Background 
Abdominal aortic aneurysm (AAA) screening using an abdominal ultrasound 
has been shown to reduce AAA mortality in asymptomatic men over the age 
of 65 (85). The uptake of national screening programs has been slow for 
several reasons. These include changing epidemiology (18, 122), lack of 
funding or awareness and varying AAA prevalence among different 
populations and ethnicities.  In NZ, the true prevalence of AAA is unknown 
and detection still relies on incidental findings from radiological modalities 
and referrals from other physicians. The global AAA burden has diminished 
between 1990 and 2010 but the AAA prevalence remains relatively high in 
Australasia and Oceania (19). However, there is some evidence of decreasing 
age-specific mortality from AAA in NZ (13). 
2.4.1 Surrogate screening with CT colonography 
To determine the prevalence of AAA in Canterbury, the wide-spread use of 
CT colonography (CTC) acted as a surrogate for detecting AAA. The use of 
CTC for detection of colorectal diseases and colonic surveillance has gained 
popularity in our region as an alternative to optical colonoscopy due to 
constraints on the public health system in providing colonoscopy for 
symptomatic patients (123). It has also been used when colonoscopy could 
not be completed and in surveillance of colonic diseases. A CTC (also referred 
to as virtual colonoscopy) is a non-invasive, low dose CT that assesses the 
entire colon by inflating air via the rectum to allow distension of the colon 
and visualisation of colonic pathology. Other potential advantages of CTC 
include detection of extra-colonic pathologies, such as AAA, at no additional 
cost or radiation risk. CT also permits assessment of the entire aorta (usually 
descending thoracic aorta to femoral bifurcation) and precise measurement 
of the aortic wall without hindrance from bowel gas or obesity.  
2.4.2 Selection process 
A pathway to triage patients with gastrointestinal symptoms was introduced 
in 2008. Depending on clinical symptoms, physical examination findings, 
family history and laboratory results, a higher score will direct referrals 
towards an endoscopic colonoscopy, while a low score will direct referrals 
to a CTC first approach (123). The point system and decision tree is included 
in appendix 8.1. 
2.4.3 CTC and AAA detection 
The retrospective options to document the prevalence of AAA would be to 
use radiological imaging modalities (such as US, CT or MRI) to measure 
aortic diameters. The reasons for choosing CTC as opposed to the other 
modalities were: first, there are mutual risk factors and demographics (age 
groups) between AAA and CRC; second, patients referred for CRC 
investigations with the primary aim of detection are likely to benefit from 
treatment should abnormal pathology be detected; and third, as CTC has 
been used as a screening test, it is likely to capture a group of patients from 
primary care whose medical conditions were not severe enough to warrant 
tertiary hospital care. 
Previous Markov-simulation-modelling studies revealed that dual screening 
for colorectal cancer and AAA using CTC was more cost-effective in a 
hypothetical population when compared to optical colonoscopy and an 
abdominal aortic ultrasound (124, 125). While AAA screening randomised 
trials used an US to measure abdominal aorta in the absence of a national US 
screening programme, the aim of this study was to use CTC as a surrogate 
for US to document the prevalence of AAA.  
2.5 Objectives 
The primary objectives of this research was to document the prevalence of 
AAA in the population undergoing CTC examination in the Canterbury region 
of the South Island and to determine the predictors of developing AAA and 
the factors that influence overall survival.  
2.6 Methods 
This was a retrospective observational study. From 1st of January 2009 to 1st 
of April 2013, consecutive CTC performed in the Canterbury, West Coast and 
Timaru regions of the South Island of NZ were retrieved from the PACS 
database. The retrospective nature of the study precluded individual patient 
consent. The study was approved by the national Health and Disability Ethics 
Committee and the Canterbury District Health Board approved locality 
assessment.  
The CTC examination was performed at seven different centres with similar 
imaging protocols. A rectal or stomal tube was inserted for air inflation, and 
a helical CT with 2.5mm slices was performed in prone and supine positions 
with a large field of view. Intravenous contrast was used if the diagnosis of 
malignancy was known or as indicated clinically. The presence of a distended 
distal bowel and rectal tube or a stomal tube ensured that the scan was a 
CTC. 
2.6.1 Measurements 
The entire available aorta from the series (usually from the descending aorta 
into the femoral bifurcation) was meticulously assessed. Measurements 
were performed with a digital magnified view, at eye level to avoid any 
parallax, using outer wall to outer wall diameters and fine electronic calipers 
also ensuring the line of measurement passed through the centre of the 
aneurysm (Figure 2.1) (126). Maximum short axis diameters were recorded 
to 0.1mm. The presence of thoracic and abdominal aorta >30mm, iliac and 
femoral arteries >20 mm and visceral artery >15mm were recorded.  The 
presence of previous aortic prosthetic grafts or endovascular stent grafts 
was also documented. All measurements were carried out by the same 






Figure 2.1 CTC transverse sections of the aorta with variations in diameter 
measurements 
(A) Aortic measurement performed in four different axes showing very similar AAA 
diameters between 3.30 and 3.39cm  
(B) An irregular-shaped AAA with diameters ranging between 3.95 and 4.48cm 
2.6.2 Patient data collection 
Death data was obtained from the hospital electronic database and 
ambiguous dates were checked by phone interview with patients or their 
family practitioner. It was noted that death records were not always accurate 
using the hospital’s patient-management software. Therefore, dates of death, 
deprivation status and ethnicity data were requested and obtained from the 
Ministry of Health National Minimum Data Set. 
Deprivation index was defined as the measure of the socioeconomic status 
of geographical areas based on the NZ 2013 census data where 1 is least 
deprived and 10 is most deprived (57).  Clinical risk factors, aneurysm 
location, CRC diagnosis and causes of death were collected from patients 
with aneurysms or previous aortic surgery. CTC radiologist reports were 
viewed to determine whether the presence of aneurysms was commented 
on and patients were on an AAA surveillance program. The largest aneurysm 
diameter was defined as the primary aneurysm and other aneurysms 
detected were referred to as secondary. Estimated predicted life-expectancy 
figures were obtained from the New Zealand life tables 2010-2012 
(www.stats.govt.nz) for a fictive population matched to age and sex (127). 
2.6.3 Validation of AAA measurement with CTC and USS 
Patients with AAA who had an US scan within 6 months before or after the 
index CTC study were identified. Maximum anterior-posterior diameter 
measurements were recorded as measured independently by the radiologist 
or sonographer at the time of the scan. At the time of the AAA measurement 
from the CTC, the investigator was blinded to the AAA US measurement. 
2.6.4 Statistical analysis 
Continuous variables were described as either mean (standard deviation, 
SD) or median (range or interquartile range, IQR) as appropriate, and 
categorical variables as percent frequencies.  Preliminary analysis indicated 
that the continuous explanatory variables (age and deprivation) were 
related to AAA presence (binary) on a linear rather than a logarithmic scale, 
therefore linear regression models were used to calculate unadjusted and 
adjusted rate differences (128). Risk ratios were also calculated for 
categorical variables using Poisson regression with robust standard errors 
due to non-convergence of log binomial models (129). Kaplan-Meier 
methodology was used for survival analysis and log-rank test was used for 
univariate group comparison. Cox proportional hazard models were used to 
calculate adjusted and unadjusted hazard ratios (HR) for variables 
influencing survival. Survival data was censored on the 1st of October 2014. 
The Pearson’s R test was used for correlation of a sample of patients that had 
a CTC and US of the AAA within a 6 months period. Statistical significance 
and 95% confidence intervals (CI) were calculated with an alpha of 0.05. 
Statistical analyses were performed using SPSS 22 for Mac (SPSS Inc., 
Chicago, IL). 
2.7 Results 
During the study period, 4915 CTC scans were performed on 4665 
individuals. Of these scans, 22 where coded on the PACS database as CTC 
studies but either were not a CTC when the scans were reviewed or the raw 
axial images were not stored and hence were excluded from any further 
analysis. Therefore, 4893 scans on 4644 patients with a male to female ratio 
of 1: 1.4 and a median (range) age of 69.2 (17.4 to 97.4) years were reviewed. 
No AAA was detected in 925 people aged <55 years old and this group has 
been excluded from any subsequent analysis (Figure 2.2). Median (range) 
age of the remaining 3719 individuals was 72.9 (55.0 to 97.4) years. There 
were 289 patients who had either an aneurysm in any location or a previous 
abdominal aortic prosthetic graft inserted.   The location of aneurysms and 
abnormal aortas detected are summarized in Table 2.1.  
Figure 2.2 Flow diagram representing the patient identification process  
 
Table 2.1 Proportion of >3cm thoracic/abdominal aneurysms and >2cm iliac/ 
femoral/ visceral aneurysms in 289 patients 
Location N 
AAA, native 223 (77.2%) 
AAA, graft † 26 (9.0%) 
Iliac 23 (8.0%) 
Thoracic 5 (1.7%) 
Femoral 1 (0.3%) 
Prosthetic graft ‡ 9 (3.1%) (6 open, 3 EVAR) 
Visceral 2 (0.7%) 
























2.7.1 Patient Demographics 
There were 223 patients with a native AAA and 3,496 without an AAA. 
Patients with an AAA were seven years older and more likely to be male than 
those without an AAA .  The proportion of patients with IHD, COPD, diabetes, 
hypertension, receiving a statin and have a smoking history was higher in 
the AAA group. The creatinine serum levels were similar between both 
groups. On the other hand, individuals without an AAA had a higher 
proportion of a cancer history than patients that had an AAA. The 
deprivation scores and ethnic composition were similar between both 
groups. The demographics and risk factors are presented in Table 2.2. 
 
Table 2.2 Demographics and baseline characteristics of patients undergoing CTC 
 AAA No AAA 
Age/ years, median (range) 79.7 (57.4-96.2) 72.2 (55-97.4) 
Males, n (%) 166 (74.4) 1387 (39.7) 












AAA diameter / cm, median (range) 3.3 (3-9.4) NA 









IHD, n (%)  113 (50.7) 683 (19.5) 
Statin, n (%)  139 (62.3) 1180 (33.8) 
Hypertension, n (%)  195 (87.4) 1822 (52.1) 
COPD, n (%)  51 (22.9) 354 (10.1) 
Creatinine/ µmol/L, mean  (SD) 106.7 (34.6) 89.0 (40.0) 
Diabetes, n (%)  43 (19.3) 455 (13.0) 
Cancer history, n (%) 19 (8.5) 484 (13.8) 












Deprivation index, n (%) 

















AAA in surveillance, n (%) 84 (37.3) NA 
Secondary aneurysm, n (%) 20 (9.0) NA 
AAA reported, n (%) 158 (70.9) NA 
Number of patients = 3719 
IHD: ischaemic heart disease, COPD: chronic obstructive pulmonary disease, SES: 
socioeconomic status, NA: not applicable 
Two hundred and fifty eight individuals had either a >3cm AAA or an 
abdominal aortic graft present. Of those, 223 had a native AAA, 26 had either 
a dilated prosthetic graft or a residual post-EVAR AAA sac > 3cm, and 9 had 
a <3cm aortic graft. The CTC identified 165 (74%) new incidental AAA and 
the rest had a known AAA on prior imaging. The median (range) age was 79.7 
(57.4-96.2) years, while 74.4% of those with AAA were male and 94.2% were 
of NZ European or European ethnicity. Native AAA in the infrarenal position 
was the most common aneurysmal site.  
2.7.2 AAA prevalence  
The overall prevalence (95%CI) of all AAA > 3cm was 258 amongst 3719 
individuals (6.9%, 95% CI: 6.1-7.8). After excluding 35 prosthetic AAA grafts, 
the prevalence was 223/3684 (6.1%, 95% CI: 5.3-6.9). The prevalence of 
native AAA in males and females 55-64.9, 65-74.9, 75-84.9 and >85 years of 
age was 1.3, 9.1, 16.8, 22.0% and 0.4, 2.0, 3.9 and 6.2% respectively 
(Figure 2.3).  
Figure 2.3 Prevalence of AAA stratified to age bracket and sex 
Number of patients = 233. Error bars present 95% confidence intervals. Blue bars 
indicate males, grey bars indicate females 
The distribution of native AAA diameter according to sex is presented in 
Figure 2.4. Regardless of gender, 72.2% (161/223) of AAA patients had a 3-
3.9cm aneurysm and 10.3% (23/223) had a >5 cm AAA.  
Figure 2.4 Distribution of AAA diameter stratified to sex  
Number of patients = 223. Blue bars indicate males, grey bars indicate females 
2.7.3 Predictors for AAA presence 
There was a significant association between presence of an AAA and 
advanced age (>55 years), with an increase in prevalence rate of 4% (95% 
CI: 3.0-5.0, P < 0.001) for each 10-year increase in age. Male gender was also 
a strong predictor for AAA presence with a risk ratio of 4.08 (95% CI: 3.1-
5.4, P < 0.001). Patients with a higher deprivation index (>5) were weakly 
associated with AAA at a univariate level (P<0.03). Ethnicity was not a 
significant predictor of AAA presence in this model (Table 2.3). 
  
Table 2.3 Predictors of AAA presence using a linear regression model 
IQR: interquartile range, CI: confidence intervals, ref: reference, † Adjusted for other 
variables in the model 
2.7.4 Location of patients undergoing CTC 
The number of CTC scans performed annually from 2009 to 2012 was 1039, 
1174, 1169 and 1178 respectively. Patients had their CTC examinations 
performed at four main locations: Timaru 2561 (55.1%), Christchurch 1113 
(24.0%), Ashburton 806 (17.4%) and the West Coast 164 (3.5%). 
Of the 3719 individuals analysed, 2012 had their CTC scans performed in 
Timaru, 936 in Christchurch, 648 in Ashburton and 123 in the West Coast 
region. The prevalence of AAA in each of the four geographical locations was 







95% CI P Risk 
difference 
95% CI P 
Age 79.7 (73.8-84.1) 
4% 3.0-5.0 < 0.01 4.0% 3.0-5.0 < 0.01 
Deprivation 6 (5) 0.3% 0-0.6 0.08 0.16% -0.1-0.5 0.2 
































































































































6.1% (95%CI: 5.10-7.19), 6.3% (95%CI: 4.92-8.05), 5.09% (95%CI: 3.65-
7.07) and 6.5% (95%CI: 3.89-13.32) respectively.  
2.7.5 Fate of patients with a native AAA 
Of the 223 individuals identified with a native AAA, 23 (10.3%) had an AAA 
greater than 5cm and of these, 12 subsequently underwent AAA repair (9 
open and 3 EVAR) during the follow-up period. Nine patients were thought 
not to benefit from repair; five due to medical comorbidities (primarily 
cognitive impairment), and four due to suprarenal extension of the 
aneurysm therefore deemed unfit for complex aortic procedures. Two 
patients were on surveillance (AAA <5.5cm). In all, 13 (56.5%) of those 
participants with a >5cm AAA were still alive at the completion of the study. 
Six died without repair, three died post-repair (>30days post operatively) 
and one died of an AAA rupture without repair. 
2.7.6 Late survival of the population 
The median (IQR) follow-up period was 3.2 (2.1-4.4) years. The Kaplan-
Meier survival curves for study participants with AAA compared to those 
without AAA is shown in Figure 2.5 and Table 2.4. The 5-year observed 
survival of those with AAA was 55.1% (standard error 5.0), compared to 
77.4% (0.9) in those without AAA (log-rank, P<0.0001). When adjusted for 
age and sex, the presence of AAA did not influence late survival, HR 1.24 
(95%CI: 0.97-1.58, P=0.086). Estimated predicted life-expectancy figures 
from the New Zealand life tables 2010-2012 were plotted on the same graph 
for comparison.   
There were 78 deaths in the AAA group. The causes of death during the study 
period were: 25 unknown causes, 19 cardiovascular, 14 cancer-related, 11 
respiratory, 5 multi-organ failures, 2 sepsis and 2 AAA ruptures in female 
patients (3.8 and 9.4cm AAA).  
A 
B 
Figure 2.5 Survival analaysis of individuals with and without AAA 
(A) Kaplan Meier observed (solid) and expected (dotted) survival curves of people 
with AAA (black line) and without AAA (grey line) (B) Cox proportional hazard of 
adjusted (age and sex) survival with expected (dotted) survival curves HR 1.24 
P<0.086  
Table 2.4 Cox proportional hazard model of variables affecting late survival 
HR: hazard ratio; CI: confidence intervals; Ref: reference † Adjusted for other variables in 
the model 
2.7.7 CTC versus US measurement study 
Of the 223 patients with a native AAA, 41 patients (18.4%) had undergone 
an US of the AAA within 6 months of the CTC examination. The investigator 
measuring AAA diameters using CTC was blinded to the results of the prior 
US scan. The median CTC and US AAA diameters were 4.1 and 4.2 cm 
respectively and there was excellent correlation between the two modalities 
(Pearson’s R Correlation coefficient r=0.96, P <0.001). The potential source 
of bias in measuring AAA between CTC and US was tested using the Bland-
Altman methodology. The mean difference was -0.06cm (limits of 




Unadjusted Adjusted † 
Variable HR 95% CI P HR 95% CI P 
Age per decade 2.46 2.25-2.69 <0.001 2.46 2.25-2.70 <0.01 
Sex (female) 0.61 0.53-0.71 <0.001 0.59 0.51-0.69 <0.01 
AAA presence 2.28 1.8-2.88 <0.001 1.24 0.97-1.58 0.083 






























Figure 2.6 Bland- Altman plot showing the differences in aortic measurements 
between CTC and US  
2.8 Discussion 
In this study the prevalence of AAA in patients undergoing investigation with 
a CTC in the South Island of New Zealand was documented. A prevalence of 
6.1% of AAA in individuals aged >55 was observed. This was similar to the 
prevalence that was observed with the randomized controlled screening 
trials that were conducted approximately 10 to 20 years ago in Western 
Australia (Health in Men Study, 7.2%) and the UK (MASS trial 4.9% and 
Chichester study, 7.6%) (22, 45, 130).   
This study specifically aimed to use CTC to determine AAA prevalence. 
Previous studies reporting extra-colonic findings from CTC varied with 
respect to AAA prevalence, ranging from 1.4% to 5.4% despite similar 
demographics of groups included (131-133) as shown in Table 2.5. In 
contrast to previous studies which did not primarily focus on the status of 
the abdominal aorta, our current study represents the largest series to date 
specifically detecting AAA within a CTC patient cohort. 
Table 2.5 Reported AAA prevalence from CTC studies  
Author Setting Year of 
publication 
N Age Male 
(%) 
Prevalence (%) 
Cash (131) USA 2012 1410 75 (NR) 58 0.5 
Moore (132) NZ 2012 2142 59 (19-87) 47 1.4 
Hellstrom 
(133) 
Sweden 2004 111 66 (19-86) 59 5.4 
Current (134) NZ 2015 4644 69 (17-97) 43 4.8 
NZ: New Zealand, NR: not reported, N: number 
2.8.1 AAA NZ prevalence 
In NZ, prior to a very recent study, the prevalence of AAA in the population 
was unknown. In the study by Majeed and colleagues published in 2015, 
10,403 patients undergoing a transthoracic echocardiogram were also 
examined by an US for the presence of AAA.  In men aged 65-74 years the 
AAA prevalence was 4.7% and rose to 8.5% in those 75-84 years (135). In 
this current study, the age-specific AAA prevalence rate detected by CTC was 
similar to that in patients undergoing echocardiography.  Although increased 
AAA prevalence has been reported in association with severe 
(angiographically confirmed) coronary artery disease (108), the large 
proportion of angiographically normal subjects under evaluation for 
valvular disease in an ‘echo-cohort’ would most-likely mask a coronary-
disease-driven prevalance effect. In addition, some of the differences 
between the echo-studied population and this study might be due to 
differences in AAA measurement between CT and US. Nevertheless, both 
studies highlight the relatively high burden of AAA prevalence in NZ as 
shown in Figure 2.7. 
2.8.2 Combining all AAA prevalence studies from NZ 
On the 3rd and 4th of July 2015, the NZ AAA screening working group met in 
Christchurch to discuss the existing knowledge of AAA prevalence, 
implications of a national program and translating contemporary evidence 
to areas where research is required. The results of six independent selective 
groups revealed a consistent high prevalence of AAA among the studies (135, 
136). The prevalence ranged between 3.2-6% depending on the average age 
of the group and the method the population was selected or invited. The 
prevalence from each study stratified to sex is presented in Figure 2.7. 
Figure 2.7 Prevalence of AAA from the CTC and transthoracic echo studies stratified 





















76.7  78.7  76.4  75.4  78.1  68.9  AAA age for 
each study 79.5  79.0  78.7  78.3  77.1  70.3  
Figure 2.8 Prevalence of AAA in each study group stratified into sex  
The average age (in years) for males and females for each group is reported above the 
bar chart 
2.8.3 International AAA prevalence  
A systematic review and meta-analysis of 14 AAA screening population 
studies revealed a prevalence range of 4.2 to 14.2% in men and 0.35 to 6.2% 
in women (137). Our estimated prevalence is similar to previous population 
studies. In this study, 942 people were over the age of 80 years, of which 554 
(58.8%) were female. This particular group has not been included previously 
in the screening trials. Data from this study has extended the knowledge of 
AAA prevalence in octogenarians; a group with an improved life expectancy 
that hasn’t been included in previous population AAA studies. It is expected, 
given that the prevalence of AAA increases with age, that more people will 
require management in terms of risk factor modification, decision 






































Variations within international AAA screening programs include differences 
with respect to the targeted population, interval of surveillance scans and 
size prior to consideration for surgical treatment (46). The epidemiology of 
AAA is changing globally with a decrease in AAA mortality observed in 
countries such as England, Australia and New Zealand, whereas an increase 
in mortality has been reported from Hungary, Denmark, Austria and 
Romania (17). Despite a lower AAA prevalence reported from Sweden and 
England, screening for AAA appears to remain cost-effective (101). 
It is unclear whether the study population is truly representative of the 
general South Island NZ population. A direct “cause and effect” between CRC 
and AAA prevalence has not been established but it has been estimated that 
approximately 0.3-3.8% of AAA will have a concomitant CRC present at the 
time of the diagnosis (140). CRC and AAA share some risk factors such as 
smoking, age and male gender. Cardiovascular risk factors for the people 
without an AAA and the prevalence of CRC were not available to allow such 
analysis. In this AAA group, the prevalence of CRC was 8.5%, higher than 
previously estimated, which is likely to be due to the selection process of 
undergoing a CTC.  
2.8.4 The impact of CTC on AAA detection 
In Canterbury, the use of CTC has gained popularity as an alternative to 
colonoscopy due to constraints in the public health sector. Between October 
2010 and February 2016, there were 568 patients with small aneurysms 
seen in a nurse-led aneurysm clinic in Christchurch Hospital. Of these, 97 
(17.1%) patients were diagnosed with their AAA by a CTC and the remaining 
were diagnosed by other radiological modalities. The patients diagnosed by 
a CTC were on average two years older, but there were no major baseline 
differences in comorbidities between the CTC cohort and patients referred 
by other radiological modalities (141). This further supports that this 
apparent potential bias for selecting individuals undergoing a CTC does not 
appear a marker of a higher risk profile. 
The survival following elective AAA repair was lower than the expected 
survival of the age- and sex-matched population (142), and the presence of 
AAA itself appeared to be an independent predictor of reduced survival. 
Previous studies have reported that non-AAA-related deaths are more 
common in patients undergoing small AAA surveillance than AAA-related 
deaths (143). Our current study is consistent with these observations, with 
the leading causes of death amongst patients with AAA undergoing CTC 
being cardiovascular and oncological conditions.  
CT was used for AAA detection in this study, whereas the randomised 
screening studies used an US and in some, a targeted aortic US scan was used. 
The advantages of a CT for screening AAA was noted in this study with 
detection of 23 isolated iliac aneurysms, 5 thoracic aneurysms, 2 visceral 
aneurysms and late graft complications following AAA repair.  A study from 
a Veteran Affairs (VA) centre where dedicated vascular technicians included 
the iliac arteries in AAA-screening ultrasound scans detected a 0.1% isolated 
iliac aneurysms (92). Our results revealed an isolated iliac aneurysm in 
23/3719 (0.6%) of patients undergoing CTC.  
2.8.5 Other potential advantages from the CTC 
Amongst the 4644 individuals identified in this study, 65 (1.4%) of the AAA 
detected did not have a formal diagnosis or comment on the presence of AAA 
during the CTC-reporting process. Such underreporting of incidental AAA 
has been observed previously in 4112 patients undergoing CT of which 53 
(1.3%) patients did not have the aortic dilatation recognised or reported 
(144). Based on these findings, it is recommend that the abdominal aorta 
should be specifically screened for an AAA when people undergo abdominal 
CT scans particularly in those over the age of 55 years. 
Therefore, in this current study, the primary general practitioners of patients 
with an aneurysm incidentally detected from the CTC who were not initially 
diagnosed or not followed were informed of the diagnosis, and US 
surveillance scan was initiated for patients who might benefit from repair 
should the AAA reach threshold.  
2.9 Limitations 
2.9.1 Population studied 
In this study, the CTC population selected to act as a surrogate for AAA 
prevalence might not represent the true sample of the general population. 
This population was relatively older and included a high proportion of 
women which differs from the population screening AAA studies. 
CRC shares some mutual risk factors with AAA disease- age (although five 
years younger in CRC), a smoking history and being a male. Other “weaker” 
association include poor diet (less fruits and vegetables) and higher 
deprivation (low SES). Therefore, the high prevalence of AAA observed in 
this study might be due to the selection process. 
This study and the other AAA prevalence cohorts were all based in the South 
Island and hence might not be generalizable to the overall NZ population as 
the certain demographics such as a higher proportion of people who identify 
as a NZ European or of European descent. This was noted in this study since 
the proportion of Maori was only 2%, which is less than the 6-7% expected 
population in this geographical region. 
The pathway and indications for obtaining a CTC includes examination 
findings such as abdominal pain and palpable masses, which both might be 
present with an AAA. Therefore this might steer physicians to refer patients 
to a CTC. This selection bias might partially explain the high prevalence of 
AAA observed in this study.  
In addition, this cohort had a lower observed survival than that expected of 
the total population, and some of the patients might have a reduced life 
expectancy due to a cancer diagnosis as demonstrated by 8.5% of AAA 
patients having a history of cancer and 13.5% in the non-AAA group. 
The selection process of patients into this study was different to population 
screening studies. This population of this study sought medical attention due 
to symptoms or clinical concerns which are different from those of invited 
participants included in other aneurysm screening studies. This was 
reflected by a representative sample from all socioeconomic groups. This is 
relevant given that it is widely accepted that people with lower 
socioeconomic status and/ or living in more deprived geographical areas 
have lower attendance rates to AAA screening and appear to be more likely 
to have the condition (145).  
2.9.2 Measurement differences 
Variations in diameter measurements between CT and US have been 
reported with CT measurements reporting a larger diameter, which might 
not represent the “true” maximal difference (138). During an US 
measurement, the transducer can be tilted to measure a true diameter even 
in the presence of aortic tortuosity.  In addition, the cardiac cycle phase 
during a CT is unknown and is not routinely controlled for. The use of CT to 
measure AAA might lead to underestimation of AAA size due to the unknown 
phase of the cardiac cycle.  US measurements carry a 1.9mm average 
difference between systolic and diastolic peak recordings (139).  Despite the 
well-documented differences between the two modalities (US and CT), the 
methods used in this study appeared to have minimized these differences 
and similar AAA diameters were attained.  
2.9.3 Retrospective nature 
This was a retrospective study and therefore the collection of clinical risk 
factors could only be as accurate as that documented on electronic medical 
charts and health records. A prospectively designed study with direct patient 
assessment would have been more ideal. However, the study time duration, 
costs and resources required to conduct such a prospective longitudinal 
study are important constraining factors that need to be considered. 
2.10 Conclusions 
In conclusion, the prevalence of AAA in a population undergoing CTC for 
gastrointestinal symptoms in the South Island of NZ is relatively high and 
warrants further evaluation. The prevalence of AAA both in males and 
females rose steeply with age. The results acquired in this observational 
study seem to support a national population AAA-screening program in men 
and possibly in women in the light of European cost-effectiveness data in a 
context with lower AAA prevalence. 
2.11 Further Work 
Using the CTC program, I was able to provide information on the prevalence 
of AAA in this selected population residing in the South Island of New 
Zealand. The presence of AAA did not appear to influence survival when age 
and sex were adjusted for. This selected population might represent a group 
that would benefit from AAA screening. 
Since aortic diameters are a continuous variable, it is important to determine 
whether a change in aortic diameter increases mortality and if there are any 
differences in certain subgroups stratified to age, ethnicity or gender. 
However, the aortic diameter of this population should be known to assist in 
defining the AAA. In addition, demographics, ethnicity and cardiovascular 
risk factors might influence aortic size and need to be taken into account. 
 
3.1 Overview 
The diameter of the aorta is a continuous variable.  The threshold to define 
an aortic aneurysms is usually set at certain cut-offs but variables influencing 
the diameter of the aorta have been reported in some populations. There are 
three key factors which influence the stage at which an AAA is clinically 
defined to be present, these being: the radiological modality used, the aortic 
wall anatomical reference points used to measure the diameter and the 
precise definition of what constitutes an AAA. 
The normal age, gender and ethnicity-specific aortic dimensions have not 
been documented within the New Zealand population. With a multi-ethnic 
society, determining the “normal” aortic diameter is important for diagnostic 
and therapeutic purposes. Māori New Zealanders, being of Polynesian 
descent, may have aortic diameters that differ from New Zealanders of 
European ancestry. Ideally, any formal aortic-screening programme should 
base its aneurysm definition on local reference-group data, rather than data 
from different populations or historical sources. 
Differences in aortic diameter between genders have also been well 
documented. However, studies rarely separate analysis into gender sub-
groups. Throughout this chapter, data is presented and analysed according 
to gender groups to provide a better understanding of AAA disease in males 
and females. 
In chapter two, the prevalence of AAA in a selected population has been 
determined.  In this chapter the focus is on the normal aorta and definition 
of AAA, predictors of AAA development and the effect of AAA diameter on 
survival. 
3.2 Contribution 
In this chapter, my responsibility was to collect, measure and analyse the 
data presented. There were two medical students that formally assisted in 
collecting some of the data presented in this chapter as part of the 2015 
summer studentship programme. M Osman assisted in acquiring some of the 
risk factors data and A Gupta measured some of the normal aortas.   
3.3 Publications  
Abstract – Conference proceedings  
Khashram M, Gupta A, Osman M, Jones G, Roake J. Evaluation of Aortic 
Diameters in a Population Undergoing CT Colonography: Prevalence and 
Effect on Survival. Journal of Vascular Surgery. 62(2):537. 
3.4 Background 
3.4.1 The “normal” aorta and definition of AAA 
The definition of an AAA varies in the reported literature as normal aortic 
diameters differ with respect to age, sex, ethnicity and body size. There are, 
however, four generally well-accepted definitions of AAA reported in the 
literature: >3cm of the infra renal aorta (146), >1.5x suprarenal aorta (147), 
>4cm or exceeding the suprarenal segment by <0.5cm (148) or >1.5x the 
normal predicted infrarenal diameter (3). 
The first attempt to document the diameters of the normal abdominal aorta 
was reported by Steinberg and colleagues in 1965 (146). Following injection 
of intravenous contrast, an anteroposterior radiological film was performed 
and the abdominal aorta was measured at different locations. Aortic 
diameters > 3cm were defined as an aneurysm in both males and females 
and the authors also noted significant differences in diameters between 
genders. 
A further method proposed by Sterpetti et al. using a transabdominal 
ultrasound measured the diameter of the aorta in the segment above the 
aneurysm (suprarenal) and the maximum AAA diameter to provide a ratio 
of the measurements (147). Using this approach requires accurate 
measurements of the suprarenal aorta, which can be technically challenging 
for sonographers and has not been routinely measured in large AAA 
population or screening studies.    
The Society for Vascular Surgery (SVS) and the International Society of 
Cardiovascular Surgery suggest using 1.5 times the predicted normal 
diameter. However, data on predicted aortic values have been limited and 
not widely used. Sonesson et al. were the first to present nomograms 
predicting aortic size from 146 healthy white male and female volunteers. It 
was noted that the aortic diameters positively correlated with body surface 
area (149). These findings were not reproducible when a larger study 
including 69,905 veterans from the USA with an infrarenal diameter of <3cm 
was conducted. The American study found that there was a very small 
association (0.1cm change) between body size, ethnicity and gender (150) 
and suggested that a simple definition of AAA (>3cm) should be used. 
To put these differences in AAA definitions into clinical practice, a study from 
the Norsjö municipality (northern Sweden) measured the aneurysms of 504 
individuals aged between 65 and 75 years old and the various definitions 
were used. The prevalence of AAA ranged between 6.9% to 16.9% in males 
and 1.2% to 9.8% in females (151). 
Variations of normal aortic diameters between different ethnicities have also 
been observed. For example, the Multi-Ethnic Study of Atherosclerosis 
reported that Hispanic, African and Chinese Americans had smaller 
infrarenal aortic diameters than Caucasian Americans after adjusting for 
body size measurements (152). Data on normal aortic diameters from non-
Western countries is very limited.  A cross-sectional study of Chinese 
hypertensive adults reported an average infrarenal aortic diameter of 
1.55cm in males and 1.38cm in females (153). A study from three centres in 
South Korea using an US to measure the abdominal aorta of 1218 individuals 
reported a mean infrarenal aortic diameter for males and females of 1.90 and 
1.79cm respectively (154). The only study reported from India examined 
142 individuals and documented a mean aortic diameter of 1.46 and 1.33cm 
for males and females respectively (155). These differences might influence 
how AAA is defined and managed when setting thresholds for surveillance 
or treatment in different ethnic groups.  
3.4.2 Aortic diameter and influence on survival 
Aortic diameter differences between genders has been well documented but 
due to aortic aneurysmal disease being more prevalent in males and a 
tendency to report overall rather than gender-specific data, the impact of 
this gender difference is not well-understood. An index referred to as the 
aortic size index (ASI), which is calculated by dividing the aortic diameter by 
the body surface area, has been proposed to standardize such differences. 
This index was first reported to predict thoracic aneurysm rupture or 
dissections (156) and subsequently has been shown to be a better predictor 
of AAA rupture in females compared to absolute AAA diameter (157). 
Individuals with aortic sizes smaller or larger than the average normal aortic 
diameter appear to be at a greater risk of death. The Western Australian AAA 
screening study (Health in Men Study) including 12,203 men revealed that 
aortic diameters of 10-18mm had an increased risk of mortality (hazard 
ratio HR of 1.23 (95% CI: 1.03-1.46)) compared to men with aortic diameters 
of 19-22mm (158). The Cardiovascular Health Study showed that the 
presence of AAA was an independent risk of cardiovascular disease events 
and mortality (159).  A further population-based study from the Tromsø, 
Norway, including 6640 individuals with a 10-year follow-up revealed that 
the presence of AAA and an increase in aortic diameter were independent 
predictors of overall and cardiovascular mortality.  
3.5 Objectives 
The objectives of this chapter were to document the normal abdominal aorta 
diameter for a large New Zealand population and to compare the aortic 
diameters of Māori and non-Māori individuals, to determine predictors of 
increased aortic size and those associated with AAA development and finally 
to report the influence of aortic diameter on overall patient survival.  
3.6 Methods 
Ethical approval was granted by the HDEC and the local hospital board also 
approved the study (Ref 13/STH/190/AM01). 
3.6.1 Study population  
Consecutive patients undergoing CT Colonography (CTC) for 
gastrointestinal symptoms in the Canterbury region of the South Island from 
January 2009 to April 2013 were identified from the PACS database. 
3.6.2 Aortic measurements 
The methods of aortic measurements have been covered in chapter 2. 
Briefly, the aorta was digitally magnified and measurements were 
performed at eye level to avoid parallax. Fine electronic calipers were placed 
on the outer to outer diameter of the aortic wall passing through the centre 
of the aorta in the maximum short axis plane.  Careful attention was applied 
to ensure that the origins of the mesenteric and renal vessels were not 
included in the measurement.  
Two investigators measured the aortic diameters: MK, principal investigator 
(PI) and AG, medical student. The student was blinded to the principal 
investigator’s measurements and was not aware of the aortic diameters or 
of which patients had a prior diagnosis of aneurysm. 
3.6.2.1 Levels of aortic measurement 
The aorta was measured at five levels: 
x Supraceliac (distal descending thoracic aorta) proximal to the crux 
complex within 1cm 
x Suprarenal within 1cm from the renal arteries (proximal)  
x Infrarenal within 1cm from the lowest renal artery (main artery, not 
accessory)  
x Mid infrarenal aorta or the maximum dilatation point  
x Distal aorta 1cm prior to the bifurcation 
3.6.2.2 Validation of measurements 
All aortas with a change in diameter were measured (chapter 2). A second 
investigator who was trained in measuring aortas recorded the diameter of 
the remaining aortas after multiple sets of validations.  
It was noted that the descending/ supraceliac aortic segment anatomically 
changes diameter and direction with a marked difference in anteroposterior 
and lateral measurements.  Therefore, all aortic diameters taken at this level 
which measured >2.5cm were re-measured taking into account this 
anatomical course, and the aortas at the infrarenal level which were >2.7cm 
were also re-measured by the PI for quality assurance. In addition, some 
scans which had no arterial contrast, no aortic calcification or a very subtle 
demarcation of the diaphragmatic crux were referred to the PI for 
measuring.  
3.6.3 Definitions 
Comorbidities were collected from hospitals’ electronic medical records and 
primary health records. In addition, further departmental databases were 
interrogated to assist and improve comorbidity-reporting accuracy: cancer, 
cardiology diagnostic/interventional and spirometry databases.  
Cardiovascular risk-factors and patient co-morbidities were defined as 
following: Cancer history was defined as having a cancer diagnosis prior to 
the CTC or having the cancer diagnosed by the CTC, and benign 
skin/cutaneous skin (non-melanoma) lesions were not included. Diabetes 
was defined as using oral hypoglycaemic or insulin therapy. Hypertension 
was defined as being treated with any anti-hypertensive agent rather than 
blood-pressure recordings. Statin use or the use of other lipid modifying 
agents was defined as being treated with a cholesterol-modifying medication 
around the time of the CTC. Ischaemic heart disease (IHD) was defined as the 
presence of coronary disease based on symptoms (angina), angiography 
findings, coronary events (myocardial ischaemia) or coronary interventions 
(coronary artery bypass grafting/percutaneous coronary interventions). 
Chronic obstructive pulmonary disease (COPD) was defined clinically or by 
the means of spirometry tests. Serum creatinine levels were recorded from 
the day nearest to the CTC study and renal impairment was defined as 
creatinine >150mmol/L. Weight and height recordings were measured from 
clinical records, departmental databases and primary general-practitioner 
records to the nearest records. For the purposes of this study, it was assumed 
that height did not change but weight recordings used were obtained closest 
to the time of the study as possible.  Subsequent body surface area (BSA) 
using Du Bois method (BSA= 0.007184 x Weight0.425 x Height0.725) and body 
mass index (BMI) were used to calculate anthropologic measurements 
(BMI=weight (kg)/height2 (m)). The aortic-size index (ASI) was calculated 
by BSA/maximum infrarenal aortic diameter (cm/m2). 
3.6.4 Data acquisition of aortic diameters in Māori 
As noted in chapter 2, the overall number of Māori from the CTC cohort was 
relatively smaller than to provide meaningful conclusions on aortic size. An 
enquiry was made into other vascular surgery departments in NZ requesting 
data on measured aortas of Māori older than 40 years. There were four 
independent datasets provided from three geographical locations: 
x Waikato Hospital – Consecutive Māori CT abdomen scans from a 
tertiary centre performed February 2014 - October 2015. 
x Waitemata primary health group- Māori primary care staff 
screening with an ultrasound in May-June 2016 as part of a pilot 
study to investigate the prevalence of AAA in Māori 
x Waitemata (Northshore) Hospital- Consecutive CTC performed on 
Māori from June 2007 to Dec 2014 
x Otago primary health group– Māori with known AAA or who had 
an elevated 5-year cardiovascular disease-risk assessment >10% 
were invited for an abdominal aortic US scan. 
Māori ethnicity was based on self-identification or identification from 
electronic health records. Since this data was requested retrospectively, 
demographics and comorbidities were missing for ~40-50% participants. 
The additional aortic diameters from Māori were only used in this chapter to 
determine the age and sex adjusted normal aortic diameter and this was 
compared to the aortic diameters of patients identifying as NZ European. 
3.6.5 Statistical analysis 
The NHI for each individual was linked to the Ministry of Health National 
Minimum Data Set. Deprivation, ethnicity and survival status were added 
into the CTC database. Continuous variables were expressed as mean (SD) 
or median (range, interquartile range) and categorical variables were 
presented as absolute values (percentages, %) where appropriate. Data was 
considered normally distributed if z-scores were within ±2.58. Limits of 
agreement between the measurements by the two investigators were 
calculated using the Bland-Altman technique (160). 
A univariate and multivariate linear regression model using the aortic 
diameter as the dependent variable determined the relationships between 
infrarenal aortic diameter and age, sex and ethnicity for the added Māori 
data. Clinically important predictors of AAA presence were entered into a 
logistic regression model and odds ratio (OR) for each variable was 
calculated. Univariate analysis was assessed individually, then statistical-
significant and clinical-relevant variables were included into the 
multivariable model where appropriate. A time-to-event survival analysis 
was undertaken to determine predictors of survival. Cox proportional 
hazard models were used to define predictors of survival and risks of 
mortality presented as hazard ratios (HR). Individual status (alive or dead) 
was censored on the 14th of March 2016. Statistical significance was set at 
P<0.05 and analyses were performed using SPSS 23 for Mac (SPSS Inc., 
Chicago, IL). 
3.7 Results 
In all 4,644 patients were included in this study with a median (range) age 
of 69.2 (17-97) years of which 2711 (58.4%) were females. The 
demographics and comorbidities stratified into sex are presented in 
Table 3.1. 
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(IQR) 
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Weight, kg (SD) 83.4 (16.9) 72.3 (18.1) 76.9 1352 (29.1) 
Height, cm (SD) 173.8 (7.0) 160.7 (6.6) 160 2261 (48.7) 
BSA, m2 (SD) 2.0 (0.2) 1.8 (0.2) 1.9 (0.2) 2264 (48.8) 
BMI, kg/m2 (SD) 27.9 (5.1) 28.6 (6.8) 28.3 (6.1) 2241 (48.3) 
ASI median (IQR) 1.02 (0.93-1.16) 0.97 (0.87-1.09) 0.99  2264 (48.8) 
IHD 413 (22.0) 412 (15.7) 825 (17.8) 133 (2.9) 
COPD 227 (12.1) 198 (7.6) 425 (9.4) 143 (3.1) 
Renal impairment 128 (6.6) 57 (2.1) 185 (4) 0 
Diabetes 248 (13.2) 296 (11.3) 544 (12.1) 135 (2.9) 
Hypertension 1187 (50.2) 1225 (46.6) 2169 (48.1) 137 (3.0) 
Statin use 692 (36.8) 721 (27.4) 1413 (31.4) 138 (3.0) 
Cancer history 298 (15.4) 265 (9.8) 563 (12.1) 0 
Numbers in parenthesis are percent unless stated otherwise. 
BSA: body surface area, BMI: body mass index, ASI: aortic size index, IHD: ischaemic heart 
disease, COPD: chronic pulmonary obstructive disease, IQR: interquartile range, SD: 
standard deviation. 
3.7.1 Aortic diameters 
There was a general decrease in median aortic diameter at each anatomical 
level in both males and females. The median (IQR) of aortic diameters at the 
supraceliac, suprarenal, proximal infrarenal, mid infrarenal and aortic 
bifurcation are presented in Table 3.2.  
Table 3.2 Aortic diameters for each anatomical site among males and females 
Anatomical  level Males Females Total 
Supraceliac 2.59 (2.42-2.72) 2.39 (2.21-2.56) 2.47 (2.28-2.65) 
Suprarenal 2.26 (2.09 2.43) 2.00 (1.85-2.18 2.11 (1.92-2.30) 
Proximal infrarenal 2.03 (1.87-2.22) 1.77 (1.62-1.93) 1.87 (1.70-2.08) 
Mid infrarenal 2.00 (1.84-2.23) 1.70 (1.57-1.86) 1.82 (1.65-2.03) 
Aortic bifurcation 1.92 (1.77-2.11) 1.62 (1.50-1.77) 1.74 (1.57-1.95) 
All diameters in centimetres. Numbers in parathesis are interquartile range 
The mid infrarenal aorta was the only aortic segment that dilated with an 











































































3.7.2 Infrarenal aortic diameters 
The infrarenal aorta diameter was not normally distributed as assessed by 
Shapiro-Wilk’s test (P<0.001) in both males and females and it was 
positively skewed in both males (z=3.36) and females (z=5.63). The median 
(Q1-Q3) aortic diameter for males and females was 2.00 (1.84-2.23) and 1.77 
(1.57-1.86) respectively. Percentile plots of the infrarenal aorta revealed 
different distributions for males and females and an exponential rise around 
the 87.5th to 90th percentile in males and the 92.5th to 95th percentile in 
females (Figure 3.2). 
Figure 3.2 Percentile plot of the infrarenal aortic diameter of males and females  
3.7.3 Influence of age and sex on infrarenal aortic diameters 
The aortic diameter of subjects increased with age and males had a larger 
aorta in all age groups compared to females. For males, the median (IQR) in 
<45, 45-54, 55-64, 65-74, 75-84, >85 years was 1.66 (1.52-1.75), 1.85 (1.73-
1.97), 1.93 (1.81-2.07), 2.03 (1.88-2.23), 2.16 (1.98-2.50) and 2.25 (2-2.94) 
respectively. The corresponding values for females were: 1.47 (1.39-1.59), 
1.61 (1.51-1.72), 1.65 (1.55-1.77), 1.72 (1.61-1.86), 1.78 (1.63-1.98) and 
1.87 (1.69-2.16), as shown graphically with statistical confidence intervals 
in Figure 3.3. 
 
 <45 45-50 50-55 55-60 60-65 65-70 70-75 75-80 80-85 >85 
Males 116 114 150 185 209 246 251 274 230 158 
Females 189 150 206 244 307 300 394 367 309 245 
Figure 3.3 Median infrarenal aortic diameter stratified according to age groups 
and sex  
Number of patients in each category is shown below  
3.7.4 Sub-group analysis of Māori Aortic Diameters 
After combining the five data sets of Māori aortic diameters, there were 1086 
individuals with infra renal aorta measured. The median (range) age was 
62.2 (40.0-96.7) years and 591 (54.4%) were females. The data comprised 
of 688 patients from Waikato, 112 from Canterbury, 100 from North Shore 
Hospital, 73 from Otago and 51 from Waitemata public health screening. 
There were 62 (5.7%) Māori with greater than or equal to 3.0 cm aortas and 
these were excluded from the model building, and there was one patient who 
had a previous EVAR stent-graft and was also excluded. To allow 
comparison, consecutive patients >40 years old identified as NZ European 
were extracted from the CTC group.  
3.7.4.1 Population Demographic  
The NZ Maori cohort was on average younger and had a higher proportion 
of current smokers, diabetes, renal impairment and IHD. Statin use was 
lower in NZ Maori and hypertension was similar between the NZ Maori and 
NZ European individuals (Table 3-3).  
Table 3.3 Baseline demographics and clinical profile of Maori and European 
subgroup 








Number in cohort  456 (9.3) 1521 (31.0) 568 (11.6) 2362 (48.1) - 
Age, years (SD) 62.4 (9.9) 67.7 (12.5) 61.1 (11.5) 68.8 (12.5) - 
Diabetes 117 (26.9) 185 (12.5) 139 (26.8) 259 (11.3) 213 (4.3) 






















Renal impairment 38 (11.9) 94 (6.2) 27 (6.3) 52 (2.2) 276 (5.6) 
Statin use 86 (27.0) 525 (35.4) 100 (23.4) 642 (28.1) 391 (8.0) 
Numbers in parenthesis are percentages (unless otherwise stated) 
3.7.4.2 Comparison of aortic diameters amongst NZ European & Māori 
The CTC cohort contributed to the NZ European aortic diameter data and 
there were 4135 NZ Europeans older than 40 years, of which 2426 (58.7%) 
were females. 249 (6.0%) individuals had a > 3cm infrarenal aorta and were 
excluded from this analysis.  
The demographic data for the non-aneurysm participants are shown in 
Table 3.4, and the age- and gender-stratified infrarenal aorta median 
diameters in Table 3.7. 













Number in cohort (%) 456 (9.3) 1523 (31.0) 568 (11.6) 2362 (48.1) 
Age, years (SD) 62.4 (9.9) 67.7 (12.5) 61.1 (11.5) 68.8 (12.5) 
Mean aortic diameter, cm (SD) 2.05 (0.29) 2.02 (0.26) 1.80 (0.27) 1.74 (0.24) 










SD: standard deviation, IQR: interquartile range. 
3.7.4.3 Predictors of larger aortic diameters  
The relevant predictors of larger aortic were entered into a linear regression 
model as independent variables. Univariate analyses indicate that older age, 
males, hypertension and renal impairment were significant in both Maori 
and NZ Europeans. A history of smoking and statin use was associated with 
larger aortic diameters in NZ European but not in NZ Maori (Table 3.5). 
  
Table 3.5 Univariate variables associated with a larger aortic diameter 
  NZ Maori 
n=1024 








P Intercept Unstandardised 
coefficients (SE) 
P 
Age (per year) 1.482 0.007 (0.001) <0.00
1 
1.366 0.007 (0) <0.001 
Males 1.799 0.248 (0.017) <0.00
1 
1.738 0.278 (0.008) <0.001 
Diabetes 1.892 0.033 (0.022) 0.136 1.844 0.040 (0.014) 0.004 
Hypertension 1.879 0.065 (0.019) 0.001 1.812 0.076 (0.009) 0.001 
Smoking 
history 
1.916 -0.009 (0.020) 0.655 1.829 0.054 (0.010) 0.001 
Renal 
impairment 
1.887 0.094 (0.41) 0.022 1.840 0.180 (0.023) 0.001 
Statin use 1.882 0.052 (0.027) 0.051 1.828 0.068 (0.010) 0.001 
 
After adjustment, only older age and males remained significant predictors 
of larger infrarenal aortic diameters in both NZ Maori and NZ European. A 
history of smoking remained a predictor in NZ European individuals but not 
in Māori (Table 3.6). 
  
Table 3.6 Multivariate linear regression model of aortic diameters 
 
 NZ Maori 
Adjusted R2 = 0.201 
 NZ European 







Age per year 0.05 (0.001) <0.001 0.007 (0) <0.001 
Males 0.242 (0.021) <0.001 0.279 (0.008) <0.001 
Diabetes 0.016 (0.026) 0.525 -0.004 (0.012) 0.736 
Hypertension 0.040 (0.023) 0.090 0.001 (0.008) 0.870 
Smoking history - - 0.030 (0.008) <0.001 
Renal impairment 0.015 (0.038) 0.689 0.028 (0.020) 0.151 
Statin use -0.012 (0.027) 0.646 0.008 (0.009) 0.373 
Intercept 1.444 (0.058) <0.001 1.217 (0.022) <0.001 
  




Males Māori Females 
NZ European 
Females 









<60 1.97 173 1.87 444 1.71 261 1.63 606 
60-64 2.03 105 1.94 173 1.75 102 1.67 284 
65-69 2.10 71 1.97 201 1.90 81 1.69 273 
70-74 2.10 62 2.03 205 1.82 54 1.73 359 
75-79 2.09 24 2.07 215 1.92 33 1.76 334 
80+ 2.10 21 2.14 285 2.00 37 1.82 507 
N= number of individuals  
Figure 3.4 Predicted linear model of infrarenal aortic diameters in Māori and 
NZ European by age  
As shown in Figure 3.4, the median aortic diameter increased with age in 
both Māori and NZ Europeans. The predicted aortic diameter of Māori 
females remained larger than NZ European females by 0.12mm throughout 
the investigated age range. In males, the difference in average aortic 
diameters was inconsistent and the slopes converged with increasing age.  
The predicted aortic diameter for a 67-year-old NZ European male, Māori 
male, NZ European female and Māori female was 2.01, 2.07, 1.73 and 1.84 
cm respectively (Table 3.8).  








aortic diameter  
2.07 (2.04-2.10) 2.01 (2.00- 2.02) 1.84 (1.82 - 1.87) 1.73 (1.72 - 1.74) 
Slope  0.05 (0.02- 0.07) 0.08 (0.07 - 0.09) 0.07 (0.05 - 0.09) 0.07 (0.06 - 0.08) 
Intercept at 67 years old (average age) 
3.8 Predictors of a larger aorta 
For patients undergoing CTC, a linear regression model was built using 
aortic diameter as the dependent variable and clinically important variables 
as possible predictors for all individuals greater than or equal to 50 years old 
with an infrarenal aortic diameter less than 3.0cm.  
Univariable analyses indicate that advanced age, height, BSA, IHD, statin use, 
hypertension and smoking history were associated with an increase in aortic 
diameter in both genders (Table 3.9).  In males only, an increase in weight 
was associated with larger aortic diameters. 
  
Table 3.9 Linear regression of predictors stratified into gender (univariate) 
Numbers in parenthesis represent standard error (SE), BSA: body surface area, BMI: body 
mass index, IHD: ischaemic heart disease, COPD: chronic pulmonary obstructive disease, 
IQR: interquartile range. 
On multivariable analysis, age, smoking history and an increase in BSA 
remained independent predictors of larger aortic diameters in both genders 
(Table 3.10). However, a history of IHD was predictive of larger aortic 






 Intercept Unstandardised 
coefficients (SE) 
P Intercept Unstandardised 
coefficients (SE) 
P 
Age per decade 1.42 0.087 (0.006) <0.001 1.21 0.077 (0.004) <0.001 
Deprivation per 
decile 
2.05 -0.013 (0.013) 0.346 1.75 0.003 (0.010) 0.751 
Weight per 10kg 1.88 0.019 (0.005) <0.001 1.71 0.005 (0.003) 0.158 
Height per 10 
cm 
1.98 0.004 (0.001) 0.001 1.74 0.005 (0.001) <0.001 
BMI per unit 1.86 .006 (0.002) <0.001 1.73 0.001 (0.001) 0.583 
BSA per unit 1.62 0.205 (0.045) <0.001 1.58 0.094 (0.035) 0.006 
IHD 2.02 0.072 (0.016) <0.001 1.74 0.077 (0.014) <0.001 
Statin use 2.01 0.047 (0.014) <0.001 1.74 0.024 (0.011) 0.028 
Hypertension 1.99 0.073 (0.013) <0.001 1.72 0.059 (0.010) <0.001 
Smoking history 2.01 0.038 (0.014) 0.006 1.74 0.024 (0.011) 0.032 
COPD 2.02 0.049 (0.021) 0.019 1.74 0.037 (0.019) 0.052 
Diabetes 2.03 0.017 (0.019) 0.379 1.75 0.023 (0.016) 0.143 
Cancer history 2.03 0.02 (0.18) 0.257 1.75 -0.008 (0.016) 0.643 













Age (per decade) 0.103 (0.009) <0.001 0.091 (0.007) <0.001 
IHD 0.018 (0.022) 0.419 0.037 (0.018) 0.043 
Statin use -0.011 (0.019) 0.543 -0.008 (0.015 0.593 
Hypertension 0.019 (0.019) 0.323 -0.014 (0.014) 0.333 
Diabetes -0.035 (0.023) 0.134 -0.030 (0.019) 0.127 
COPD 0.026 (0.025) 0.310 0.023 (0.024) 0.342 
Smoking history 0.048 (0.017) 0.006 0.055 (0.015) <0.001 
BSA 0.365 (0.044) <0.001 0.238 (0.034) <0.001 
Intercept 0.561 (0.121) <0.001 0.676 (0.089) <0.001 
Numbers in parenthesis represent standard error (SE), BSA: body surface area, BMI: body 
mass index, IHD: ischaemic heart disease, COPD: chronic pulmonary obstructive disease, 
IQR: interquartile range. 
3.8.1 Predicting the presence of AAA  
A logistics regression model was built by using clinically known parameters 
that have been previously reported to be associated with AAA disease. The 
model only included data from individuals over 50 years of age, with younger 
individuals being excluded as there were no aneurysms observed in this 
subgroup. Variables missing >10% of data points were not included in the 
model. Univariate predictors stratified into gender are presented in 
Table 3.11.  
  
Table 3.11 Predictors of AAA presence (univariate analysis)  
 Males Females 
 OR (95%CI) P OR (95%CI) P 







4.50 (2.97 to 6.84) 
10.56 (5.59 to 20.00) 
<0.001  
Reference 
2.62 (1.46 to 4.70) 
7.03 (3.14 to 15.80) 
<0.001 
IHD 1.33 (0.91 to 1.93) 0.137 2.95 (1.70 to 5.12) <0.001 
COPD 1.22 (0.81 to 1.85) 0.346 2.26 (1.17 to 4.35) 0.015 
Renal 
impairment 
0.96 (0.57 to 1.63) 0.876 0.43 (0.09 to 2.00) 0.342 
Diabetes 1.05 (0.67 to 1.63) 0.842 1.04 (0.52 to 2.06) 0.919 
Hypertension 2.19 (1.36 to 3.52) <0.001 3.12 (1.36 to 7.16) <0.001 
Statin use 2.17 (1.49 to 3.17) <0.001 1.79 (1.03 to 3.12) 0.039 
Cancer history 1.10 (0.71 to 1.70) 0.668 1.50 (0.68 to 3.31) 0.315 
AAA: abdominal aortic aneurysm, IHD: ischaemic heart disease, COPD: chronic obstructive 
pulmonary disease. 
Males and females shared similar predictors for developing AAA including 
age, history of smoking and hypertension. However, a history of IHD and 
COPD were independent predictors of AAA presence in females but not in 
males as shown in Table 3.12. 
  






P Adjusted odds 
ratio 
P 
Age. per year _ 1.09 (1.07-1.10) <0.001 1.10 (1.07-1.12) <0.001 































IHD (%) 115 (51.6) 4.65 (3.53-6.12) <0.001 1.72 (1.25-2.38) <0.001 
COPD (%) 57 (25.6) 3.20 (2.32-4.40) <0.001 1.47 (1.02-2.11) 0.040 
Renal 
impairment 
24 (10.8) 2.78 (1.77-4.37) <0.001 0.74 (0.44-1.26) 0.268 
Diabetes 44 (19.7) 1.66 (1.2-2.34) 0.004 1.08 (0.73-1.60) 0.702 
Hypertension 197 (88.3) 7.29 (4.82-11.04) <0.001 2.80 (1.78-4.41) <0.001 
Statin use 141 (63.2) 3.46 (2.61-4.58) <0.001 2.00(1.43-2.77) <0.001 
Cancer history 36 (16.1) 1.26 (0.87-1.82) 0.221 1.11 (0.74-1.67) 0.624 
AAA: abdominal aortic aneurysm, IHD: ischaemic heart disease, COPD: chronic obstructive 
pulmonary disease. 
3.8.2 Aortic size index and effect on survival 
There were 956 (20.6%) individuals who died by the end of the follow-up 
period, with a median (range) length of follow-up being 54.4 (0.02-86.23) 
months.  Preliminary analysis indicated that having a history of cancer and 
being octogenarian were factors that competed with the background 
mortality rate (hazard ratio >3) and were therefore associated with reduced 
survival. For these reasons, two analyses were carried out, one including all 
the cohort (Table 3.13) and the other excluding cancer patients and those 
older than 80 years old (Table 3.14). 
  
Table 3.13 Multivariate analysis of factors associated with overall survival in 
patients >50 years old 
 Males 
HR (95%CI) P 
Females 
HR (95%CI) P 
Age per year 1.07 (1.05-1.09) <0.001 1.06 (1.04-1.08) <0.001 
Diabetes 1.40 (1.02-1.93) 0.036 1.56 (1.08-2.26) 0.019 
COPD 2.39 (1.77-3.22) <0.001 2.27 (1.56-3.30) <0.001 
Statin use 0.93 (0.70-1.23) 0.603 1.02 (0.75-1.40) 0.893 
IHD 1.09 (0.80-1.48) 0.590 1.18 (0.83-1.66) 0.363 
Renal 
impairment 
2.32 (1.62-3.32) <0.001 2.55 (1.46-4.45) <0.001 
Aortic size index 1.10 (0.81-1.49) 0.544 1.69 (1.22-2.33) 0.002 
Cancer history 2.73 (2.07-3.61) <0.001 3.27 (2.38-4.54) <0.001 
HR: hazard ratio, CI: confidence interval, COPD: chronic obstructive pulmonary disease, 
IHD: ischaemic heart disease 
Advanced age, the presence of comorbidities (diabetes, COPD, renal 
impairment) and a history of cancer were predictors of reduced survival in 
this model. ASI was among the predictors associated with a lower survival in 
females, with a HR of 1.69 (95%CI: 1.22-2.33), but not in males (HR 1.10 
(95% CI: 0.81-1.49)). Restricting the analysis to individuals without a history 
of cancer and patients aged between 50 to 80 years old revealed that ASI 
remained a significant predictor in females only (Table 3.14).  
Table 3.14 Multivariate analysis of factors associated with overall survival for 50-80 
year-old patients excluding those with a cancer history  
 Males 
HR (95%CI) P 
Females 
HR (95%CI) P 
Age per year 1.11 (1.07-1.14) <0.001 1.06 (1.03-1.09) <0.001 
Diabetes 1.26 (0.78-2.02) 0.339 1.49 (0.86-2.56) 0.155 
COPD 2.27 (1.43-3.61) <0.001 3.22 (1.98-5.21) <0.001 
Statin use 0.79 (0.50-1.23) 0.291 0.79 (0.81-2.05) 0.728 
IHD 1.13 (0.69-1.85) 0.621 0.75 (0.43-1.30) 0.302 
Renal 
impairment 
3.33 (1.85-6.00) <0.001 3.00 (1.40-6.45) <0.001 
Aortic size index 1.39 (0.77-2.49) 0.273 1.74 (1.07-2.84) 0.025 
HR: hazard ratio, CI: confidence interval, COPD: chronic obstructive pulmonary disease, 
IHD: ischaemic heart disease 
3.8.3 Adjusted effect of infrarenal aortic diameter on survival  
Within the group which excluded those patients with a cancer history, two 
further models were investigated. The aortic diameter was kept as a 
continuous variable in the first model and as a categorical covariate in the 
second to determine if the aortic diameter predicted overall mortality. In 
males, the aortic diameter was categorized into four strata according to the 
<12.5, 12.5 to 62.5, 62.6 to 87.5 and >87.5 percentiles since the distribution 
was positively skewed. The IQR can be compared to the ‘tail ends’, and the 
largest category (12.5 to 62.5) represented the reference category (161, 
162).  
When the group was separated into these aortic size strata, the adjusted 
analysis suggested that amongst males a bimodal mortality association was 
present in those with smaller (<1.78cm, <12.5 percentile) and larger than 
average (>1.78cm, the highest 35.5 percentiles) aortic diameters when 
compared to the 50% of the population in the 1.78-2.12cm aortic size range 
(Table 3.15). When the aorta was left as a continuous variable, an increase 
by 1cm was associated with a non-significant HR of 1.12 (95%CI: 0.98- 1.27).  
Table 3.15 Adjusted analysis of aortic size on overall survival in males 
Aorta category (cm) Number of deaths HR (95% CI)* P Value 
<1.78 27/181 (14.9) 1.71 (1.11-2.62) 0.015 
1.78-2.12 112/709 (15.8) Ref - 
2.12-2.67 113/346 (32.7) 1.43 (1.10-1.87) 0.009 
>2.67 74/176 (42.0) 1.39 (1.02-1.88) 0.035 
Adjusted to age, ischaemic heart disease, statin use, renal impairment, smoking history 
and chronic pulmonary obstructive disease 
For females, when the aorta was kept as a continuous variable, an increase 
in aortic diameter per 1cm was associated with a HR of 1.26 (95%CI: 1.05-
1.51). However, categorizing the aorta was not associated with any 
significant effect on survival. 
3.8.4 Validity of CT measurements (Inter-observer error) 
A potential source of bias in measuring aortic diameters might be the inter-
observer error between the two investigators and this association was 
tested using the Bland-Altman methodology. After training the investigator 
in measuring aortic diameters, a validation of “normal” aortic diameters 
(<2.5cm) was conducted. The mean difference in the first set of validation 
was 0.15cm (limits of agreement: -0.08 to 0.38). A further refinement in 
measuring technique was conducted and a second validation comprising of 
42 aortic diameters revealed an improvement in aortic difference of 0.02cm 
(limits of agreement: -0.15 to 0.15). The results of the validation were well 
in the range of the accepted intra-observer measurement error reported in 
the literature (+/- 0.4cm) (158). 
  
Figure 3.5 Bland-Altman plot showing the differences in aortic measurements 
between the investigators.   
Top (A): first validation (n=28) and bottom (B): final validation (n=42) 
Dashed lines indicate limits of agreement (1.96*standard deviation) 
A 
B 
3.9 Discussion  
In this study, the abdominal aortic diameters from a large population were 
measured at five levels and predictors of developing a larger aortic diameter 
and an AAA were determined. Some of these predictors were also prognostic 
factors independent of reduced overall survival. 
In New Zealand, the indigenous Māori people are of Polynesian descent and 
are believed to have migrated to NZ around 12th -13th century. To date, there 
is very limited information on the normal aortic diameter in Māori and this 
data is important as Māori appear to have an increased mortality related to 
AAA (120). In this chapter, the infrarenal aortic diameter of Maori was 
slightly larger (1-2mm) than NZ European after age and sex adjustment. This 
finding highlights that Māori do not appear to have small aortic diameters as 
observed in the Asian population.  
While smoking was found to be an independent predictor of larger aortic 
diameters in the NZ European population, this association was not observed 
in the Maori population. This might be due to the higher baseline proportion 
of Māori with a smoking history included in the combined datasets. The 
slightly larger diameters observed in Māori might be explained by the overall 
higher burden of comorbidities. Due to the well-established effects of 
smoking on AAA development, the aortic diameters are likely to decrease if 
the prevalence of smoking falls in Maori. The time taken for this affect to 
occur is an area of where further research is required. 
Obtaining information on contemporary aortic sizes is required in order to 
improve the management of abdominal aortic aneurysms and to provide 
reference groups should AAA screening become established in New Zealand. 
Data from Gloucestershire, United Kingdom indicate that the mean aortic 
diameter in men has decreased from 2.1 cm (0.56) in 1990 to 1.7 cm (0.35) 
in 2009 (88). Updated data from the NAAASP report a mean aortic diameter 
of 1.8cm (115). The reasons for this apparent decline may be related to 
changes in smoking patterns (18, 163), the ultrasound-measuring 
techniques used (42) and increased rates of diabetes which itself has an 
inverse association with aortic diameter dilatation (164).  
The aortic diameters presented in this study are consistent with previous 
population studies. Aortas measured by CT scan from the Framingham Heart 
Study revealed a mean aortic diameter of the mid abdominal aorta and aortic 
bifurcation of 1.93 and 1.87 for males and 1.67 and 1.60cm for females 
respectively (165).  In comparison, the aortic diameters recorded in this 
study (when similar age limits were applied) were 2.01 and 1.92 for males 
and 1.70 and 1.62 for females respectively.   In a study of patients undergoing 
coronary calcium scanning the descending thoracic aorta diameter in males 
and females was 2.56 and 2.30 respectively (166) (cf. supra celiac artery 2.52 
in males and 2.35 cm in females in this current study). 
In addition, the AAA risk-factor associations and resulting odds ratios 
presented in this study were consistent with previous results reported in 
two other meta-analyses (11, 137) (Table 3.16). Although the current study 
observed the odds ratio for smoking history as being almost twice as high as 
the previous studies, this might be due to the relatively smaller numbers of 
patients included in the study as reflected in the wide confidence intervals. 
The results of both meta-analyses for smoking were inconsistent as evident 
by significant heterogeneity within the studies included (11, 137). This could 
be related to the population selected for AAA screening.  
  
Table 3.16: Two meta-analysis with pooled OR of risk factors influencing the 
presence of AAA 
 Cornuz et al. (137) Li et al. (11) Current study 
 N of 
Studies 
OR (95%CI)1 N of 
Studies 
OR (95%CI)† OR (95%CI) 
Sex (Males) 6 5.69 (3.36-9.64) NR NR 3.30 (2.35-4.62) 
History of MI 6 2.28 (1.90-2.74) 10 1.82 (1.65-2.00) 1.72 (1.25-2.38) 
PAD 8 2.50 (2.12-2.95) 3 3.00 (1.74-5.19) NR 
Smoking 
history 
11 2.41 (1.94-2.01) 11 2.07 (1.87-2.28) 5.08 (3.58-7.21) 
Hypertension 9 1.33 (1.14-1.55) 12 1.26 (1.15-1.39) 2.80 (1.78-4.41) 
Diabetes 6 1.02 (0.81-1.29) 10 1.04 (0.90-1.19) 1.08 (0.73-1.60) 
MI: Myocardial infarction, PAD: Peripheral artery disease 
† Random-effect model due to expected heterogeneity between studies  
In this study, IHD and COPD were associated with AAA presence in females 
but not in males. This finding has not been previously reported and might be 
due to the background comorbid profile of this cohort. If these gender-
specific predictors can be validated, they could be potentially useful to help 
identify ‘at risk’ women and thereby improve detection of AAA in this group. 
This study might differ from other AAA screening or population studies in 
that the population sought medical attention for symptoms or health 
concerns. This is evident by an equal proportion of individuals living in more 
deprived and less deprived locations. In addition, this population had a 
higher prevalence of baseline health conditions as observed by the higher 
prevalence of diabetes and cancer history compared to other population 
studies.  
Since body measurements appear to affect aortic diameters, the search for a 
tool to express aneurysm size and a morphometric measurement to index 
this relationship has been proposed. Ouriel et al. was the first to use 
morphometric measurements in an attempt to predict AAA rupture (167). 
Lumbar vertebral body diameter was used as an index to patient body-size 
to predict AAA rupture. More recently, Sconfienza et al proposed the use of 
wrist circumference as a surrogate for body build and reported that the use 
of this body size adjustment resulted in an improved definition of AAA. These 
authors evaluated 1200 patients and correlated wrist circumferences with 
mid infrarenal diameters. An aortic diameter to wrist circumference ratio of 
greater than 0.15 was thought to be a more useful definition of AAA (168). 
In this current study, due to its retrospective nature, morphometric 
measurements were limited to BSA and BMI. Previous studies have used 
anatomical landmarks such as femur and pelvic measurements, in order to 
perform body size adjustments (169). Obtaining such measurements from 
the available CT investigations was challenging, as these measurements 
require additional 3-D reconstruction. The other hindrance in using the CTC 
data was that the air insufflation distorts the abdominal anatomy and the 
amount of body-wall and anatomical changes are variable amongst 
individuals. With the large number of individuals missing height and weight 
recordings, it was challenging to develop such tools. A prospective clinical 
study correlated with radiological imaging might provide such information.  
In this study, the influence of aortic size and ASI differed between genders. 
In females, larger aortic diameters and ASI were independent predictors of 
death. However, in males, this association was not clearly evident and it was 
not possible to confirm that the aortic diameter influenced survival in a 
bimodal fashion as previously reported by Norman and colleagues in the 
Western Australian Health in Men Study (162). Information on aortic 
diameter and association with survival has been limited to a small number 
of studies (Table 14). All these studies recruited patients more than 10 to 20 
years ago, which has implications on the generalisability of these findings in 
current clinical practice where cardiovascular modification has improved 
and life expectancy has risen. ASI has only been previously investigated as a 
marker of aneurysm rupture but not as a surrogate marker of mortality as 
demonstrated in this study (156, 157).  
  
Table 3.17: Summary of studies reporting on the effect of aortic diameter on 
survival 





























































































Numbers in parenthesis represent standard deviation or as otherwise stated, M=males, 
F=females All aortic diameters are in mm. 
As anticipated, there are limitations to the studies presented in Table 3.17), 
relating in particular to the group-selection criteria and age-range limits 
which were included in the analysis. In addition, there were differences in 
the way that the various studies stratified aortic diameters.  
3.10 Limitations 
The relatively large cohort with data on aortic diameters in a NZ context and 
a relatively long survival follow-up are strengths of this study. However, 
some limitations need to be discussed.  
Firstly, the retrospective nature of the design prevented a complete capture 
of all demographical and clinical data, particularly noted in the high 
percentage of missing height recordings. However, we attempted to estimate 
the weight and height recordings from other databases. Comparing the 
weights and heights of 9,000 patients (from the same geographical 
catchment) with an average age of 65.1 years who underwent coronary 
interventions or percutaneous cardiac procedures revealed an average 
weight and height of 83.7 kg and 169.7cm respectively.  Other more useful 
measures such as waist to hip ratios, which might be more useful to predict 
cardiovascular risks, were not available. 
Secondly, the potential selection bias of such a cohort meant that some of the 
observations should be interpreted with caution, particularly in the survival 
analyses. Where possible, the competing effects of cancer and advanced age 
were excluded to improve the generalisability of the findings to a 
community-based population. Unlike other studies, the age included in the 
regression analysis was limited to > 50 years old. 
In the Canterbury region, Māori comprise of about 8-9% of the population 
but they were underrepresented in this study (2.2%). This has limited the 
generalisability of reporting ethnic data. To overcome this, data from other 
regions were gathered to provide the best current data on Māori aortic 
diameters. This approach in itself might have introduced bias with 
measuring aortas and identification of Māori. Furthermore, other possible 
confounders and adjustments could not be performed as risk profiles for the 
datasets were not available or the definitions were not consistent. 
Furthermore, although patients were included consecutively from each 
centre, the selection process and indication for obtaining the radiological 
scan differed between volunteers in the general population as in the 
Waitemata primary health group and those with gastrointestinal symptoms 
undergoing a CTC. Furthermore, other possible confounders and 
adjustments as body size measurements could not be performed as risk 
profiles for the datasets were not available or the definitions were not 
consistent (18). The small number of NZ Maori over 80 year olds has limited 
the ability to reliably report on the aortic diameter in this group Survival 
data for Māori patients added from different locations was not available; 
therefore testing the influence of aortic diameters on survival in the Māori 
population could not be performed.  
3.11 Conclusions 
In a region where information on the normal aortic diameter is absent, the 
diameter of aortas, predictors of larger diameters and AAA presence were 
determined in a cohort of individuals undergoing CTC in New Zealand. Māori 
appear to have aortic diameters at least equivalent to NZ Europeans and this 
should be considered when defining aneurysms. A history of IHD was a 
predictor of larger aortas, and COPD and IHD were significant predictors of 
AAA development in females but not in males. Aortic diameter appeared to 
be an independent but modest predictor of overall survival in females. In 
males a bimodal association may exist, whereby both relatively small and 
large aortic size predict poor survival compared to intermediate sized aorta.  
3.12 Future Work 
Given the limitations discussed in this work, studies reporting on Māori will 
require a multicentre approach to yield large numbers within a reasonable 
study period. If an aortic screening program is introduced, obtaining aortic 
measurements and initiating cardiovascular risk assessments are warranted 
to reduce overall mortality in those with larger aortas.
 
4.1 Overview 
After an abdominal aortic aneurysm (AAA) is diagnosed and the diameter 
reaches a threshold for repair, a risk and benefit analysis is required to 
determine whether the risk of surgery outweighs the risk of AAA rupture 
along with the patients’ life expectancy. 
Predicting late survival prior to elective AAA repair remains the Achilles heel 
in AAA management. Risk calculators to predict 30-day mortality are well 
established with some 15 different preoperative models having been 
developed to predict mortality. Some of the parameters of these models rely 
entirely on preoperative factors whereas others rely on intra-operative 
parameters and include both open and endovascular repair. However, 
predictive models to aid in decision making for long-term prognosis are not 
widely available or used. 
In order to provide information for such predictive modelling, reliable 
estimates for determinants that influence survival are required. This 
information can either be obtained directly from acquired survival data or 
from pooling relevant data from the published literature.  
This chapter reports the results of a systematic review and a meta-analysis 
that provide quantitative and qualitative information on factors that may 
influence survival following AAA repair. Knowledge of such factors and their 
impact can be used in predictive model development to assist clinicians in 
decision-making surrounding AAA management.  
4.2 Contribution 
This chapter has led to three publications in peer-reviewed journals and I 
was the principal investigator in all the studies with the responsibilities of 
data searching, extraction, analysing and writing the manuscripts. Jonathan 
Williman and Phil Hider provided specific assistance with the meta-
regression and subgroup analysis.     
4.3 Publications 
Khashram M, Williman JA, Hider PN, Jones GT, Roake JA. Systematic Review 
and Meta-analysis of Factors Influencing Survival Following Abdominal 
Aortic Aneurysm Repair. European Journal of Vascular and Endovascular 
Surgery. 2016; 51(2):203-15 
Khashram M, Hider PN, Williman JA, Jones GT, Roake JA. Does the diameter 
of abdominal aortic aneurysm influence late survival following abdominal 
aortic aneurysm repair? A systematic review and meta-analysis. Vascular. 
2016; 24(6):658-67 
Khashram M, Williman JA, Hider PN, Jones GT, Roake JA. Management of 
modifiable vascular risk factors improves late survival following abdominal 
aortic aneurysm repair: A systematic review and meta-analysis. Annals of 
Vascular Surgery. 2016; doi: 10.1016/j.avsg.2016.07.066 
4.4 Background 
Weighing the risks of AAA rupture against the risks of operative mortality 
remains one of the most challenging decisions in AAA management. In the 
clinical setting, this judgment is usually part of a shared medical decision 
process between clinicians and patients. Ideally, this process would take into 
account co-morbidities and estimates of life expectancy with or without 
repair. Unfortunately, predictive models to identify high-risk patients and 
aid this process are not available (172). 
Results from a large Medicare database and a meta-analysis of randomized 
controlled trials have shown that there is no difference in overall long-term 
patient survival between endovascular aneurysm repair (EVAR) or open 
aneurysm repair (OAR) (59, 64). Therefore, existing patient co-morbidities 
and cardiovascular risk factors appear to have the strongest impact on 
overall late mortality following AAA repair. 
Prognostic demographical and clinical variables associated with poor late 
survival following AAA repair have been well described but are often 
reported as single outcomes in multiple studies and are susceptible to 
selection and publication bias. These prognostic factors have included 
patient demographics, associated comorbidities and AAA anatomical factors.  
4.5 Objectives 
Given the importance of clinical decision-making in the management of AAA, 
the aim of this systematic review and meta-analysis was to report and 
quantify the impact of prognostic factors associated with long-term survival 
after AAA repair from the best available information in the literature. 
4.6 Methods 
A systematic review of published articles was conducted according to the 
Preferred Reporting Items for Systematic review and Meta-Analyses 
(PRISMA) guidelines (173) and the Meta-analysis and systematic reviews Of 
Observational Studies in Epidemiology (MOOSE) (174).  
In the PICOT (175, 176) format, this topic was defined as:  
x Population: patients undergoing elective AAA repair, (via either OAR 
or EVAR);  
x Intervention and comparison: presence/absence or magnitude of 
modifiable clinical preoperative risk factors; 
x Outcome: all-cause mortality; 
x Time frame: greater than or equal to one year.  
4.6.1 Search strategy  
Two researchers (MK & JR) independently conducted the study selection, 
data extraction and assessment of methodological quality. When 
disagreement arose, the reviewers met to resolve any issues. Medline, 
EMBASE and the Cochrane Library Database were searched via the OVID SP 
database. With the assistance of a clinical librarian, “exploded” medical 
subject headings (MeSH) terms for Medline and Cochrane and EMTREE 
terms for EMBASE were used to broaden the keyword search for “abdominal 
aortic aneurysm”, “risk factors”, “long term survival” and “survival rate” 
along with their synonyms. The search history is included in appendix 8.2. 
The search did not have any date restriction, and no limitations on 
publication language or study type were applied. The first search was 
conducted in May 2014, and it was updated in April 2015. A manual search 
of additional articles was conducted using references from relevant articles 
and review papers. The journals of Annals of Vascular Surgery, European 
Journal of Endovascular and Vascular Surgery, Journal of Endovascular 
Therapy, Journal of Vascular Surgery, Vascular Medicine and Vascular were 
searched for any relevant articles published “online first”. Abstracts of 
conference proceedings were searched for full-text publication. Eligible 
titles or abstracts were imported into Endnote X7 (Thomson Reuters) library 
and full-text articles were obtained. 
4.6.2 Inclusion and exclusion selection criteria 
Two independent reviewers adhered to the following inclusion criteria: any 
studies reporting survival data and information about factors that may 
influence survival following elective AAA repair (OAR or EVAR), with at least 
one year follow-up with the primary endpoint of outcome being all-cause 
mortality; studies with greater than 100 patients; studies with symptomatic 
or rupture AAA in the analysis were included if the total number of 
symptomatic/rupture AAA was less than 20% of study participants; studies 
containing up to a small proportion of patients (<40%) undergoing complex 
open (suprarenal clamping/visceral debranching) or fenestrated EVAR; 
studies that included AAA repair as well as other vascular operations were 
included if the analysis was done separately for each type of surgery. 
However, the other vascular operations were not included. The exclusion 
criteria were studies that only included small AAA (<5cm), non-elective 
repairs, octogenarians, studies reporting intra or postoperative factors 
rather than preoperative factors, and non-patient-related factors such as 
hospital/surgeon volume status. 
4.6.3 Study selection 
When studies from large registries or known databases were included, the 
most recent study or the paper which contained the largest number of 
patients and relevant data was used. Data from national databases were also 
checked to ensure data from individuals were not duplicated in other 
published series. If two articles presented data from the same database but 
different variables were reported, then both studies were included for the 
two variables. Study authors were contacted when clarification was 
required.  
4.6.4 Data extraction and quality assessment 
Data extracted from studies meeting the inclusion criteria were entered into 
a Microsoft Excel spreadsheet (Microsoft Corporation, Richmond, VA). The 
Grading of Recommendations Assessment, Development, and Evaluation 
(GRADE) system was used to rate the quality of evidence and strength of 
each factor identified; this was conducted using GradePro 
(www.gradepro.org). The Newcastle-Ottawa Scale (NOS) was also used to 
assess study quality, as it was anticipated that the majority would be 
observational studies (177). This scale employs a 9-point (star) system that 
assesses three domains: patient selection, comparability of the study groups, 
and the ascertainment of study outcome. Studies with a score of 9 stars 
indicate a low risk of bias, whereas 7 to 8 stars indicate medium bias risk, 
and a score of < 6 stars indicates a high chance of bias.  
4.6.5 Statistical analysis  
A meta-analysis of time-to-event data was performed. Reported hazard 
ratios (HR) and confidence intervals (CI) from multivariable Cox 
proportional hazard models were extracted from individual studies. Pooled 
estimates with 95% CIs were calculated using a random effects model, due 
to expected heterogeneity among the studies. Heterogeneity was expressed 
with the I2 statistic, and degrees of heterogeneity were defined as greater 
than 25%, 50%, and 75% respectively (178). When CIs were not reported, 
estimates were calculated using reported ratios and p-values (179). Sub-
group analyses were performed according to a priori groupings related to: 
study design, duration of follow-up, type of repair (EVAR vs OAR), location 
and number of participants (<1000 vs. >1000). Meta-regression was 
performed in R using the metaphor package, with heterogeneity estimated 
using the DerSimonian-Laird method with inverse variance weights for 
meta-analysis containing 10 or more studies (180, 181). Statistical 
significance was set at a p-value <0.05. The meta-analysis was performed 
using Review Manager (RevMan) Version 5.2. Copenhagen: The Nordic 
Cochrane Centre, the Cochrane Collaboration, 2012. 
4.7 Results 
A total of 304 articles were assessed in full and 59 studies met the inclusion 
criteria and were included in the analysis (Figure 4.1). Seven studies were 
included in the systematic review but were excluded from the meta-analysis 
as their data were descriptive without any reported hazard risk ratios (182-
185), ambiguous without any variables defined (186) or included factors not 
relevant to this review (187, 188). In all, 21 authors were contacted and 11 
provided information regarding the data or the study. 
The individual study design, location and setting of the studies, number of 
participants and follow-up duration are presented in Table 4.1. Of the 59 
studies, 29 were based in Northern America, 24 in Europe, 4 in Asia, one in 
Australia and one in South America. Fifty-seven studies were observational 
and two were post hoc analyses from prospective controlled trials. There 
were 54 studies that included elective procedures and the remaining five 
studies included both elective and emergency procedures.  The majority of 
the studies were of high quality with an average NOS (standard deviation) 






























Figure 4.1:  Literature PRISMA search flow diagram
EMBASE 4061 
Medline 1108 
Cochrane 580  
Hand searching: 
Cross-references: 11 
Articles in press: 6 
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4.7.1 Demographical factors 
4.7.1.1 Age 
Age was the most common covariate identified and was reported as a 
continuous variable in 21 eligible studies (189-209) and as a categorical 
variable in 11 other studies (78, 210-219). Two studies were excluded since 
one did not define how age was categorised (220) and the other used 
patients aged over 80 years old as the reference category and meaningful 
HRs were not obtainable (221). The pooled HR from the 21 studies was 1.05 
(95%CI: 1.04:1.06), I2=81% related to each one-year increase in age. When 
the studies were stratified into groups of less than or greater than 1000 
participants, heterogeneity was confined to the group of studies with > 1000 
participants (Figure 4.2). When participants were categorised into age 
groups of 65-75 (n=8) and >75 (n=5) years old vs. the reference category 
(<65years), the estimated pooled HRs were 1.77 (95%CI: 1.36-2.30), I2=77% 
and 2.32 (95%CI: 1.93-2.80), I2=37% respectively. 
  
Figure 4.2 Forest plot of age (continuous/year) with sub analysis of number of 
patients included 
4.7.1.2 Gender 
Sex was the second most reported covariate and all reported hazard ratios 
were adjusted for age differences. Sixteen studies reported on the influence 
of gender on late survival (190-193, 195, 196, 199, 201, 202, 207, 209, 211, 
213, 221-223). Females had a worse overall survival than males with a HR 
1.16 (95%CI: 1.07-1.27), I2=45% as represented in Figure 4.3. 
  
Figure 4.3 Forest plot of the effect of gender on survival 
4.7.2 Clinical assessments/investigations 
4.7.2.1 American Society of Anaesthesiologists (ASA) classification 
The ASA physical status classification system of a 5-score categorical 
variable was kept in an ordinal (continuous) form in three studies (189, 196, 
224) and categorised as greater than ASA 3 or 4 vs. less than 3 in one study 
(190). Pooled HRs related to each successive increase in ASA score and high 
ASA (3 and 4) were 1.30 (95%CI: 1.16-1.47), I2 =0% and 1.63 (95%CI: 1.42-
1.87) respectively. 
4.7.2.2 Hypertension 
Of the nine (190-192, 201, 202, 207, 211, 221, 222) studies reporting on the 
influence of hypertension on survival, only two attempted to define 
hypertension or comment on treatment (221, 222). The pooled HR of the 
nine studies was 0.90 (95%CI 0.79-1.03), I2=60%. When a history of 
hypertension was confined to the presence of left ventricular hypertrophy 
(LVH) on ECG, the effect on survival was harmful and heterogeneity was 
eliminated HR 2.25 (95%CI: 1.66-3.04), I2=0% (78, 200, 212). 
4.7.2.3 Body Mass Index 
Anthropometric measurements were reported as body mass index (BMI) in 
three studies (190, 224, 225).  However, there was inconsistency in the 
assessments and a lack of definitions for BMI categories. The Eurostar (190) 
and the investigational device exemption trial (224) reported BMI as 
“obesity”, whereas Matsumara et al. reported body measurements as 
“smaller BMI”. The combined HR for these two studies was 0.86 (95% CI: 
0.76-0.99), revealing a protective effect with obesity. However, Matsumura 
et al. (225) reported that a smaller BMI was associated with improved 
survival: HR 0.29 (95%CI: 0.12-0.69). Given the differences and lack of 
definitions for BMI, the pooled estimates of all three studies could not be 
performed. 
4.7.2.4 Haemoglobin 
Three studies included information on preoperative haemoglobin 
concentration, and levels were analysed as a continuous variable (208, 226, 
227). A higher baseline haemoglobin level was a protective factor, with a HR 
of 0.84 (95%CI: 0.74-0.96), I2=47%.  
4.7.3 Comorbidities & risk factors 
4.7.3.1 Cardiac disease 
Ischaemic heart disease  
IHD was inconsistently defined among the included studies. Definitions 
included: a history of angina or myocardial infarction (MI), the presence of 
coronary disease on angiogram, and signs from ECG findings or cardiac 
stress test results. Eighteen studies reported the influence of IHD (however 
defined) on late survival with a pooled of HR 1.29 (95%CI: 1.18-1.48), 
I2=46% (78, 189-194, 197, 204, 206, 207, 209, 211, 217, 218, 222, 228, 229). 
Seven studies reported specifically on the influence of a previous history of 
MI (78, 194, 197, 200, 202, 222, 223). When the analysis was confined to the 
presence of IHD based on a history of MI or ECG findings, heterogeneity 
disappeared (I2= 0%) but the pooled HR remained broadly consistent at 1.52 
(95%CI: 1.32-1.73).  
Cardiac failure  
The impact of cardiac failure or congestive heart failure was also variably 
defined in the studies and was based on a mixture of clinical, radiological and 
echocardiographic criteria. The impact of heart failure, however defined, 
was reported in 14 studies (193, 194, 196, 207, 213, 215, 216, 218, 219, 222, 
230-233). The pooled HR was 1.91 (95%CI: 1.58-2.30), I2=70%. Subgroup 
analysis into type of repair reduced heterogeneity in OAR with an I2=22%, 
but heterogeneity for EVAR and both types of repair remained high I2=77%. 
Cardiac revascularization  
One study reported the survival advantage of planned coronary 
revascularization prior to AAA repair with a HR of 0.76 (95%CI: 0.59-0.98) 
(214) and two studies specified the risk associated with uncorrected IHD 
with a HR of 2.59 (95%CI: 1.14-5.88) (201, 229). 
4.7.3.2 Respiratory disease 
There were 18 studies reporting the influence of COPD on long term 
mortality following AAA repair (189-191, 196, 203, 205, 207, 211-214, 217, 
218, 220, 225, 228, 230, 232). The pooled HR was 1.53 (95%CI: 1.37-1.70), 
I2=70% (Figure 4.4). Three studies reported on COPD patients requiring 
supplementary oxygen therapy with a HR of 3.05 (95%CI: 1.93-4.80), 
I2=63% (198, 216, 218). A subgroup analysis was undertaken to determine 
if the average duration of follow-up could explain the high heterogeneity. 
Studies with longer than 4-year follow-up resulted in I2=0% compared to 
shorter follow-up studies with heterogeneity of I2=82%. 
 
Figure 4.4 Forest plot of COPD and sub-group analysis of follow-up duration 
4.7.3.3 Renal disease 
There was inconsistency among the studies in the methods used to report 
renal impairment and differences in the units of measurement. Some of the 
differences were overcome by converting creatinine units in mg/dl into 
µmol/L. Creatinine values were either reported as categorical data or kept 
in a continuous form. Three separate analyses were performed: (1) a 
categorical group was defined based on creatinine levels between 150 to 200 
µmol/L, (2) creatinine clearance or estimated glomerular filtration rate 
(eGFR) data were used for another analysis and (3) studies reporting on 
patients receiving haemodialysis or patients with end stage renal disease 
(ESRD) (creatinine >350µmol/L) were assessed. The results from the first 
analysis which included 16 studies (189-191, 194, 196, 201, 203, 207-211, 
214, 218, 222, 234) indicated that the presence of renal impairment was 
associated with increased mortality risk HR of 1.54 (95%CI: 1.43-1.67), 
I2=11%. Four studies reporting on eGFR or creatinine clearance had a HR of 
0.98 (95% CI: 0.96-0.99), I2=88%, for each increase in measurement unit 
(ml/min) (202, 204, 205, 228). Five studies included patients with severe 
disease on dialysis or with ESRD and had a resulting HR of 3.15 (95%CI: 2.45-
4.04) I2=0% (198, 205, 216, 219, 233). 
4.7.3.4 Cerebrovascular disease 
Cerebrovascular disease when defined was reported as a history of a 
previous stroke or transient ischaemic attack. Two studies reported the 
influence of carotid disease but these were not included in this group as 
carotid disease is not primarily associated with all strokes and carotid 
disease was poorly defined (190, 211). Nine studies (191, 193, 198, 201, 202, 
205, 212, 217, 234) reported the influence of cerebrovascular disease on late 
survival resulting in a pooled HR of 1.57 (95%CI: 1.40-1.77) I2 =0%. The 
presence of carotid disease had a HR of 1.27 (95%CI: 0.93-1.73). 
4.7.3.5 Peripheral artery disease (PAD) 
Three studies reported the influence of PAD on the overall survival following 
AAA repair (196, 202, 224) with a pooled HR of 1.36 (95%CI: 1.18-1.58), I2 
=0%. One additional study included ankle brachial pressure indices (ABPI) 
with lower ABPI values predicting worse survival (225). However, given 
differences in the definitions, the results could not be pooled.  
4.7.3.6 Diabetes 
Fourteen studies (190-193, 201-203, 207-209, 211, 213, 217, 222) reported 
on the influence of diabetes in relation to survival. The type of diabetes, the 
treatment and the presence of any complication was only defined in one 
study (222). One study included “diabetes with complications” but this was 
not described (213). The pooled HR was 1.34 (95%CI: 1.20-1.49), I2 =26%. 
4.7.3.7 Smoking history 
Seven studies (190, 198, 201, 204, 211, 217, 221) used various definitions 
for smoking, which ranged from current smokers to history of 
smoking/nicotine use to never smoked. Two studies specified “current 
smokers/smokers” rather than a history of smoking (204, 221). The pooled 
HR for any history of smoking and current use was 1.27 (95%CI: 1.07-1.51), 
I2 =45%.  
4.7.3.8 Cancer history 
A total of six studies reported on the impact of a history of a cancer diagnosis 
(201, 215, 226, 235), intraoperative tumour finding (197) or current cancer 
treatment (216) on the late survival following AAA repair. The pooled HR for 
any definition was 2.89 (95%CI: 1.29-6.47), I2=76%. The heterogeneity 
remained high despite sub analysis according to the different definitions 
used. 
4.7.4 Medication use 
4.7.4.1 Lipid lowering agent use: 
There were a total of 11 studies reporting the influence of statin/lipid-
lowering use on survival (198, 202, 205, 206, 209, 211, 213, 218, 221, 228, 
236). There was some variation in the definition of use; nine studies 
reported “statin use”, one study examined “medication for 
hypercholesterolemia” (198), and another included all types of “lipid 
modifying drug therapy” (221). Statin/lipid-lowering use had a protective 
role on overall survival, with a pooled HR of 0.72 (95%CI: 0.67-0.78), I2=35% 
(Figure 4.5). When analysis was confined to the nine studies reporting 
“statin use” the heterogeneity was reduced: HR 0.76 (95%CI: 0.71-0.81), 
I2=6%.  
In those studies, the proportion of patients using statins varied from 12.4% 
to 69.9%. In 2000, approximately 38% (95%CI: 28-48) of participants in 
AAA studies used statins. Since 2000, the proportion of participants who 
used statins increased at a rate of about 2.7% each year (95%CI: 0.7-4.8, p = 
0.016) (Figure 4.6). 
 
  
Figure 4.5 Forest plot of statin use according to proportion of patients using 
statin in each study  
Top to bottom= highest to lowest percentage 
Figure 4.6 A weighted linear regression of study mid-year and proportion of 
patients using statin  
Size of circle proportional to study size, shading represents 95% confidence intervals 
4.7.4.2 Aspirin and anticoagulant use: 
Six studies reported the effect of antiplatelet or anticoagulation use after 
AAA repair (198, 209, 211, 218, 222, 230). Definition of use varied by study; 
three studies (218, 222, 230) specified antiplatelet use as “aspirin,” and the 
other three defined it as “antiplatelet,” (209) “antiplatelet/anticoagulant”, 
(211) or “Coumadin” use (198). Antiplatelet use in four of these studies was 
associated with an overall protective effect, with an HR of 0.81 (95%CI: 0.73-
0.89), I2=9% when compared to non-aspirin/antiplatelet users. In one study, 
antiplatelet/anticoagulation use was combined and 76.6% of the patients 
were receiving either one or both drugs (211). This study was therefore not 
included in the analysis as the patients were inseparable. Anticoagulation 
(Coumadin) use was associated with reduced survival compared to non-
anticoagulation users, with a HR of 1.41 (95%CI: 1.07-1.85) in one study 
(198). 
4.7.4.3 Beta Blockers 
Two studies reported the effects of preoperative beta-blocker use (211, 222) 
compared to patients not receiving beta-blockers. Information on specific 
beta-blocker agents or doses were not specified. The pooled HR was 0.75 
(95%CI: 0.61-0.93) indicating a protective role following AAA repair. 
4.7.5 AAA diameter 
There were 16 studies comprising of 19,722 patients that reported data on 
AAA diameter. All of the studies adjusted for age while several also adjusted 
for comorbid conditions. Larger AAA diameter measured prior to AAA repair 
was associated with lower reported survival compared with smaller 
aneurysms. A 1cm increase in AAA diameter was associated with a pooled 
HR of 1.13 (95%CI: 1.10-1.18), I2=48% (Figure 2). Excluding four studies 
with either categorical (204, 237, 238) or logarithmic (239) AAA diameter 
did not influence the overall risk- HR 1.13 (95%CI: 1.09-1.18), I2=50% for 
each increase in 1cm of AAA diameter. 
Thirteen studies were included in a subgroup analysis according to AAA 
repair type (OAR or EVAR), each contributing an equal weight (50%) into 
the sub-analysis. EVAR was associated with a significantly higher mortality 
risk compared with OAR for each 1cm increase in AAA diameter. Pooled HR 
for EVAR and OAR was 1.20 (95%CI: 1.15-1.25), I2=0% and 1.08 (95%CI: 
1.03-1.12), I2=12% respectively (Figure 4.7). This subgroup analysis 
excluded two studies that included both EVAR and OAR in the same analysis 
(235, 237), one study that categorized AAA diameter (204) and one that did 
not report how the AAA was repaired (239).  
 
 
Figure 4.7 Subgroup analysis of AAA diameter according to type of repair  
Per 1cm increase, EVAR: endovascular aneurysm repair, OAR: open aneurysm repair 
Meta-regression was undertaken to determine if the between-study 
heterogeneity could be accounted for by the mid-year of study or duration of 
follow-up. Sixteen studies contributed to mid-year of the study and 15 
studies contributed to the duration of follow-up. There was an association 
for a decrease in log(HR) by duration of follow up (β = 0.998, 95%CI: 0.996- 
1.000, I2 = 24%, p < 0.013) (Figure 4.8). There was no evidence of a change 
in log(HR) by mid-year study (β = 1.004, 95%CI: 0.999-1.010, I2 = 47%, p = 
0.13). 
Figure 4.8 Log(HR) of AAA size vs. study follow-up duration 
The solid line represents the regression line and the dotted lines correspond to the 
95% confidence intervals. Each circle represents a different study and the size of the 
circle is proportional to the weight of study (inverse variance = 1/standard error2 of 
the HR) 
4.8 Discussion 
In this comprehensive review, the pooled best-available prognostic data 
from studies reporting on late AAA-repair survival during the past 25 years 
were analysed and presented, including 81,928 individuals. The results from 
this review highlight several important issues in relation to long-term 
survival following AAA repair. The impact of some factors has been 
inconsistent in isolated studies such as gender and AAA diameter. This 
review also highlights that ESRD on dialysis and COPD on supplementary 
oxygen are associated with a three-fold increase in mortality.  
There is some debate about whether gender influences survival following 
AAA repair. Data from the EUROSTAR and Lifeline registries and the Mayo 
Clinic revealed no difference in late survival between genders (190, 195, 
207). In the general population, women have been shown to have a higher 
life expectancy than males. However, following AAA repair, this difference 
appears to be negated and females had a significantly higher risk of death 
compared to males (HR 1.16 (95%CI: 1.07-1.27)) after adjusting for age.  
Recent evidence from the United States Renal Data System suggests that late 
survival after AAA repair among patients with ESRD receiving dialysis may 
be poor, with an estimated 3-year survival of 23.1% compared to 41.9% 
survival of patients with ESRD without an AAA (192). This conclusion is 
consistent with the results from this review that also report that late 
mortality is high among these patients (HR 3.15 (95%CI: 2.45-4.04)) and 
brings into question the long-term benefits of elective AAA repair for this 
group, suggesting that careful selection should be considered on a case-by-
case basis. 
The results from this study underline the importance of making efforts to 
improve patient cardiovascular risk factors prior to AAA repair to increase 
survival. Despite improvements in medical therapy and operative repair 
technology, a systematic review reported that estimated 5-year survival 
following elective AAA repair (OAR and EVAR) remained at about 69% 
(95%CI: 67-71) for over 40 years (75). Further improvements in survival 
may require better utilization of medical therapy, and future studies need to 
follow established guidelines to improve reporting of specific medications, 
doses, and durations of therapy and assess whether medical therapy has 
been optimized.  
4.8.1 AAA diameter 
Based on the results from this meta-analysis there appears to be two factors 
that could explain why larger AAAs may have worse survival.   
First, this association was found in both types of repairs therefore a 
biological cause seems plausible; larger AAA diameters might exhibit more 
inflammatory mediators, or larger-size AAA might be associated with more 
advanced cardiovascular disease (204, 240, 241). Five studies provided 
subgroup comparisons between small and large AAA. The results from three 
large studies (185, 224, 241) suggested that patients with larger AAA were 
older and had a greater burden of cardiovascular disease than patients with 
small AAA. In the two other smaller studies (204, 242), there was no 
difference in morbidities between the groups. However, patient co-
morbidities were adjusted for within the survival models and the influence 
of AAA size remained an independent predictor of late survival. 
Secondly, the effect estimate of AAA size of EVAR treatment was significantly 
higher in this analysis compared to the OAR group. However, this does not 
adequately explain why the association was greater in EVAR than OAR. 
Results from the Lifeline and EUROSTAR registries have also shown that an 
increase in AAA diameter was independently associated with a higher AAA-
related mortality, higher rupture post repair, re-intervention and surgical 
conversion to OAR. (207, 224, 241) One might speculate that each re-
intervention might have an additive mortality risk. 
Roger et al. were the first to include AAA size in a multivariate model but 
AAA diameter was not a significant mortality predictor in their study (201). 
Almost a decade later, Koskas and Kfieifer were the first to show that 
preoperative AAA size was an independent predictor of poor late-survival. 
Interestingly, this finding appeared to generate little discussion, including 
within the reporting paper. It was not until subsequent EVAR data began to 
emerge, highlighting morphological aortic neck and iliac artery differences 
between small and large AAA, that interest in this area began to increase 
(224, 241).  
4.8.2 Strengths and weaknesses 
As with most systematic reviews, this analysis is not immune to selection, 
publication and reporting bias. A key limitation of this study was that each 
of the factors have been analysed in isolation from any others, whereas in 
practice patients have more than one demographic and co-morbid factors to 
be considered in any decision about their care. It is possible that the effects 
of the various factors may be additive or multiplicative on the risk of late 
survival. Alternatively, the risks associated with some co-morbidities may 
even be subsumed into the risks associated with another comorbidity.  
Publication bias is a concern with any systematic review and studies from 
centres with good or excellent results are more likely to publish their data 
than units with poor outcomes. However it is notable that the data included 
in this review included reports from national registries, post hoc RCT data 
along with the data provided by smaller groups of surgeons based at 
specialist institutions. The GRADE score was low for the majority of 
outcomes and this was predominantly due to the high bias and types of study 
included. 
In this review the search and patient selection was broadened to quantify 
risks from the literature that would enable us to present generalizable 
hazard ratios for each factor analysed.  In so doing, it was noted that there 
was a lack of consistency in risk factor definitions, a tendency towards 
categorising continuous variables or reporting categorical data as a 
continuous variable such as the ASA grade. These factors may reduce 
statistical power of subsequent meta-analysis (243). To improve future 
studies there is a need for standardisation in the reporting of variables that 
might influence survival following AAA repair. 
4.9 Conclusions 
In conclusion, using the best available estimates of risk from the literature, 
important preoperative risk factors were identified and effect estimates for 
factors influencing late-survival among patients undergoing elective AAA 
repair were calculated. COPD requiring supplementary oxygen and ESRD 
had the highest impact on survival, which raises questions with regards to 
the benefits of elective AAA repair in their presence. The inclusion of these 
reported factors in the clinical decision-making process, therefore, seems 
warranted when considering the most appropriate surgical management 
option for individualizing patient care. These data are particularly useful in 
preoperative assessment and model development to aid clinical decision-
making. 
4.10 Further Work 
This review suggests that decision-making regarding AAA treatment and 
long-term survival needs to consider patient-related factors including age 
and gender along with a range of important clinical comorbidities. Further 
work is needed to determine the relative importance of each and how the 
risks from different combinations of the comorbidities may interact. 
Attention needs to be given to ensure these factors are consistently 
measured and reported in future studies so that updated and improved 
estimates can be readily obtained in future assessments and the obtained 
estimates could then be validated against AAA datasets. The factors and 
associated risks identified in this systematic review can be used to develop 
a predictive model to aid management of AAA repair.  
 
5.1 Overview  
Abdominal Aortic Aneurysm (AAA) repair is a well-established and effective 
prophylactic treatment against death caused by AAA rupture. Data from 
randomised trials summarized in a meta-analysis indicate lower 
perioperative mortality with EVAR compared to open aneurysm repair 
(OAR) (59). At two years and beyond, patient survival is very similar in both 
repair methods and patient pre-existing comorbidities are the predominant 
factors influencing overall survival, as presented in the previous chapter. 
Since the late 1990s there have been significant changes in the detection and 
management of AAA. The incidence and mortality of AAA have fallen as 
observed in studies from New Zealand (NZ) and elsewhere. However, this 
finding has not been consistent internationally. Understanding the reasons 
for these changes is invaluable when attempting to document the national 
burden of AAA disease. 
The overall theme of this thesis was to describe the contemporary 
presentation, management and outcomes of AAA disease in NZ, and to use 
patient outcome data to develop a predictive model that takes into account 
NZ-specific data.  This chapter describes the process of acquiring and 
cleaning national AAA data and the validation process to provide accurate 
outcome data which can be used in the development of the predictive model 
(Chapter 6). 
5.2 Contribution 
I was responsible for analysing and presenting the data in the format shown 
in this chapter. The data presented required obtaining, matching and 
cleaning of large administrative and clinical databases to provide the best 
available information on AAA disease in NZ.  
5.3 Publication 
Khashram M, Thomson IA, Jones GT, Roake JA. Abdominal Aortic Aneurysm 
Repair in New Zealand: A Validation of the Australasian Vascular Audit. ANZ 
J Surg 2016. doi: 10.1111/ans.13702 
5.4 Background 
Clinical governance and accountability require that operative outcome-data 
are routinely collected by national health bodies. The majority of surgical 
units are also required to collect their own data for reporting, audit and 
research purposes. Surgeons and health-policy decision-makers rely on end 
outcomes such as 30-day or 1-year mortality for reporting operative 
outcomes. However, these relatively simple measures can differ depending 
on the data source. For example, in AAA repair, variation has been 
documented in 30-day mortality figures for elective repairs depending on 
the source of data: prospective population-based data reported 8.2% 
mortality compared to 3.8% from prospective hospital-based (244). This 
wide range of mortality may have implications on the quality of care 
provided to patients, establishing national standards and in auditing 
purposes.  
In healthcare, there are broadly two types of data sources: administrative 
and clinical. The accuracy and reliability of each is an important issue and 
surgeons need to understand differences between them. The main purpose 
for collecting each dataset differs and therefore the variables recorded and 
the quality and accuracy of the data are likely to differ (245).  
Models to predict perioperative mortality are usually derived from large 
clinical datasets and validated with administrative datasets or vice versa. 
Several AAA-specific validated and reasonably accurate 30-day morbidity 
and mortality predictive-models have been developed to aid in medical 
decision-making (246, 247). However, these models are not routinely used 
in the clinical setting (248). Most of the models rely on preoperative clinical 
factors to predict short-term mortality. However, some well-validated 
models such as the Physiological and Operative Severity Score for the 
enumeration of Mortality and Morbidity (POSSUM) (249), the Vascular 
Biochemical and Haematological Outcome (VBHOM) (250) and AAA SCORE 
rely on intra-operative data (246, 248) such as blood loss and operative time. 
In 2014, an additional model -British Aneurysm Repair (BAR)- was 
developed for both EVAR and OAR using 11 preoperative variables (251). 
This model was tested against two other models and the BAR model has 
improved predictability and discrimination (252).   
5.5 Objectives 
The aims of this chapter were: first, to document the national trends of AAA 
disease and presentation during the 2000-2014 period; second, to validate 
the quality and accuracy of the datasets used; third, to report the 30 day, 1 
year and 5 year outcomes of all AAA repairs; and finally, to determine 
prognostic predictors of short- and long-term survival following AAA repair 
in relation to the NZ context.  
5.6 Methods 
5.6.1 Ethics 
The Health and Disability Ethics Committee approved this observational 
study and the obtaining of data from the Ministry of Health National 
Minimum Data Set (NMDS) for matching purposes. Written individual 
patient consent was not possible due to the nature of the study design.  
5.6.2 Data sources used 
As this was a NZ-based project, the best available data were sought to feed 
into predictive model building. In NZ, each patient has a unique seven-digit 
code comprised of three letters followed by four numbers (ABC1234), 
known as the National Health Index (NHI), which allows linkage to 
demographical data such as ethnicity and deprivation anywhere in the 
country. 
To obtain national trends, outcomes and prognostic factors, the datasets 
discussed below were interrogated. 
5.6.2.1 Ministry of Health - National Minimum Data Set  
A data request to the Ministry of Health- Analytical Services was made for all 
International Classification of Diseases (ICD)-10 AAA diagnostic codes and 
procedures from 1st Jan 2010 to 31st December 2014 (Appendix 8.3.1). 
Patient’s demographics, up to 20 diagnoses and up to 20 procedures were 
provided for each patient encounter.  
Initially, a request for all patients with a primary diagnosis of I71.3 
(abdominal aortic aneurysm, ruptured) and I71.4 (abdominal aortic 
aneurysm, without mention of rupture) was made, but it was noted that 
there were substantial missing cases. Therefore, an additional request was 
made for all patients who had an AAA diagnosis in their first 20 diagnoses 
(I71.3 and I71.4), and these were included to ensure a complete capture of 
all AAA cases recorded.  
The operative codes for AAA-related procedures were reviewed and selected 
by two investigators independently to ensure that this method would 
capture all the patients. Aortic procedures for bypass operations were not 
included as these are more likely to be for arterial occlusive disease rather 
than aneurysmal disease. 
Several validation and data checks were then performed. Operative codes for 
rupture procedures were checked to ensure that diagnosis of rupture AAA 
was recorded (I71.3). Two investigators cleaned and checked the data 
independently and the final datasets were checked for consistency and 
completion.  
A total of 23,501 health encounters (hospitalizations) were provided from 
the 1st of July 2000 to the 31st of December 2014, of which 14,343 were 
unique individuals. 
These data were then grouped into three broad categories to allow analysis: 
1) Those diagnosed with an AAA and have not undergone an AAA repair 
N=6,775 (examples: small AAA or large AAA turned down for elective 
surgery or repaired at private hospital); 
2) Those diagnosed with an AAA and have undergone an AAA-related 
procedure N=6,494;  
3) Those without an AAA diagnosis but with an AAA-related procedure 
N=1,065 (examples: aorto-iliac or iliac procedures). 
Patient comorbidities were extracted from ICD codes for individual patients 
and were chosen a priori according to factors that have been shown to 
influence late survival after AAA repair (253). The most prevalent ICD codes 
in the dataset were grouped and used to define the following co-morbidities: 
ischaemic heart disease (IHD), smoking status (ex-smoker/current), 
respiratory disease, hypertension, cerebrovascular disease, atrial fibrillation 
and diabetes (Appendix 8.3.2).  
5.6.2.2 Australian Vascular Audit 
The Australasian Vascular Audit (AVA) is a bi-national web-based audit and 
is the official audit for the Australia & New Zealand Society of Vascular 
Surgery (254). It collects demographic data, risk factors, operative details 
and outcomes for all vascular inpatient events. Data entry was commenced 
in January 2010 with gradual uptake from the majority of vascular units at 
both private and public hospitals in NZ and has replaced several individual 
hospital databases and the Otago Clinical Audit from that date. Since 2012, it 
has been compulsory for vascular surgery trainees to use AVA for generating 
their operative logbook. 
The Australian data in the AVA has been subjected to internal validation 
using 4% of the sample with a reported error rate of 2.6%.  With regards to 
external validation, AVA in Australia captures 62% of AAA-related 
procedures (61). However, this form of validation in NZ has not been 
formally documented. 
The AVA was filtered to capture those AAA procedures performed within 
New Zealand. Between 1st of January 2010 and 31st December 2014, all AAA 
procedures identified from the AVA were obtained. Duplicate patients and 
secondary procedures were removed and the primary AAA procedure was 
considered the index case. The database was checked for procedures 
performed for graft infections, mycotic aneurysms, isolated iliac aneurysms, 
EVAR conversions to open surgery and all re-interventions, and these were 
excluded from the analysis and matching. Of the NHI identified, all except 
one was matched with the NMDS database and three additional fields were 
returned and added into the AVA dataset: ethnicity, deprivation from the 
2013 census data and date of death for patients that died and were 
registered in NZ. 
The AVA collects data on pre-intra operative data and inpatient 
postoperative morbidity and complications. The variables used in this study 
include: age, sex, history of IHD, diabetes, hypertension, renal impairment, 
smoking history, type of repair and maximum AAA diameter.  
5.6.2.3 National Mortality Collection  
All deaths registered in NZ are recorded on the National Mortality collection 
dataset and this database was interrogated to retrieve all deaths with a 
primary diagnosis of aortic diseases (I71.0 to I71.9) from December 1987 to 
December 2013. This dataset included demographic information but did not 
include existing co-morbidities. This permitted defining aneurysm-related 
mortality for those patients who had an AAA repair and died because of an 
AAA-specific cause.  In addition, two further groups were created for 
patients who died with a ruptured AAA in the community or those presented 
to the emergency department and died prior to hospital admission. 
These datasets were then “cleaned”, combined and duplicates removed. A 












Figure 5.1 Diagram showing data synthesis from the three datasets 
5.6.3 Definitions 
5.6.3.1 Mortality 
Early mortality was presented as inpatient (in-hospital) deaths and deaths 
occurring within 30 days. Inpatient mortality as recorded in the AVA was 
defined as a death occurring while under the vascular team or occurring in 
the same hospital admission. 
For patients who were discharged but died within 30 days, the entries were 
checked and confirmed against the NMDS. For patients re-admitted within 
30 days and died, this was included as a 30-day mortality and not as an 
inpatient death. The turn-down rate of patients not offered aneurysm repair 
was calculated by dividing the number of patients who presented to hospital 
with a ruptured aneurysm and did not undergo surgery by the total number 
of patients diagnosed with a ruptured AAA. 
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5.6.3.2 Co-morbidities  
Risk factors were defined as outlined in the AVA manual; briefly: renal 
impairment as creatinine ≥150mmol/L; IHD based on history, 
revascularization or stress tests/ECG; hypertension if on anti-hypertension 
medications or if systolic >140mm Hg systolic and diastolic >90mm Hg; 
current smokers if consumption of cigarettes occurred within 2 weeks of 
operative procedure. 
Hospital volume was grouped into two categories: individual hospitals 
performing greater than 10% of total (national) AAA repair and individual 
hospitals performing less than 10%. Procedures in private hospitals were 
included in the high-volume group because the majority of the procedures 
were performed by vascular surgeons affiliated with high-volume 
institutions. Procedures performed in a private institution but subsequently 
requiring a transfer to a public hospital were included in the private hospital 
group. Mode of admission (arranged or unplanned), length of hospital stay 
and number of AAA-related hospitalizations were recorded. Early mortality 
was defined as a postoperative death occurring within 30 days of surgery 
date. 
5.6.3.3 Ethnicity  
New Zealand national ethnicity standards dictate the use of prioritization of 
ethnicities. This means that if a patient identifies with more than one 
ethnicity, specific protocols are put in place to determine which ethnic group 
a patient will be counted within for the purposes of statistical analysis. This 
is designed to ensure indigenous communities are counted and prioritized. 
It also works to ensure other ethnic minorities are enabled with the largest 
possible inclusion of membership to enable appropriate statistical analysis 
to be undertaken. New Zealand national ethnicity standards encourage all 
primary, secondary and tertiary health institutions to have patients 
complete a form in which they can self-identify with the ethnic group or 
groups that they believe best describes their ethnic affiliations. There were 
32 patients that had more than one ethnicity, which were manually 
prioritized.  
Four ethnic categories were created: NZ European, NZ Māori, Pacific and 
Asian/Other. The NZ European included: NZ European, other European and 
European not further defined. The Pacific group consisted of: Pacific Island 
not further defined, Samoan, Cook Island Māori, Tongan, Niuean, Fijian and 
other Pacific Island. The Asian/other group comprised: Asian not further 
defined, Southeast Asian, Chinese, Indian, other Asian, Middle Eastern, 
African and other. 
5.6.3.4 Deprivation 
The New Zealand Index of Deprivation (NZiDep) is a measure obtained from 
census data and is linked to geographical location rather than individuals 
(255). The NZiDep was calculated based on nine domains: access to 
transport, access to communication, living space, income, recipient of 
benefit, single-parent family, home ownership, qualifications and 
employment) and was collected in the NZ 2006 and NZ 2013 census. Each 
patient in the study was assigned an NZiDep score based on their domiciliary 
address. A deprivation 1 indicates least deprived (high SES) and 10 indicate 
most deprived (low SES). Deprivation categories were grouped into 
quintiles.  
5.6.4 Statistical analysis 
Data validation, cleaning and initial coding was carried out on Microsoft 
Excel (Microsoft Office 2011). Aberrant and incorrect values were checked, 
corrected or removed where applicable.  Continuous variables were 
reported as median (range) or interquartile range (IQR) where appropriate 
or as means and standard deviation (SD) depending on the distribution of 
the data. Categorical variables were reported as counts (percentages). 
5.6.4.1 Incidence calculation 
Age, sex and ethnic (when applicable) specific rates per 100,000 population 
per year were calculated from the NZ population at each respective year. The 
World Health Organization standard population was used to age-
standardize the rates. All cases identified were assumed to be new cases and 
each case was identified once only. Those less than or equal to 44 years of 
age were excluded from the majority incidence calculation as the number of 
patients <44 years old who had an AAA was very small and this skewed the 
incidence rates.  
5.6.4.2 AVA and NMDS validation 
The following information was used for data validation: patient 
demographics (age and sex), date of admission, length of hospital stay, mode 
of presentation (acute/arranged) and risk factors: IHD, diabetes, smoking 
history and hypertension. For admission dates and date of birth differences> 
+/-1 day, a manual check across the datasets was performed to ensure that 
procedures matched. Discrepancies among binary outcomes were expressed 
as odds ratios (OR) and 95% confidence intervals (CI). For the purpose of 
dataset validation, it was assumed that demographic data and survival status 
were correctly coded in NMDS, and clinical risk factors and operative details 
were correctly recorded in the AVA.  
5.6.4.3 Predictors of death at defined points in time 
Clinically-known variables that may have an impact on 30-day and one-year 
death were entered into a logistic regression model and analysed at a 
univariate level. Clinically-important and significant predictors were then 
added into a multivariate logistic regression model and the impact of 
predictors was expressed as OR and 95% CI. 
5.6.4.4 Time-to-Event analysis (survival) 
Dichotomous univariate outcomes were analysed with the log rank test and 
Kaplan-Meier methodology. Continuous and multivariable data were 
expressed as hazard ratios (HR). Clinically-meaningful and statistically-
significant covariates were entered into a multivariate Cox proportional 
hazard model. Patients dying within 30 days were excluded from this 
analysis as including them violated the rules of the Cox model. Censoring for 
survival analysis was set at the 17th of December 2015; this allowed nearly 
one year of minimum follow-up.  A P-value of <0.05 was considered 
statistically significant. Statistical analyses were performed using SPSS 23 
for Mac (SPSS Inc., Chicago, IL) and R statistical software (180) version 3.2.3. 
5.7 Results 
5.7.1 Trends of AAA repair & presentations 
Between the 1st of July 2000 and 31st of December 2014, some 14,700 
patients were diagnosed with an AAA or registered as having died of an AAA-
related death in NZ.  The median (IQR) age was 71 (77-83) years and 10,183 
(69.3%) were males. Of these patients, 10,503 (71.4%) had an intact AAA 
and 4,197 (28.6%) had a ruptured AAA. Of those with a diagnosis of ruptured 
aneurysm, 1,819 (43.3%) had a repair, 1,473 (35.1%) where 
palliated/treated conservatively in hospital and 906 (21.6%) died prior to 
hospitalization. The turndown rate for patients with a ruptured AAA 
reaching hospital was therefore 44.7%. 
The average annual number of AAA repairs remained fairly constant during 
the studied period. There were approximately 350 cases/year of intact 
repairs and 125 cases/year of ruptured repairs. The most noticeable decline 
was observed in the number of AAA diagnosed but not repaired between 
2007 and 2009 (Figure 5.2).  
  
Figure 5.2 Crude counts of AAA cases grouped according to presentation 
† For the pre-hospital rupture group data was only available up to December 2013 
Crude counts were then age-standardized to represent incidence per 
100,000 persons. A pronounced decline in the total of AAA presentations 
was observed in men from 2001 to 2010 and to a lesser extent in females 
(Figure 5.3).  
Figure 5.3 Age-standardized AAA presentations in New Zealand by sex, 2001-
2014 





















AAA non-repaired AAA rupture palliated




























The largest decline in aneurysm incidence was observed in those where AAA 
was diagnosed but no documented AAA repair was recorded. This group was 
then excluded, as it did not represent a clinically meaningful AAA 
presentation-type since patients did not undergo repair or die from the 
condition and very little was known about them. Therefore, it was deemed 
to have little contribution to the national burden for the purposes of the 
analysis in this chapter. After exclusion, the decline was still observed but to 
a lesser extent (Figure 5.4).  
Figure 5.4 AAA age-standardized incidence after excluding those diagnosed 
with AAA but not repaired  
Includes <45 years old  
When the data was separated by presentation, the largest decline in 
incidence was observed in those in which AAA was diagnosed but no repair 

























Figure 5.5 Age standardized presentations of AAA from 2001 to 2014 in males 
and females 
Dotted lines represent linear trends 
5.7.2 AAA presentations according to sex 
There were some differences in AAA presentations between sexes 
(Figure 5.6). Females were more likely to die from a ruptured AAA than 
males (21% versus 14%) and were 3.5 years older. On the other hand, males 
were more likely to undergo an AAA repair (54% versus 34%) at a very 
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Figure 5.6 Proportion of AAA presentation among males and females 
Males n=10,183, females n=4,517. Blue indicates AAA repairs, grey indicates those 
patients that did not undergo repair, and green indicates patients who ruptured their 
AAA prior to hospitalization  
5.7.2.1 Methods of AAA repair 
EVAR has gradually replaced OAR for the majority of patients requiring 
repair for an intact AAA. There was a marked rise in the use of EVAR in all 
age groups and this effect was most profound in those older than 75 years of 
age during the study period (Figure 5.7). 
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5.7.3 Trends of operative mortality  
As shown in Figure 5.8, an approximately 50 percent decline in the 30-day 
mortality for patients undergoing intact AAA repair was observed over the 
last decade. This appeared to coincide with the rise of EVAR usage from 17% 
in 2001 to 55% in 2014. 
Figure 5.8 Dual-axis line graph representing intact AAA mortality and 
proportion of EVAR usage  
5.7.4 Validation of AVA data 
Since the datasets used have not been subjected to any formal validation 
previously, it was of importance to understand the reliability and accuracy 
of such databases. Of the 1713 patients included from AVA, there were 1608 
(93.9%) patients found in the NMDS administrative dataset and this 
comprised the group used for validation. 
There were some demographic data errors identified in the AVA. 39 patients 
(2.4%) had an incorrect date of birth (error of greater than +/-2 days) 
recorded and 14 patients (0.9%) had incorrect gender identification. 
Admission date and length of stay details (error of greater than +/-2 days) 




































Evar / total operated Mortality / total operated
The NMDS, however, correctly identified 98.1% of the patients as receiving 
an EVAR and 94.2% as an elective (arranged) admission. Of the 
comorbidities crosschecked, there was major underreporting in the 
presence of IHD and hypertension in the NMDS compared to the AVA. The 
proportion of patients with a smoking history was similar between the two 
datasets but there was a 32.8% lack of concordance between them (OR 1.56 
(95% CI: 1.34-1.83), P <0.001). The presence of diabetes was more 
consistently recorded in both databases as presented in Table 5.1. 
Table 5.1 Validation of 1604 verified patients between the NMDS and the AVA  
OR: odds ratio, NMDS: National Minimum Data Set, AVA: Australasian Vascular Audit. 
† (> +/-2 days), Range difference: (-5,330 – 31,047) days, ‡ (> +/-2 days), Range 
difference: (-173 – 590) days, § t-test, || Odds ratio of data recorded by NMDS compared 
with AVA data  
5.7.5 AVA data  
The NHI for each entry was entered manually into a free-text space. Thirteen 
patients had incomplete NHIs and a further 30 patients had an incorrect 
NHIs. Hence, the NHIs were grouped into their respective locations and 
surgeons from each unit were contacted and the correct data was requested. 
All the incorrect/missing NHIs were obtained from the treating hospitals 
and corrected for the analysis except for one patient whose correct NHI was 
 NMDS (%) AVA (%) Discrepancy 
(%) 
OR (95%CI) P Value 
Males 1278 (79.7) 1284 (80.0) 14 patients 0.98 (0.82-1.16) 0.79 
Age, mean (SD) 74.3 (7.8) 74.2 (8.2) 39 patients† - 0.72§ 
Date of 
Admission 
- - 33 patients‡ - - 
IHD 161 (10.0) 774 (48.3) 687 (42.9) 0.12 (0.10-0.14) <0.001 
Diabetes 198 (12.3) 187 (11.7) 148 (9.2) 1.07 (0.86-1.32) 0.55 
Hypertension 563 (35.1) 1236 (77.1) 829 (51.7) 0.16 (0.14-0.19) <0.001 
Smoking 
history 




1117 (69.6) 1124 (70.1) 93 (5.8) 0.98 (0.84-1.14) 0.79 
EVAR 745 (46.4) 737 (45.9) 30 (1.9) 1.02 (0.89-1.17) 0.77 
not obtainable and hence was excluded from any analysis (the patient was a 
60-year-old man with a 5 cm AAA who had undergone an elective open 
repair at a private hospital). 
There were two patients with negative survival times, and both were due to 
human errors in entering the fields (one was delayed entry and the 
subsequent date was added as the default date and the second was due to an 
operation finishing on the next day- the operation date was entered on the 
second day). 
5.7.5.1  Overall AVA summary 
Between 1st January 2010 and 31st December 2014, there were 1,804 aortic-
aneurysm-related procedures recorded and after applying the exclusion 
criteria, 1,717 procedures on 1,713 patients were included. The median, 
minimum and maximum age was 75, 35 and 93 years old respectively. The 
population consisted of 1369 (79.9%) males and 344 (20.1%) females.   
The overall proportion of patients undergoing OAR and EVAR was 
938/1,713 (54.6%) and 775/1,713 (45.2%) respectively. Stratifying the 
population into the indication for AAA repair changed the proportion of OAR 
to 543/ 1,220 (44.5%) for elective, 135/207 (65.2%) for symptomatic and 
260/286 (90.9%) for ruptured AAA.  
The inpatient (in-hospital) mortality recorded for elective, symptomatic and 
rupture AAA repair was 1.8, 4.3 and 34.3% respectively.  The corresponding 
values for 30-day mortality matched to the national death records were 2.0, 
5.3 and 34.3% (Table 5.2) indicating that the majority of early deaths 
occurred while in hospital. 
  
Table 5.2 Operative Mortality stratified into type of repair and presentation from 
the AVA and NMDS returns 
 Elective Symptomatic Ruptured 
OAR 19/543 (3.5) 10/135 (7.4) 92/257 (35.8) 
EVAR 6/677 (0.9) 1/72 (1.4) 6/29 (20.7) 
IP deaths from AVA (verified 
from NMDS) 
21/1220 (1.7) 9/207 (4.3) 97/286 (33.9) 
IP deaths recorded on AVA 20/1220 (1.6) 9/207 (4.3) 92/286 (32.2) 
Total (AVA 30 day from NMDS) 25/1220 (2.0) 11/207 (5.3) 98/286 (34.3) 
Total 30 days NMDS (n=2078) 42/1697 (2.5) N/A 120/381 (31.5) 
Percentages presented in parenthesis, deaths as defined by AVA (discharged from AVA), 
N/A: not available 
IP: Inpatient, AVA: Australasian vascular audit, NMDS: National Minimum Data SetThere 
were 97 patients who underwent repair at a private hospital: 57 open AAA repair and 40 
EVAR. There were no 30-day mortality in this group and the majority of indications were 
asymptomatic AAA (93 patients), and in 4 patients were due to pain. 
5.7.5.2 Predictors of 30-day mortality  
A predictive model for early mortality was built using the population of 
patients undergoing intact AAA repair. Both elective (asymptomatic) and 
acute (symptomatic but non-rupture) AAA were included for this analysis. 
These were combined for the following reasons: the ICD coding for 
procedures only codes non-rupture (intact) and rupture diagnoses; the 30-
day mortality of the combined group was considered low; the addition of 
symptomatic AAA was not a predictor of 30-day mortality in the multivariate 
analysis; and combining the groups would increase the power of the model.  
  
Table 5.3: Univariate analysis of perioperative factors associated with 30-day 
mortality after intact AAA repair  





































































































































ASA 1 & 2 




































Number of patients n=1427. †25 missing ‡ 7 missing, - no analysis performed due to no or 
low events 
  
Univariate analysis suggested a trend towards higher 30-day mortality in 
female patients, NZ Māori, patients with a history of IHD or renal 
impairment, patients who had an AAA diameter greater than 6cm, had 
undergone OAR or presented with a symptomatic aneurysm (Table 5.3). On 
multivariate analysis, only females, patients with renal impairment or IHD, 
larger AAA diameter and patients undergoing OAR remained significant 
predictors in the model (Table 5.4).  
Table 5.4 Multivariate analysis of factors associated with 30-day mortality 
 Odds ratio (95% CI) P Value 
Age (continuous, per year) 1.01 (0.96-1.06) 0.66 
Female sex 2.12 (1.02-4.40) 0.040 
Renal impairment 2.85 (1.24-6.57) 0.014 
IHD 1.63 (1.08-4.52) 0.029 
AAA diameter (per 1cm increase) 1.27 (1.011-1.59) 0.04 
Open aneurysm repair  4.55 (1.92-10.74) 0.001 
IHD: ischaemic heart disease 
5.7.5.3 One year predictors of death 
There were 103 (7.2%) deaths within one year from the date of surgery. The 
variables that showed a trend towards a higher one year mortality were: 
IHD, renal impairment, ASA grade >3, larger AAA size and symptomatic 
presentations. The association of gender, Māori ethnicity and type of repair 
with 30-day mortality did not remain significantly associated with one-year 
death rates (Table 5.5). 
  
Table 5.5 Univariate analysis of perioperative factors associated with one-year 
mortality after intact AAA repair  
 Category Odds ratio (95% CI) P value 































































ASA 1 & 2  



















Number of patients n=1427. †25 missing, ‡ 4 missing, ASA: American Society of 
Anaesthesiology  
Predictors that remained significant in a multivariate model after adjusting 
for age and sex were: renal impairment, the presence of IHD and a large AAA 
diameter, as shown in Table 5.6. 
  
Table 5.6: Multivariate predictors of one-year mortality  
 Odds ratio 
(95% CI) 
P Value 
Age (continuous, per year) 1.02 (0.99-1.05) 0.16 
Female sex 1.45 (0.88-2.34) 0.13 
Renal impairment 2.28 (1.32-3.93) 0.003 
IHD 1.64 (1.08-2.49) 0.021 
AAA diameter (per 1cm increase) 1.26 (1.08-1.47) 0.004 
Number of patients n=1427. IHD: ischaemic heart disease 
5.7.5.4 Mid-term survival prognostic factors 
After excluding 30-day postoperative deaths (36 patients), there were 224 
(16.1%) deaths during the follow-up period. The median (range) follow-up 
was 35.3 (1.4-70.1) months in 1,392 patients. 
Covariates that remained significant in the multivariate model and were 
associated with a lower overall mid-term survival included: age, the 
presence of renal impairment, ASA 3 or 4 and receiving an EVAR (Table 5.7).  
 
  
Table 5.7 Univariate and multivariate risk factors asscoiated with mid-term survival 
aftr intact AAA repair 
















0.96 0.99 (0.71-1.39) 0.97 








































0.024 1.08 (0.82-1.43) 0.58 




0.001 1.73 (1.22-1.5) 0.002 




0.67 - - 




0.79 - - 




0.16 1.04 (0.73-1.48) 0.82 
ASA  1 & 2 
3 & 4 
Reference  
2.1 (1.55-2.83) 
0.001 1.78 (1.30-2.45) 0.001 
AAA diameter  Continuous 
per cm 
1.04 (0.93-1.18) 0.48 - - 











0.95 - - 
HR: Hazard ratio 
  
5.7.5.5 Outcomes from the NMDS  
NMDS was filtered to report on the long-term outcomes of infrarenal AAA 
repair (those who had an AAA diagnosis and an AAA-related procedure). The 
demographic and clinical profile of the patients presenting with intact and 
rupture aneurysm is shown in Table 5.8. 
There were 32,699 patient-years follow-up and the median survival for all-
cause mortality after 30 days of surgery was 5.2 years. There were 2,521 
(44.7%) deaths during this follow-up period. The 1, 5 and 10-year survival 
for those who survived 30 days was 94.9, 72.5 and 42.6% respectively. 
The HRs for all included covariates are presented in Table 5.9. On univariate 
analysis, increasing patient age, female sex, higher hospital volumes, 
deprivation greater than or equal to 7, IHD, atrial fibrillation, PAD, 
respiratory and cerebrovascular disease showed a trend to decreasing 
survival. Asian people had in improved survival compared to NZ Europeans.  
Multivariate analysis on Cox proportional hazard model showed that an 
increase in age, and a history of smoking, IHD, chronic respiratory disease 
and cerebrovascular disease were predictors of reduced survival. In 
addition, those undergoing EVAR and repairs performed in high-volume 
centres were also predictors of mortality. After adjustment for confounders 
and excluding in-hospital mortality, NZ Māori had a 48 percent higher all-
cause mortality compared to all other ethnic groups (Figure 5.9). Living in 
areas of high social deprivation greater than or equal to 7 was also an 
independent predictor of worse survival when compared to living in 
deprivation deciles 1 or 2. 
 
  
Table 5.8 Demographics of patients undergoing infrarenal AAA repair from the 
National Minimum Data Set between July 2000 and December 2014  


























































































































† 30 missing, ‡ 182 missing 
 
Table 5.9 Factors of post 30-day all-cause mortality from NMDS following AAA repair 
 Category HR (95%CI) P 
Value 
HR (95%CI)† P 
Value 
Age  per year 1.06 (1.06-1.07) 0.001 1.07 (1.06-1.08) 0.001 





























































































































































N=5,368 excluding patients who died within 30 days and those with unknown ethnicity  
† Adjusted (multivariate) analysis  
Figure 5.9 Difference in predicted survival post-discharge by ethnic groups  
Lines represent predicted probability of survival for a 75- year old man, non-smoker 
with no comorbidities after hospital discharge from an elective open aneurysm repair 
5.8 Discussion 
In this chapter, the trends in AAA presentations, repairs and outcomes were 
presented using the best information available from NZ by interrogating 
both the national (administrative) and the vascular surgery (clinical) 
datasets. This enabled accurate and reliable calculation of short and long-
term outcomes, description of AAA incidence and presentations during a 
14.5-year period, and highlighting some sources of errors between these 
datasets.  
The salient findings observed in this study were: first, the outcomes of intact 
AAA repair have improved during the last decade; second, the overall counts 
of AAA repairs have remained fairly steady but the age-standardized 
incidence has declined; third, the incidence of ruptured aneurysms and the 
proportion of patient’s turndown for surgery has only decreased slightly. In 
describing these findings, the disparity of sex on aneurysm presentations 
and outcomes has also become more apparent. 
5.8.1 NZ aortic aneurysm outcome data 
Every year on average in New Zealand, approximately 220 people are 
recorded as dying of AAA, of which 75% are the result of a ruptured AAA 
without undergoing any form of repair, and the remaining are a consequence 
of undergoing AAA procedures predominantly for ruptured aneurysms. The 
proportion of patients dying with a ruptured aneurysm before reaching 
hospital (21.6%) appears 30 to 50% lower than what was previously 
reported (6, 256). This underreporting therefore might equate to an 
additional 15 to 20 deaths missed every year. 
Data on aortic aneurysms from NZ has been limited to a few studies. Nair et 
al. used the NMDS to report on AAA outcomes in 2002-2006 (121). The 30-
day mortality rate reported for intact AAA was 6.7%. This figure was higher 
than the 4.8% figure obtained in this study for the same study period. This 
difference might be attributed to the data-mining and cleaning process used 
to correctly identify those who had rupture or intact AAA code based on 
presentation type and operative coding. However, the operative mortality 
for ruptured aneurysms was very similar at around 35%. It also appears that 
operative mortality has decreased from 46% as reported by a study from 
Auckland in the mid-1990s (118). 
Previous studies identified a higher 30-day mortality in NZ Māori compared 
to NZ Europeans (119, 121). In this study, this was only statistically 
significant in univariate analysis, with the difference diminishing after 
adjusting for possible confounders. Māori, however, had worse long-term 
overall survival compared to NZ Europeans. Moreover, Māori women had 
significantly higher AAA-related mortality compared to other women and 
these figures were comparable with NZ European males. This rate has not 
changed between 1996 and 2007 (11.7 per 100 000 and 9.2 per 100 000 
population respectively) compared to all other groups (120). The reasons for 
this apparent disparity are unknown, but may well be because of the known 
high smoking rates of Māori women (257). 
The high mortality associated with ruptured AAA and the unchanged 
ruptured AAA incidence underline the importance of detecting and 
managing aneurysms before they rupture.  
5.8.2 Incidence of aortic aneurysm 
Sandiford and colleagues reported that the incidence and mortality of AAA 
hospitalizations between 1995 and 2008 in NZ have declined (13). This 
study overlaps the data presented in this chapter. The AAA incidence during 
the overlapping years was very similar between both studies and the 
incidence of aneurysms appears to have plateaued from 2008 onwards.  
In contrast to Sandiford’s report, AAA presentations in this study were 
separated in order to provide some explanation for this decrease in age-
standardized incidence. In doing so, one of the major contributors to this 
decline appeared to be those patients who had an AAA diagnosis but did not 
have a repair. Multiple methods to try to understand what this group 
consisted of were made and the reasons for this sharp decline from 2007 to 
2009. A random sample of patients from Christchurch Hospital was taken 
and checked against the electronic medical charts. This revealed that the 
majority of those patients had small AAAs, and other minor reasons for the 
decline were: patients with AAA who had their repair in private hospitals, 
patients with threshold AAA who were turned down for elective repair and 
miscoding of the I71.4.  
These data were then separated by district health boards (DHB), which 
showed that the number of AAA patients in some locations did not 
correspond to the expected volume of patients with AAA clinically managed 
by the population served. The coding team at Christchurch hospital was then 
contacted and the explanation was that, prior to this period, patients who 
had a diagnosis of AAA but presented to hospital with any other condition 
were coded as having an aneurysm, whereas after 2007, the Ministry of 
Health discouraged this practice and AAA was only coded if it was the 
principal reason for hospitalization.  
5.8.3 Changes to AAA management and outcomes 
The first EVAR for treating AAA in NZ was performed in 1997 at Waikato 
Hospital and since then it has complemented conventional OAR and has 
slowly replaced open surgery across the country. NZ remains conservative 
with the use of EVAR, which is similar to some European countries and parts 
of the UK but unlike the majority of Australia and the USA centres (62, 258).  
This can be partly explained by access to universal national healthcare and 
vascular surgeons offering both types of procedures.  
The decline in 30-day mortality following intact AAA repair has been 
observed elsewhere and has been predominantly related to the rise in EVAR 
usage (65, 259), but advancement in medical and surgical care with 
specialization in vascular surgery and some centralization might have also 
contributed to the lower operative mortality. 
Although the mortality from AAA has been shown to have declined in the last 
two decades in several countries (14, 15, 19), this has not been consistent in 
all regions of the world (17). Analysis from the Global Burden of Disease 
Study suggests that the mortality from AAA has actually increased by 45% 
from 1990 to 2010 (25).  
In this study, when possible, aneurysm incidence and presentation was 
separated by sex to document differences. Although the overall incidence of 
AAA is decreasing in males, the incidence of AAA appears to decreasing a 
slower rate in females, with almost 30% of females presenting with ruptured 
aneurysms. More efforts to reduce this apparent disparity is required. 
5.8.4 Predictors of 30-day mortality  
There are well-documented predictors of 30-day mortality after AAA repair 
that have been incorporated into most predictive logistic models (246). The 
predictors of thirty-day mortality in this study (age, AAA diameter and renal 
impairment) were consistent with contemporary data from Australia and 
Europe (258). 
The 30-day mortality after AAA repair has consistently been higher in 
females compared to males for both OAR and EVAR. A meta-analysis 
reported that the pooled OR for women after elective OAR and EVAR was 
1.28 (95%CI: 1.09-1.49) and 2.41 (95%CI: 1.14-5.15) respectively (105). 
Interestingly, in the AAA SCORE model, gender was not shown to be a 
predictor in the model-validating process and hence was not included (248). 
In this study, despite the relatively small number of patients included, 
females had a higher operative mortality than men, OR 2.13 (95%CI: 1.03-
4.54). 
5.8.5 Long-term outcomes & prognostic factors 
A meta-analysis that included published studies from the majority of 
continents reported that the 5-year survival after AAA repair was 69% (75). 
In the NZ data reported here, the observed actuarial 5-year survival was 72% 
and therefore consistent with others findings. 
Some of the predictors of late survival were consistent with the factors 
reported in chapter 4, including age, IHD, current smoking, respiratory 
disease and cerebrovascular disease (Table 5.10). However, female sex and 
PAD were not predictors of mortality but they did show a weak association 
in univariate analysis. This might be due to the smaller number of patients 
included in this study compared to the meta-analysis and the method used 
for case definition. For example, the use of ICD coding to detect PAD has been 
shown to be an insensitive method to capture the prevalence of the disease 
in the general population (260). 
Although hospital volume was not included in the data extraction in the 
previous chapter, it was noted that patients who had their AAA repaired in 
high-volume institutions had a lower overall survival. This may be due to 
referral of high-risk patients from small-volume hospitals and perhaps a 
tendency by smaller units to turn down higher-risk patients for procedures 
particularly ruptured AAA (261). 
 
  
Table 5.10 Comparison between the impact of prognostic factors in this study and 
the meta-analysis from Chapter 4 
 HR 95%CI 
 Current study Meta-analysis 
Age 1.06 (1.05-1.07) 1.05 (1.04-1.06) 
Females 1.05 (0.95-1.15) 1.15 (1.07-1.27) 
Smoking history 1.16 (1.06-1.27) 1.27 (1.07-1.51) 
IHD 1.22 (1.11-1.34) 1.29 (1.18-1.48) 
Respiratory disease 1.61 (1.44-1.80) 1.53 (1.37-1.70) 
Diabetes 1.13 (1.00-1.29) 1.34 (1.20-1.49) 
Hypertension 0.96 (0.87-1.04) 0.90 (0.79-1.03) 
Cerebrovascular Disease 1.94 (1.66-2.27) 1.57 (1.40-1.77) 
PAD 1.10 (0.98-1.24) 1.36 (1.18-1.58) 
IHD: ischaemic heart disease, PAD: peripheral artery disease, HR: hazard ratio, CI: 
confidence interval 
Social deprivation has been associated with worse outcomes and survival 
following cardiac surgery (262) but its impact on AAA is unknown. This 
relationship has not been well investigated in countries with universal 
health care. The generally worse outcomes observed with uninsured 
patients and ethnic minorities has been reported in the Unites States (263, 
264) and does not appear to have changed during the last decade (213). In 
NZ and most European countries, national healthcare access is free. Despite 
this, we identified vulnerable groups that had higher mortality after AAA 
repair. 
5.8.6 Data validation and accuracy 
There were missing patients from each dataset, however the mortality rates 
were similar. Regulatory bodies are very likely to use the most accessible 
data rather than the “best” available data when policy decisions are made, 
therefore understanding the limitations of each dataset is important. 
This type of validation study has been reported elsewhere in different 
geographical settings. Several similar studies linking administrative and 
clinical databases have been conducted in the UK and conflicting results have 
been reported. Holt et al. compared 1102 elective AAA patients from the 
English Hospital Episode Statistics with clinical case records and 86% of the 
cases were confirmed as an elective AAA repair (265). Johal et al. reported 
that of patients undergoing AAA replacement, the diagnosis of AAA was 
consistent in greater than 90% (266). However, a study from Scotland 
highlighted that such discrepancies between clinical and national data can 
lead to significant under-reporting of mortality in national figures (267). In 
our study, the results were similar, but including both datasets allowed more 
accurate documentation of outcome data. 
The mortality rates for AAA repairs from each dataset were very similar and 
the results compare favourably with reported contemporary international 
elective AAA repair figures (258). However, differences between the two 
datasets might be attributed to the unclassified diagnosis of “symptomatic” 
but non-ruptured AAA, which occurred in about 12% of AAA presentations. 
The majority of private AAA procedures performed were not found on the 
NMDS. Therefore, the total number of repairs performed in the private 
sector is unknown. Excluding private AAA repairs from national figures 
could also partially account for the 0.5% higher mortality reported in the 
NMDS. 
5.8.7 Strengths and limitations 
Each dataset has inherent strengths and weaknesses that are worth 
mentioning. Unlike most data from large population database or registries 
where data-pooling and analysis is automatically performed, in this study, 
there were multiple levels of data-cleaning and matching to ensure that any 
errors and biases were reduced. To date, this is the first study of this nature 
to report such data from NZ. The number of patients included is relatively 
large and the outcomes presented reflect current local AAA practice.  
There are potential limitations that are inherent to administrative national 
datasets and the design of studies of this type. First, the deprivation index is 
not linked to individuals but to geographical neighbourhoods, hence cannot 
be directly related to unique patients. Second, there were several other 
important predictors of long-term survival that could not be included 
because of lack of recording, such as medications (aspirin, statins), renal 
impairment and AAA diameter. Third, the influence of other lifestyle and 
behavioural factors such as physical exercise, psychological stress and diet 
are not well-reported in AAA literature. Furthermore, the mortality 
collection records that were used included only those deaths that occurred 
within New Zealand; any deaths occurring outside New Zealand would not 
be captured and this would likely have resulted in some degree of under-
reporting.  
For the period of July 2000 to Dec 2009, the previous national audit of 
vascular surgery (Otago Surgical Audit) could not be retrieved as the 
software was outdated. Therefore, data matching could not be performed for 
that phase and potentially some patients might have been missed. If the 
numbers of AAA performed in private were constant during the past 15 
years, then an approximately 160 patients might have been missed. 
5.9 Conclusions 
This study highlights the contemporary incidence, presentation and 
outcomes of patients with AAA in NZ by using the best information available. 
There were major changes to AAA management during this period with 
important implications for early outcomes. 
While the overall age-standardized incidence of AAA is slowly decreasing, 
the number of recorded ruptures occurring prior to hospitalization has not 
changed. The reduction of AAA mortality has been predominantly related to 
the increase in EVAR usage. 
Along with the known predictors of overall survival, Māori ethnicity and 
patients living in high deprivation areas are associated with higher mortality 
after repair. Efforts should target this higher-risk group to improve 
outcomes and reduce disparity. 
All AAA datasets used (clinical and administrative) were incomplete, but this 
analysis has allowed us to understand the differences and to combine the 
databases, therefore providing the best estimates to date, ensuring a better 
representation of absolute national work load, enabling accurate survival 
status and increasing the utility of such datasets to reflect real world clinical 
outcomes. 
5.10 Future Work  
This data synthesis has highlighted several novel findings within the NZ 
population that are worthy of further exploratory work, in particular the 
disparity in outcomes among different ethnic groups and social deprivation. 
In addition, exploring the reasons for lower survival seen in patients who 
underwent repair in high-volume centres and understanding the referral 
pattern of patients among services is important for provincial vascular 
surgery service-planning. The contemporary short- and long-term outcome 
data and factors influencing survival can be used in predictive modelling and 
in any national policy-making surrounding AAA management.   
 
6.1 Overview 
Randomised controlled trials are the ‘gold standard’ to test the effects of 
different treatments on participants. As discussed earlier, some aspects of 
AAA management have been subjected to good-quality trials during the last 
three decades. However, applying such evidence to individual patient care 
can be complex, as several factors need to be taken into consideration. As 
mentioned in chapters 4 and 5, there are ample models that predict short-
term preoperative mortality, but the literature lacks well-developed long-
term decision models. 
The main determinants of an individuals’ life expectancy are baseline 
demographics and comorbidities. Patients with an untreated AAA have an 
additional factor of ongoing rupture risk. Predictive models require such 
inputs to inform the results of undergoing or not undergoing an AAA 
treatment. 
In this chapter, the outcome and prognostic data synthesized from the 
previous chapters compounded by evidence established from the literature 
will be compiled and used to develop and validate a predictive model to aid 
personalized decision-making for AAA management. 
6.2 Contribution 
Data obtained in the past chapters come together to provide information to 
design a decision-aid predictive tool to assist in the management of AAA. 
Some of the parameters used in this model were obtained from chapters 4 
and 5. Mr Giorgi Kvizhinadze helped develop the simulation software of the 
predictive model. I have tested and validated the model using several 
datasets that required data collection and cleaning. 
6.3 Significance 
Tools to assist clinical decision-making for patients with AAA are limited in 
the literature and have predominantly been developed to predict the short-
term outcomes of aneurysm intervention. It has also been highlighted as a 
research area of need (246, 268, 269). The simulation model developed in 
this chapter shows very promising results with good predictability and 
discrimination. Further external validation from other datasets will be 
required to test the model’s generalisability in different clinical settings. This 
work has not been presented at a conference, but the manuscript is being 
prepared for submission to a peer-reviewed journal.  
6.4 Background 
The ongoing risk of AAA-related death, uncertainty of aneurysm expansion 
and rupture, and the background mortality risk from other causes make 
AAA-management pathways ideal for predictive modelling.  
The clinical decision-process usually involves consideration of both patient 
and AAA factors. The patients’ clinical profile which determines their 
likelihood of survival with or without repair is usually predominantly 
determined by their demographic and clinical comorbidities. The aneurysm 
diameter is the most important determinant of rupture probability and 
therefore forms a crucial element in the probability matrix (1). Additional 
considerations include anatomical complexity characteristics of the 
aneurysm and the proposed procedure. A decision on the best management 
options usually involves a discussion between surgeons, the patient and 
their families and is most often based on gut feeling (268) and clinical 
experience rather than validated predictive tools designed to assist decision-
making. 
However, as described earlier, integrating all possible scenarios can be 
complex for each patient encountered in a clinical environment. There are 
four general modes of death for a patient with an aortic aneurysm: mortality 
post scheduled repair, aneurysm rupture prior to repair, death from a non-
AAA related (i.e. cardiac or oncological) cause and death as a consequence of 
long-term AAA-treatment-related complications, such as late graft rupture 
or graft infection. Therefore, weighing the risks and benefits of treatment in 
any individual can be a complex process.  
Questions that require clinical decision-making include whether or not to 
offer AAA treatment based on an individual’s life expectancy, which 
treatment modality to offer (open aneurysm repair vs. EVAR) and at what 
AAA diameter should a patient be offered treatment. For patients in the 
extreme profile ranges (very low risk or high risk) the clinical decision-
making is usually straight forward with experience, but for those 
intermediate-risk patients, the decision is not always so (270). Although 
there are good evidence-based treatment strategies for some aspects of AAA 
care such as type of repair and size of AAA (51, 59), management of patients 
outside the studied population cannot always be generalised to those in 
extreme age groups or those with no or extensive co-morbidities.  
Tools to inform clinicians of the predicted outcomes to aid in decision-
making are becoming increasingly important as a part of individualizing 
patient care. However, unlike cardiac surgery where predictive scores such 
as the European System for Cardiac Operative Risk Evaluation (EuroSCORE) 
has been widely and routinely used clinically (271), prediction tools for AAA 
repair have not been commonly adopted in clinical vascular surgery practice 
(252).  
Possible reasons that surgeons or interventionists might be reluctant to use 
such predictive models for decision-making surrounding AAA management 
include: a decline in perioperative aneurysm mortality in the recent era, 
particularly with the use of EVAR (65); the advancement of this technology 
(EVAR) which enabled procedures to be performed with percutaneous 
femoral access (272), as a day case and often a under local anaesthetic (273, 
274), indicating that morbidity is also reduced;  and furthermore, there 
might be financial rewards in some countries with over-treating patients 
with smaller AAA particularly using EVAR (275).  These compounded factors 
have made inpatient or 30-day mortality an uncommon event, thus limiting 
the requirement of early predictive models.  
Patients with an AAA have a lower expected survival compared to an age-sex 
matched population (276). In addition, contemporary data suggests that the 
5-year overall survival after an aneurysm repair is 70% (75). A model that 
can predict this long-term survival might therefore be a more beneficial tool 
for clinicians and patients particularly when considering management of 
elderly patients with relatively small aneurysms, as prevalence data 
included in Chapter 2 shows that this is potentially a very large group.  
6.4.1 Model definition and reasons for its use 
Models can be defined as mathematical tools that allow complex systems to 
be simplified to represent essential components of reality (277, 278). In this 
chapter, such models are used to predict health outcomes and therefore are 
considered as prognostic research models (279). This method of research 
involves reporting the relationship between baseline health profiles and 
future end outcomes, such as the comorbidities of a patient undergoing AAA 
repair at baseline and the outcome of interest of either morbidity or death 
over a specified time. On the other hand, simulation refers to the process of 
imitating an actual system by an interactive representation in a model 
format (278). These terms are often used interchangeably and therefore it is 
worth defining them in the context they are used in.   
The use of decision-making models has increasingly become an important 
component of clinical research. The number of decision-analysis 
publications in the literature has exponentially risen during 2004 to 2014 
(280). They are particularly useful in situations of uncertainty and high 
complexity especially when randomized controlled trial data are lacking and 
it is important to individualize care.  
In healthcare, there are many unknowns with regards to predicting clinical 
outcomes, and direct experimentation is not always possible. Clinical trials 
can be very costly and often require a long time to complete (281). Moreover, 
implications of economic analyses and cost effectiveness in an era of ongoing 
financial constraints can be simulated to assist decision-makers and 
stakeholders. In response to growing knowledge of diseases, national or 
societal guidelines and protocols have been developed to assist in clinical 
decision-making. However, such documents are not always individualised to 
unique patients and therefore generalizability cannot be applied to all. In 
such instances health models and simulations might be a more appropriate 
strategy.  
Another advantage in using models is that the selection or personal bias in 
choices can be reduced and better streamlined.  Rather than being based on 
gut feeling or instincts formed by clinical experience (282), properly 
designed analytical models can consider all clinically relevant inputs prior to 
contemplating a treatment decision.  
However, health models also have limitations. These are confronted when 
uncertainties are encountered and assumptions have to be made since 
creating reality is impossible (283). Another limitation of models is that they 
can be complex and require reasonable understanding to interpret the 
behaviour and the background structure, which requires transparent model-
development-process reporting from developers.  Guidelines for good 
practices have been proposed to help uniform model development and 
standardize reporting, (284). 
6.4.2 Types of models & simulations 
There are several methods of modelling that are commonly used in 
healthcare (278), whose application may vary depending on the intended 
use of the model. There are generally two types of patient-modelling 
approaches used: population-based models (also referred to as cohort 
modelling) and models of individuals within a population (also known as 
patient-level simulation or individual-simulation) (285). 
The most common use for modelling is to compare different strategies of 
care in terms of health economics and cost-effectiveness analysis. The 
common types of predictive and prognostic models used in healthcare are 
briefly discussed below. 
6.4.2.1 Survival calculators 
Prognostic calculators that are sometimes represented as nomograms are a 
well-established form of prediction-models used commonly in oncological 
conditions (286) to estimate survival. They provide a simple graphical 
probability of clinical events based on a formula (287). They can lack the 
complexity of the models where interaction and changing background 
mortality can occur.  
6.4.2.2 Decision trees 
These represent the simplest model design and remain the basic framework 
for the majority of decision analyses and thus the most widely used (278). 
The structure involves branches that are mutually exclusive with associated 
probabilities. The limitations of this approach are the inability of events to 
interact and that the analyses are based on fixed time-frames (288), 
therefore any changes that occur in the system or in time would require a 
separate run of the model. 
6.4.2.3 Discrete event simulation  
Discrete event simulation (DES) was described in the 1950s in the 
operational field (289) and is now used in a wide range of industries. This 
modelling approach focuses on the individuals’ defined characteristics, their 
associated events over time and the consequences of those events at a 
patient-level. This micro simulation and flexibility of DES allows the model 
to take into account the patients’ clinical profiles and therefore take 
heterogeneity into consideration. The process randomly samples time-to-
event distributions making it ideal for time-to-event analysis. Another 
important feature of DES is that it allows individuals to queue for events and 
involves competition for resources (288). The strength of DES is that it is a 
very flexible model and allows interaction within the system (278).  
6.4.2.4 Markov models 
Markov models were first introduced by a Russian mathematician in 1906 
(290) and are probability-based models that allow transitions between 
states to occur during a defined time period (time-horizon). These 
transitions occur at random, follow a stochastic process and are independent 
of other transitions (291). The number of patients remaining in each cycle is 
determined by probability transitions. Historically, Markov models are the 
most commonly used models in economic analyses (292). They are useful to 
simulate ongoing risks in a particular situation.  
6.4.3 Comparison of model types 
With widespread development and use of decision-analysis tools, selecting 
the most appropriate approach is a vital initial step. The choice between a 
cohort-simulation and an individual-simulation approach is the first step. 
When simulating a certain target patient-group, individuals do not usually 
have the same proportion of comorbidities. A cohort-simulation approach 
such as a Markov model assumes that the proportion of comorbidities is 
averaged in the population, whereas a patient-level simulation takes into 
account each individual’s risk profile (285). In reality, an individual with 
more comorbidity is more likely to reach the end outcome than someone 
without comorbidity.  
The academic community has been more familiar and has had more 
experience with the Markov family of approaches and therefore they were 
more commonly used (285). Emerging evidence, however, suggests that DES 
models might be a more useful approach in areas where Markov models have 
shortcomings. DES allows patients to interact and compete, the timing of 
each event can be an independent rather than a “fixed” length cycle like 
Markov models, and each interaction can create a change in the model state 
(293). 
In DES, the explicit element is the patient rather than the “state” or outcome 
as seen in Markov models (294). Another limitation of Markov models when 
compared to DES is that it has fixed equal states and it fits all the cohort in a 
series of states. This might lead to inaccuracies if some patients in the cohort 
have not completed the state (285).  
DES has consistently been shown in cost effectiveness and clinical outcomes 
studies to be superior to Markov modeming in predicting long-term survival 
(288, 295). Furthermore, a comparative analysis of Markov and DES models 
which included 22 studies concluded that when the patient’s history is an 
important prognostic factor, a DES model is the preferred approach (290). 
Therefore, the DES was chosen over a Markov model because the time-to-
event can occur at random rather than in a fixed cycle as in Markov models, 
and the concept of competing risks for events is critical in AAA clinical 
management (296). 
6.4.4 Existing models in predicting long-term AAA survival  
The use of models and simulations in the AAA literature has often been 
reserved for economic analyses to determine cost effectiveness of AAA 
screening and costs associated with type of treatments (68, 98). While there 
are several perioperative scores to predict outcomes of AAA repair in the 
elective and the emergency setting, there is very limited data on models that 
can predict longer-term mortality and therefore might be more relevant to 
patients and physicians (268).  
The first reported model to predict long-term outcomes used the Glasgow 
Aneurysm Score (GAS) in two different datasets to predict long-term 
survival following AAA repair. The GAS score is calculated using the 
following formula: age +7 points for myocardial infarction +10 points for 
cerebrovascular disease +14 points for renal disease (297). Using the 
EUROpean collaborators on Stent-graft Techniques for abdominal aortic 
Aneurysm Repair (EUROSTAR) registry, the GAS was able to distinguish the 
long-term survival of patients undergoing EVAR when stratified into GAS 
tertiles (298). Following this, the DREAM investigators used the GAS on their 
trial cohort for further validation, and the plotted receiver-operated- 
characteristic (ROC) curve for OAR and EVAR was 0.74 and 0.78 respectively, 
indicating reasonable reliability at predicting 2-year survival (299). 
Mastracci et al. developed a nomogram to predict 2, 4 and 8-year survival 
after EVAR using predictors of survival for 412 patients (230). This model 
was internally and externally validated using normal and high-risk cohorts 
and the c-statistic was 0.68 (95% CI: 0.65-0.71), demonstrating a fair 
predictability. However, there have been no further attempts at using this 
predictive tool or further validation. 
Stuart and colleagues developed a DES to aid decision-making in aneurysm 
repair (269) using parameters from the British Aneurysm Repair (BAR) 
score to predict in-hospital mortality (251) and RESCAN data to estimate 
AAA growth and rupture rates (32, 300). The outputs of the model include 
survival probabilities and life expectancy. However, this model has not been 
tested or validated to date and was developed on a complex statistical 
software package, therefore its use has not been translated into the clinical 
environment. 
Carlisle developed a survival-predicting calculator that estimates 
trajectories of survival with and without aneurysm repair taking into 
account the patient’s clinical profile and cardiopulmonary exercise (CPX) 
testing variables (301). The concept of this model was well-documented and 
has been validated externally on 1096 patients (302). The calculator is also 
simple to use and is available freely online. The limitations of such a model, 
however, are the complexity of variables required, such as CPX and 
anthropometric measurements. In addition, the growth and rupture risk of 
AAA were based on linear calculations from the RESCAN data which were 
not adjusted to gender differences.  
As the experience with EVAR increased, certain arterial anatomical features 
have been attributed to early failure and endoleak development (303-305). 
An interactive decision tool was developed by Barnes and colleagues to 
predict the short- and long-term outcomes after EVAR (306).  This model 
uses patients’ age, sex, American Society of Anaesthesiologists (ASA) grade, 
AAA diameter and creatinine, along with three additional aortic morphology 
features- aortic angle, neck diameter and neck length, and 17 possible 
outputs are generated. This model has been validated by a centre in the UK 
(307) and another centre in Queensland, Australia (308) and was shown to 
be a good predictor of early mortality and endoleak complications. However, 
when the model was tested in a clinical setting in the Netherlands, it did not 
appear to be adequately accurate (309). In addition, the fact that this model 
only addresses a proportion of patients that undergo aneurysm repair 
(EVAR) limits its use in the wider clinical setting. 
The general limitations of all the above-mentioned prognostic models are 
the lack of robust validation against other datasets and that prognostic 
variables have been developed from specific patient populations (most 
models included EVAR patients only), and therefore their utilisation in the 
clinical setting has been restricted.  
6.5 Objectives 
The primary objective of this chapter was to develop an interactive model 
that can assist in clinical decision-making of AAA management for individual 
patients and externally validate it against existing databases of patients with 
small AAA and those who have had an aneurysm repair. 
6.6 Methods 
The clinical management and natural history of AAA were mapped at an 
individual patient level by two persons (MK and JR), then the probability 
estimates at each level were obtained from national and international data. 
6.6.1 Input variables 
A comprehensive search for the best available information from the 
literature revealed that the RESCAN data provided the largest and most 
accurate contemporary estimates of AAA growth and rupture (Table 6.1 and 
Table 6.2) and hence they were used to represent the natural history of AAA 
(32, 300). 
  
Table 6.1 Annual growth rates of AAA per mm per year according to diameter  
 Mean expansion rate (mm per year) 
AAA diameter (cm) Males Female 
3 1.28 1.46 
3.5 1.86 1.98 
4 2.44 2.51 
4.5 3.02 3.06 
5 3.61 3.62 
5.5 4.21 4.22 
6 4.81 4.82 
 
Table 6.2 AAA annual probability of rupture risk according to diameter and gender 
AAA diameter (cm) Males (%) Females (%) 
3 0.05 0.22 
3.5 0.09 0.45 
4 0.17 0.79 
4.5 0.32 1.47 
5 0.64 2.97 
5.5 1.28 5.94 
6 2.56 11.88 
6.5 5.12 23.76 
7 20 40 
8 50 50 
Table 6.1 and Table 6.2 were both adapted from Stuart et al. Calculating when elective 
abdominal aortic aneurysm repair improves survival for individual patients (209) 
Data on >5cm AAA is extrapolated 
  
6.6.1.1 Selection of comorbidities  
The reported hazard ratio (HR) obtained in chapters 4 and 5 was used to 
predict additional (excess) mortality after AAA repair. The process of 
selecting comorbidities for model inclusion is highlighted below. 
Age as a continuous variable (per year), gender and ethnicity (NZ Māori or 
non-NZ Māori) were used to adjust for background mortality in the general 
population which was derived from the NZ life tables, 2010-2012 (127). The 
natural history of AAA requires an aneurysm diameter to be included in 
order to predict future growth rates and rupture risk as it is an important 
prognostic factor and an independent predictor of survival in the long term 
(310).   
The remaining comorbidities were selected if the HR had a significant impact 
on survival (harmful or protective), large number of participants 
contributed to the meta-analysis (more than 5,000 participants) or was 
present in a large proportion of the AAA repair cohort. The following 
comorbidities were included: ischaemic heart disease (IHD), myocardial 
infarction (MI), cardiac failure, chronic obstructive pulmonary disease 
(COPD), cerebrovascular disease, diabetes and a history of smoking. Renal 
disease was kept categorical and defined as a creatinine plasma 
concentration greater than 150mmol/L. The uses of statin and antiplatelet 
therapy were the only protective factors and were also included in the 
model. Although relatively uncommon comorbidities, COPD on 
supplementary oxygen and end stage renal disease (ESRD) were included as 
their impact on mortality was associated with a HR greater than three.  A 
summary of the variables included is shown in  
Table 6.3. 
Hypertension, Peripheral artery disease (PAD), the use of beta-blockers or 
anticoagulation, coronary revascularisation, cancer history, ASA grade, body 
mass index (BMI) and haemoglobin concentration were all excluded from 
the model due to having no or small hazard effects, small numbers of 
participants contributing to the meta-analysis, or a large unexplained 
inconsistency (effect heterogeneity) making the results difficult to interpret.  
Table 6.3 Summary of hazard ratios and estimated proportion of variables included 
in the model development  




HR (95%CI) Proportion 
(%) range 
Demographic:     
Age (continuous)/year 31,100 21 1.05 (1.04-1.06) 72-76 years † 
Gender (females, males as 
a reference) 
49,653 16 1.15 (1.07-1.27) 22 
NZ Māori 420 1 1.43 (1.21-1.69) 6.5 





































Cerebrovascular disease 7,726 9 1.57 (1.40-1.77) 7 
Diabetes 44,211 14 1.34 (1.20-1.49) 13.8 (11-15) 
AAA diameter (per cm) 19,722 16 1.14 (1.10-1.18) 51-64mm † 
Statin use 38,252 11 0.75 (0.70-0.80) 46-70 
Antiplatelet use 8,447 4 0.81 (0.73-0.89) 60 
History of smoking (any) 12,663 7 1.27 (1.07-1.51) 77 (75-80) 
† Median (range) 
IHD: ischaemic heart disease, MI: myocardial infarction, COPD: chronic obstructive 
pulmonary disease, O2: oxygen, ESRD: end stage renal disease, AAA: abdominal aortic 
aneurysm, HR: hazard ratio, CI: confidence intervals 
6.6.1.2 Predicted survival  
Patient survival post-AAA is well documented in the literature with an 
approximately 30% probability of dying within 5 years. Survival post 
ruptured AAA is different to survival post intact repair in the initial 30-day 
period, but when the early period is excluded, they are very similar. The 
average contemporary elective mortality of intact AAA was assumed to be 
4%. The preoperative (pre-hospitalization & hospital non-operated) rupture 
mortality was 60% and the operative mortality risk for a ruptured AAA was 
35%. The actual survival curves for rupture and intact repair are shown in 
Figure 6.1.  
6.6.2 Model structure & development 
An individual with an AAA diameter range of 3 to 10 cm is entered into the 
simulation model and three management options are considered: immediate 
elective repair, surveillance or conservative management. The first decision 
is made when setting an aneurysm threshold for AAA treatment (usually 
5.5cm for males and 5cm for females), but the threshold for intervention can 
be altered depending on age, sex, and patient or surgeon preferences. If the 
aneurysm diameter is larger than the threshold then a surveillance survival 
is not calculated.   
The surveillance survival is based on AAA expansion until threshold is 
reached, then the patient undergoes elective aneurysm repair. The 
conservative management arm is based on the aneurysm rupture risk 
depending on the selected baseline AAA diameter and no elective repair is 
permitted. For those with an AAA diameter less than the operative threshold, 
three survival probabilities are calculated: elective repair, AAA surveillance 
and conservative management (no repair or surveillance). If the AAA size is 
greater than the threshold set, then the surveillance survival probability is 




Figure 6.1 Kaplan-Meier survival of patients undergoing AAA repair from the 
National Minimum Data Set 
A: All-cause mortality, B: Excluding 30-day mortality, C: Excluding 1 year mortality  
Grey line is intact AAA and blue indicates rupture AAA. The numbers of intact and 





 Figure 6.2 Model diagram used to produce the simulation of AAA management  
6.6.2.1 Assumptions 
Some assumptions had to be made to allow the model to behave as close to 
contemporary natural AAA history as possible and to reflect current clinical 
practice. 
1) Once an AAA is detected and planned for scheduled repair, no 
preoperative rupture occurred.  
2) If aneurysm surveillance is chosen, no aneurysm acute or rupture 
presentations occurred. 
3) Conservative treatment assumes that the AAA can rupture based on 
estimated annual rupture risks and no elective surgery occurs. 
4) There was no late overall survival difference following EVAR and 
OAR, in contrast to 30-day mortality where an odds ratio of 0.2 for 
EVAR compared to OAR was chosen. 





















6) The risk of late AAA-related mortality (re-rupture or graft-related 
complications) was in fact very small and hence was included in the 
overall background mortality.  
7) Baseline comorbidities did not change over time. 
8) There were some limits to the continuous variables: age 35 to 90 
years old and AAA size 3 to 10cm.  
6.6.2.2 Model behaviour  
A DES was built to simulate the natural history of AAA where time to death 
from all causes competes with time to death from aneurysm rupture and 
post-operative mortality. Time to death from all causes was drawn from an 
all-cause cumulative mortality distribution function. Time to aneurysm 
rupture was modelled based on AAA growth and the annual probability of 
rupture, whereas time to post-operative mortality was drawn from the 
patient’s specific profile cumulative mortality distribution function.   
The model interface and platform was built on Microsoft Excel and is shown 
in Figure 6.3. For each patient, the life events were iterated 2,000 times using 
their baseline demographics, AAA diameter and comorbidities.  The 
simulation for each patient entry takes 15-25 seconds to complete the 













































































































































































































































6.6.2.3 Model performance  
Reports from the International Society for Pharmaeconomics and Outcomes 
Research (ISPOR) and the Society for Medical Decision Making (SMDM) 
guided the reporting and validation (311) of the model development. The 
predictive performance of the model was tested and externally validated 
using a systematic approach proposed by Steyerberg and Vergouwe (312). 
Calibration refers to the agreement between the observed (actual) endpoints 
and the model’s prediction. It is presented as a calibration plot where the 
intercept alpha (A) relates to the calibration-in-the-large (ideally being 0) 
and the calibration slope beta (B) being 1. The line should be close to 45 
degrees. Discrimination refers to the ability of the model to distinguish a 
patient who has reached the binary endpoint (dead) to a patient who has not 
(alive). This is usually quantified with the concordance (c) statistic, and for a 
binary outcome, c is identical to the area under the receiver operating 
characteristic (ROC) curve. A value of 0.5 suggests no discrimination, 0.5 to 
0.69 indicates poor discrimination, 0.7 to 0.8 considered acceptable 
discrimination and a value of 1 indicates perfect discrimination (313). ROC 
values greater than 0.85 are uncommon in the AAA model literature (246, 
252, 268). 
6.7 Results 
The DES model produced three outputs for each patient: 30-day mortality 
for EVAR and open, probability of survival between 0 and 10 years and 
predicted life expectancy for the elective, surveillance or conservative 
management treatment options. The model predicted a range of survival 
probabilities that increased during the follow-up period as shown in 
Figure 6.4. 
The predicted 1-year and 5-year survival probability for the validation 
dataset (n=270) ranged from 77.5 to 95.7% and 6.5% to 87.3% respectively, 
indicating that the model had a wide range of probability and enabled 
stratifying patients into different risk groups. 
Model predictions for less than 5 years will not be discussed further as the 
event rates were too low to provide any clinically or statistically meaningful 
information. Therefore, five-year survival will be used as a surrogate for 




Figure 6.4 Range of predicted 30-day, 1, 3 and 5-year survival probability of 
270 patients used for external validation 
Note: same x-axis scale used  
6.7.1 External validation 
To test the model’s performance several independent datasets discussed 
below were used. 
6.7.1.1 Dataset 1: AAA performed in 2010 
Consecutive patients who underwent an intact AAA repair during 2010 
identified from the Australasian Vascular Audit and the National Minimum 
Data Set were extracted and risk profiles were collected. Those patients with 
a small AAA (<5cm) and those lost to follow-up were excluded. A total of 270 
patients were included and there were 80 (70.4%) deaths in this cohort at 5 
years follow-up. The average age was 74.9 years old, 210 (77.8%) were 
males and the remaining demographics are shown in Table 6.4. 
Table 6.4 Demographics of consecutive patients who underwent intact AAA  
Age/ years, average (SD)  74.9 (7.0) 
> 80 years old, n (%) 77 (28.5) 
Males, n (%) 210 (77.8) 
NZ Māori, n (%)  22 (8.1) 
AAA diameter/cm, median (IQR) 6.2 (5.3 - 6.5) 
OAR, n (%) 146 (54.1)  
IHD, n (%) 129 (47.8) 
MI, n (%) 24 (8.9) 
Cardiac failure, n (%) 14 (5.2) 
COPD, n (%) 20 (7.4) 
Renal impairment, n (%) 29 (10.7) 
ESRD, n (%) 2 (0.7) 
Diabetes, n (%) 28 (10.4) 
Cerebrovascular disease, n (%) 7 (2.6) 
Statin use, n (%) 176 (63.0) 
Aspirin use, n (%) 200 (76.7) 
Smoking history, n (%) 187 (69.3) 
Number of patients =270. Values in parenthesis are percentages of binary variables unless 
otherwise stated. SD: standard deviation, IQR: interquartile range 
The calibration intercept (A) was -0.36 (95%CI: -0.63 to -0.08) and the slope 
(B) was 1.17 (95%CI: 0.74-1.59) indicating that the model over-predicted 
mortality (Figure 6.5). The confidence intervals of A did not overlap 0, 
indicating that the model consistently predicted a worse outcome than 
actually observed. The confidence intervals for B included 1, suggesting that 
there was no evidence that the model was better or worse at predicting an 
outcome for someone with a short versus long life expectancy. The model 
appears to under-predict survival in all risk groups (Table 6.5). The 
discrimination was acceptable with a c-statistic of 0.71 (95%CI: 0.64-0.78) 
(Figure 6.6). 
Table 6.5 Observed and predicted survival for 270 patients who underwent intact 











1st 31 38.94 42.49 1.09 
2nd 18 56.93 66.67 1.17 
3rd 13 66.17 75.92 1.15 
4th 11 72.74 79.62 1.09 
5th 7 81.39 87.03 1.07 
1st represents lowest survival, 5th represents highest survival 
  
 
Figure 6.5 Probability of 5-year mortality represented as a calibration plot in a 
logistic regression model  
0 indicates alive, 1 indicates dead 
Figure 6.6 Receiver operating characteristic curve for the 5-year prediction of 
the model 
The diagonal grey line represents the line of equality 
6.7.1.2 Dataset 2: age & sex 
To test the model’s performance using only age and sex as predictive 
variables, a random sample comprising of 651 patients with an AAA repaired 
between 2008 and 2010 who had at least 5 years follow-up from the National 
Minimum Data Set were entered into the model. The mean (standard 
deviation) patient age was 73.4 (7.4) years and 499 (76.7%) were males. 
There were 187 (28.9%) people who were deceased at 5 years and the 
remaining were censored. The AAA diameter was set at 6cm (the average 
AAA diameter in NZ) and all other variables were entered as “not present”. 
The calibration intercept and slope of the model were -0.21 (95%CI: -0.39 to 
-0.04) and 0.84 (0.57-1.0) respectively, suggesting over-predicting 
mortality. The c-statistic was 0.64 (95%CI: 0.60-0.69), indicating poor 
discrimination. Separating data into gender did not change the c-statistic for 
either males (0.66, 95%CI: 0.60-0.72) or females (0.59, 95%CI: 0.49-0.70). 
6.7.1.3 Dataset 3: small AAA  
Since the model was structured and developed to manage all patients with 
an intact AAA and not just patients with those undergoing repair, a dataset 
of small aneurysms on surveillance was interrogated. Between October 2010 
and November 2011, there were 122 patients with an aneurysm diameter 
less than 5cm who had at least 5 year follow-up. Their baseline clinical 
profiles are shown in Table 6.6. There were 33 (27.0%) patients who died 
during follow-up and the predicted 5-year mortality was 24.4%. The 
calibration intercept (A) was 0.16 (95%CI: -0.27 to 0.60) and the slope (B) 
was 0.71 (95%CI: 0.25-1.17), indicating that the model under-predicted 
mortality. The c-statistic was 0.67 (95%CI: 0.57-0.78), indicating poor 
discrimination.  
  
Table 6.6 Baseline demographics of 122 patients with small AAA (<5cm) 
Age/ years, mean (SD) 74.1 (8.2) 
Males, n (%) 84 (68.9) 
NZ Māori, n (%) 5 (4.1) 
AAA diameter in cm, mean (SD) 3.8 (0.6) 
IHD, n (%) 23 (18.9) 
MI, n (%) 28 (23.0) 
Cardiac Failure, n (%) 12 (9.8) 
COPD, n (%) 16 (13.1) 
Renal impairment, n (%) 5 (4.1) 
Cerebrovascular disease, n (%) 15 (12.3) 
Diabetes, n (%) 23 (18.9) 
Smoking history, n (%) 97 (79.5) 
Antiplatelet use, n (%) 68 (55.7) 
Statin use, n (%) 83 (68) 
Values in parenthesis are percentages of binary variables unless otherwise stated 
Note: continuous variables followed a parametric pattern; there were no patients who had 
COPD requiring supplementary oxygen or ESRD receiving dialysis  
6.7.2 Tightness of the model runs 
Both AAA repair and small AAA datasets were run three times to test the 
reproducibility of the model’s predicted outcomes.  Figure 6.7 below shows 
the standard deviation by the mean of each participants replicate predictions 
(expressed as percentage surviving). The red line and text in top left corner 
indicates the mean of the standard deviation. Standard deviations are 
smaller in early years where most participants are expected to survive, but 
even at five years the mean standard deviations do not exceed 1%. 
 
Figure 6.7 Triplicate runs of model representing the mean and standard 
deviation 
 
6.7.3 Sensitivity analyses 
Sensitivity analyses were undertaken to test the internal validity of the 
model using the effect of age, AAA diameter and number of comorbidities 
present on the model’s outcomes.  
6.7.3.1 Age  
The predicted life expectancy for 40, 50, 60, 70, 80 and 90 year-old men with 
a 6cm AAA that had been repaired was 32.2, 24.9, 18.8, 11.6, 6.4 and 3.3 years 
respectively. The corresponding values for men with an unrepaired 6cm 
aneurysm were 10.8, 9.2, 7.5, 5.5, 3.9 and 2.6 years. The predicted 5-year 
survival probability for men who have had an aneurysm repair and those 




















































Figure 6.8 Sensitivity analysis for 5-year survival probabilities according to age 
group  
(A) Patients without aneurysm repair and (B) patients with an aneurysm repair 
6.7.3.2 AAA diameter 
The predicted life expectancy for a hypothetical 70 year-old man without any 
comorbidities and an aneurysm repaired at a diameter of 3, 4, 5, 6, 7 or 8cm 
was 12.2, 12.1, 11.8, 11.5, 11.2 and 10.9 years respectively. The 
corresponding values for a man with an unrepaired aneurysm were 13.8, 
12.9, 12.0, 5.6, 4.4 and 4.1 years. The survival probabilities of 4, 5.5 and 6cm 
aneurysm diameters undergoing a repair with the range of non-operated 
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Figure 6.9 Sensitivity analysis of the impact of AAA diameter on the survival 
probability 
Solid lines indicate a repaired AAA and dotted lines indicate non-operated aneurysms  
6.7.3.3 Patient comorbidities  
There were ten comorbidities included in this model that reduced survival. 
These were added onto the clinical profile of a hypothetical 70-year-old, non-
Māori man with a 6 cm AAA by adding two comorbidities at a time from the 
most prevalent risk factors (IHD & smoking) to the least common (having 
COPD on oxygen therapy and being on renal dialysis). The predicted 
survivals for this patient having an aneurysm repair and not having an 























3cm AAA no repair
4cm AAA no repair
5cm AAA no repair
6cm AAA no repair
7cm AAA no repair
8cm AAA no repair
Figure 6.10 Predicted survival probability according to number of 
comorbidities present 
The number in the legend corresponds to the number of comorbidities from the 
above curve, i.e. “2+ COPD & diabetes” means IHD + smoking + COPD + diabetes  
6.7.3.4 Case scenario 
A 72-year-old woman on antiplatelet therapy with a history of MI, ex-
smoking, diabetes, COPD and a 4cm AAA. The predicted life expectancy and 
survival according to AAA diameter and treatment options is shown in 
Table 6.7. For this patient, the time taken for the 4cm AAA to reach 5cm is 
approximately 3.5 to 4 years, indicating that surveillance is the safest 























2 + COPD & Diabetes
4 + Renal impairment & CVD
6 + MI & Cardiac failure























2+ COPD & diabetes
4 + Renal impairment & CVD
6 +MI & cardiac failure
8 + COPD on O2 & Dialysis
equal to that in a repair at 4cm was estimated to be at 8 years. This point is 
potentially reduced to 5 years if the patient was using antiplatelet therapy 
and did not have a history of MI, smoking, COPD or diabetes.   
Table 6.7 Decision repair output for a 72-year-old woman with a history of MI, ex-
smoking, diabetes, COPD and on antiplatelet therapy 
 AAA elective repair (cm) Surveillance Conservative 
Outputs 4 5 5.5 6 6.5 at 4cm at 6.5cm 
Life expectancy 
(age) 
80 79.5 79.2 78.8 78.6 81.8 75.3 
Survival (%) 
at 1 year 
94.3 92.9 93.1 94.1 92.2 97.8 68.8 
3 year 77.0 73.7 72 72.9 69.2 91.5 33.1 
 
6.8 Discussion 
Clinical decision-making surrounding AAA management can be a challenging 
process. In this chapter, a DES model was developed and validated to assist 
in the clinical decision-making process surrounding AAA management. 
Using the best available information in the published literature, this decision 
tool included a comprehensive list of comorbidities that impact upon the 
survival of patients with AAA. 
The model’s structure and design reported in this current study is novel in 
this field and the predictability appears promising. The model appeared to 
perform better when it was validated by an external dataset comprising of 
270 patients than with a model which only included age and gender data.  
The EVAR-2 trial conducted in the early 2000s randomised high-risk 
patients who were unfit for open repair to undergo either EVAR or best 
medical management (conservative) (66). This study showed that there was 
no apparent difference in overall survival, but the aneurysm related 
mortality decreased in those treated with EVAR. While the definition of 
“high-risk” is inconsistent, other observational studies have also shown that 
in certain high-risk groups (COPD on oxygen, ESRD and congestive heart 
failure), aneurysm repair was associated with poor outcomes (192, 216, 
218). This questions aneurysm treatment in some individuals.  
As seen in Figure 5.8, there has been a rise in the number of EVAR procedures 
performed in patients older than 75 years. With the improvement in life 
expectancy, it is likely that these rates will continue to rise. This simulation 
model can be used to prioritise patients who are more likely not to benefit 
from surgery, particularly in countries with universal health care access and 
constraints on health systems. 
6.8.1 Strengths of the model 
To avoid any bias towards right censoring using time-to-event analysis, all 
patients included in external validation within this study had a minimum of 
five years of follow-up. This, in turn, has reduced the number of patients 
available for external validation in both the repaired AAA and the small 
aneurysm datasets. 
The co-morbidities added to this simulation model were derived from meta-
analyses rather than a stepwise method derived from an internal validation 
set. It is, therefore, unlikely that this would lead to over-fitting of the model. 
This approach might lead to an increase in the applicability of this model in 
other AAA patient groups. 
How does this model compare to other models? 
Some authors tended to report the model’s discrimination performance and 
the calibration was tested using the goodness of fit (247, 248, 252). However, 
this method of calibration might not provide the reader with information on 
the direction of the slope line and only provides a p-value for the differences 
between observed and predicted outcomes (312). 
It is not uncommon for preoperative AAA-mortality models to achieve high 
model discrimination as demonstrated by the c-statistic values reported. 
This is very likely due to the relatively direct impacts of certain clinical risk-
factors on early mortality and the influence of background mortality within 
this short time period, a situation which is somewhat unusual in the boarder 
context of risk modelling. 
The AAA calculator developed by Carlisle requires an extensive list of 
variables and some that are not routinely tested (301), therefore the clinical 
utility of this calculator is limited. In addition, although the calculator has 
been validated using some 1000 patients, only about 60% completed follow-
up, which will likely lead to serious right censoring (302). The c-statistic for 
the AAA calculator at 5-years was 0.68 compared to 0.71 observed in this 
study. 
6.8.2 Other benefits of the model 
Although management of small AAA is well-established with non-operative 
treatment until the aneurysm diameter reaches threshold (51), some 
patients with a high-predicted life expectancy (those with few or no 
comorbidities) might benefit from treatment at lower AAA diameters than 
the 5.5cm set threshold. There is some interest in treating selected patients 
with good risk profiles who might benefit from AAA repair at lower 
thresholds than the 5.5cm defined threshold. A comparative survival 
analysis of a hypothetical patient with and without comorbidities and the 
projected survival if the aneurysm was repaired or managed conservatively 
is summarized in Figure 6.11.   
In a 70 year-old-man with an aneurysm repaired at 4cm without 
comorbidities, there was a small (1%) difference in survival compared to a 
repair conducted at 5.5cm and therefore might be justified provided the 
baseline predicted life-expectancy is high. In contrast, in a similar aged man 
with co-morbidities, repair of a 4cm aneurysm was associated with a 6% 
difference in survival compared to a repair at 5.5cm confirming the 
associated harm with this strategy. 
 
Figure 6.11 Survival probabilities of a 70 year old man with different 
comorbidities and AAA diameter undergoing a repair and no repair treatment 
options 
A: patient has no comorbidities, B: patient has ischaemic heart disease, smoking 
history & diabetes.  
Blue lines indicate 4cm AAA and grey indicate 5.5cm AAA, solid lines indicate a non-
operative management and dotted lines indicate a repair option 
The aim of this model was not to decide on whether patients should be 
treated with OAR or EVAR as this remains a shared clinical decision between 
the vascular surgeon and the patient. However, the model may give surgeons 
an indication on expected life years remaining and therefore a judgment for 









































with long life-expectancy might be better candidates to undergo OAR to 
reduce long-term EVAR-related interventions and endograft ruptures (315).  
Moreover, in some healthcare systems where there are financial constraints 
and limited access to resources, a decision-making tool that can prioritize 
and predict which patients are more likely to benefit from corrective 
aneurysm surgery using a well-developed approach is of significant value. 
Such tools are used clinically in prioritising ESRD patients on waiting lists 
for renal transplantation (314). This model can potentially be used to triage 
AAA patient on an elective waiting list according to the life years gained and 
predicted life expectancy from the procedure. This strategy might ensure 
that resources are used for those most likely to benefit from intervention.  
Moreover, the model might be utilised in determining which patients with 
small AAA might benefit from surveillance. The status quo for most AAA 
surveillance programs is that patient will continue to be enrolled unless they 
wish not to attend further surveillance. It is expected that in this cohort some 
patients mainly due to comorbidities would not benefit from any AAA related 
procedures in the future and hence can be removed from surveillance by 
using such models.  
6.9 Limitations 
Like with any mathematical model, the inputs, design and behaviour 
determines the overall applicability of its use and performance. The specific 
limitations of this model are discussed below. 
6.9.1 Model specific 
An embedded limitation of DES models is that they try to facilitate a realistic 
environment and hence minor details that would not play an important role 
in reality would be accounted for in the model (294). This might explain the 
reason for the higher 5-year predicted mortality than the actual mortality, as 
surgeons would have excluded some patients based on their co-morbidities 
and this group would not have been included in this validation testing. In 
New Zealand, management of AAA sways towards the conservative side and 
this is evident by the larger average diameters, the relatively high proportion 
of OAR used and the higher turn-down rates for ruptured AAA compared to 
other Western countries (275, 316). 
6.9.2 Variables included 
Despite the fact that cancer is one of the leading causes of death within the 
post-AAA repair population (197, 317), history of cancer was not included in 
this model as a variable. The reason for this was due to the lack of a clear 
definition of cancer observed within the systematic review, which led to a 
wide confidence interval and high heterogeneity (I2>70%). This might have 
limited the long-term survival prediction of the model. 
Other important patient factors such as patient frailty, functional status and 
ASA and hospital volume might appear to have an independent impact on 
survival but were not included in this model. 
6.9.3 Input variables 
Growth patterns and the risk of AAA rupture used in this model were based 
on the RESCAN data which in itself has some limitations, including 
heterogeneity in measurement methods and modalities used (300).  In this 
model, variables were only sex-adjusted while other interactions such as 
slower growth-rates in diabetics and faster aneurysm expansion in current 
smokers or those with hypertension were not included as interactions (32). 
There were no patients in the validation sets with COPD on supplementary 
oxygen and only two patients with ESRD requiring dialysis, therefore testing 
the usefulness of such variables is limited in this study. With an all-inclusive 
strategy of enrolling AAA patients, further validation of the utility of such 
parameters can be directly assessed.  
6.9.4 Model validation 
Another limitation in the validation of the DES AAA model was the relatively 
small number of patients available for external validation and this was 
evident by the wide confidence intervals in the discrimination and 
calibration analyses observed in the small AAA under surveillance and those 
patients who had a repair in 2010. 
The internal validation set used to provide the 30 day mortality, the range of 
overall 10 year survival and the limits for the low and high risk groups where 
derived from the national minimum data set which also included a 
proportion of patients from 2010 that underwent AAA repair and were 
included in the external validation. This however, is unlikely to lead to a 
major bias, as the outcome of elective AAA is similar among most published 
series. Ideally, a different dataset should have been used to provide such 
estimates but this was not available at the time the model was developed.  
6.10 Conclusions 
The AAA DES model developed in this chapter performed well in predicting 
5-year survival for those participants who underwent repair, but less so for 
those enrolled in a small aneurysm surveillance programme. Overall, this 
approach to guiding AAA management is encouraging but requires further 
testing and validation with different patient groups in other clinical settings.   
6.11 Future Work 
This AAA clinical decision tool is still in its infancy and requires further 
prospective testing and refinement. However, it showed promising results 
with acceptable calibration and discrimination.  The structure of the DES 
model can be updated or modified to reflect any changes to background 
mortality, hazard ratios of risk factors or the comorbidities included.  
The ultimate testing of the model requires inclusion of all patients seen with 
an intact AAA, including those turned down or those that did not want 
follow-up or repair. Such a prospective study comparing actual survival and 




The impact of Abdominal Aortic Aneurysms (AAA) on the NZ health system 
remains a considerable health concern. This study estimated that there were 
450 patients who underwent repair every year, and at least 220 patients who 
have had a death attributed to AAA. The mortality rate has not greatly 
changed from what was reported a decade ago (121) and is similar to the 
annual road death rate in NZ. 
The overall prevalence of AAA was relatively high in a selective group 
undergoing CT colonography for gastrointestinal symptoms, and the 
numbers of aneurysms increased in both males and females with age. This 
supports that the burden of AAA that require management is still high and is 
likely to continue with the aging population and improved life expectancy.  
In NZ, in the absence of a formal aortic screening programme, patients rely 
on incidental radiological imaging for AAA detection. It has been noted that 
there was a large proportion of patients with AAA who have not had their 
aneurysm measured, reported or diagnosed and therefore were not able to 
be managed. This has implications when a condition such as aneurysm can 
be monitored for growth and repaired when the threshold for treatment is 
reached.  
Prognostic factors that influence patient survival after AAA repair have 
usually been reported from single or multi-centred studies. In this thesis, the 
systematic review allowed documentation of a number of factors and 
quantifying the impact of each variable on long-term survival after aneurysm 
repair. This information, compounded with data from the literature, has 
enabled the development of a predictive model that can be used in clinical 
decision-making surrounding AAA management  
The authors of the PROGnosis RESearch Strategy (PROGRESS) propose four 
research themes for developing prognostic models (279):  
1) Describing the nature and quality of current care.  
2) Documenting specific factors associated with the disease prognosis. 
3) Development and validation of prognostic models.   
4) Using the model to aid in decision-making for individuals.  
This framework was used throughout the thesis in understanding the 
prevalence of AAA and the impact of outcomes, then deriving specific 
prognostic factors that are associated with survival from the published 
literature, and finally developing and validating a predictive individualized 
model. The final stage requires further prospective work to test the model’s 
ability to be used in the clinical setting.  
The aims of this chapter were to consider and discuss the significance and 
implications of the thesis findings and consider the limitations and future 
directions for further research.  
7.2 Major findings and Implications  
This thesis has contributed to the AAA literature with five papers published 
and four additional manuscripts in preparation. I was the principal 
investigator in the majority of these studies.  
Prior to this work, the natural history and clinical outcome data on AAA 
disease in NZ has been limited to less than ten published studies. The work 
from the thesis has contributed to the existing literature in the areas 
discussed below. 
7.2.1 Abdominal aortic aneurysm prevalence and definition  
Prior to 2010, there was very little knowledge on AAA prevalence in NZ. The 
information from this thesis has highlighted that the prevalence of AAA was 
high in a selected population undergoing CTC in the South Island of NZ. This 
relatively high aneurysm prevalence has also been reported by other authors 
in other selected populations in NZ (135, 136).  
For practical purposes, the 3cm definition of AAA has provided consistency 
in measuring and diagnosing aneurysms (318). However, this current binary 
definition of AAA seems limited for an aorta that dynamically changes 
diameter with age in both males and females. Therefore, it seems logical that 
this definition should be tailored to individuals when considering the 
definition of ‘abnormal’ aortic diameter.   
Although the relationship between male aortic diameters, cardiovascular 
survival and overall mortality has been previously reported (170, 171, 319), 
the association in females has been less documented. In this thesis, I was able 
to demonstrate that larger aortic diameters in females appeared to be 
associated with a higher mortality, an association which remained valid 
when body size measurements were considered. This relationship appeared 
novel, and the association of aortic diameter and survival might be a further 
prognostic marker of overall survival that can be used in risk classification 
and requires further exploratory work. 
7.2.2 Women & AAA disease 
After years of focused strategies to reduce AAA-related mortality by 
detecting aneurysms in males, it appears that some attention has turned into 
research into women with AAA, as the prevalence in males has declined.  
The work in this thesis has shown that women comprised of 30.7% of all 
patients defined as having an AAA in NZ from 2000 to 2014. This proportion 
differs from those who have had an aneurysm repair (21.1%), and of the 223 
AAAs diagnosed in the CTC study, 57 (25.6%) patients were women. 
In the CTC cohort, despite the selective nature for inclusion, women had a 
similar AAA prevalence to that reported in the literature (320), which was  
consistent with other targeted screening groups from NZ (135, 136). 
Screening women without a history of smoking and younger than 75 years 
old is unlikely to yield sufficient AAA prevalence. In the CTC study, of the 57 
women with AAA detected, a third did not have a history of smoking and all 
the patients were older than 75 years.  
Therefore, a screening program that includes women with a history of 
smoking might be justifiable, as the prevalence in this group was similar to 
prevalence rates of 65-year-old men reported by national screening 
programs from the UK and Sweden (115, 321).  
7.2.3 Outcome of repair in women 
Although AAA disease has been traditionally considered a male predominant 
condition (322), this thesis highlights some concerns with this.  
From this work and others, it was noted that women were more likely to die 
from a ruptured AAA prior hospital admission and were less likely to 
undergo corrective AAA surgery for ruptured aneurysms (110, 323). In 
scheduled aneurysm repair, the reported 30-day mortality has consistently 
been higher in women compared to males for both OAR and EVAR and has 
also been supported by data from this thesis, with our New Zealand data 
suggesting an adjusted odds ratio of 2.12 (95% CI: 1.02-4.4) for female 30- 
day post-operative mortality compared to their male counterparts. A meta-
analysis reported that the pooled odds ratio for women after elective OAR 
and EVAR was 1.28 (95%CI: 1.09-1.49) and 2.41 (95%CI: 1.14-5.15) 
respectively (105).   
With regards to long-term survival, the results of the systematic review in 
chapter 4 have provided further important information that has previously 
been inconsistent. After adjusting for confounders, women had a 15% 
increase in mortality after AAA repair compared to men. This is despite the 
fact that women in the general population have a longer life-expectancy than 
men. This finding was also reported later from the UK national data, in which 
women had an 8% additional risk of death compared to men after adjusting 
for age (324).  
Both the definition of aneurysm (threshold diameter) and better 
understanding of the natural history (particularly expansion rates) of aortas 
in women need future work to reduce the disparity in outcomes. This 
information should be considered with decision-making regarding AAA 
screening or repair of small aneurysms in women.  
7.2.4 Māori and AAA disease 
The New Zealand population composition consists of several ethnic groups, 
and understanding the burden of a disease might reduce ethnic health-
related inequalities. This thesis has highlighted important findings regarding 
AAA disease in Māori that has not been previously reported. 
First, using multiple data sources, reliable information on the normal aortic 
diameters of NZ Māori have been documented and compared to the NZ 
European population. This provided baseline aortic diameter data that can 
aid in decision-making with defining an AAA in Māori. It also highlights that 
the association of smaller aortic diameters observed in other ethnic groups, 
such as Asian, is not relevant.  
Second, previous studies reported that the 30-day mortality following AAA 
repair in Māori was higher than NZ Europeans (119, 121).  This study 
supports these findings, but this association was only observed at univariate 
analysis. When potential confounders were added into the logistic 
regression model, Māori did not appear to have a higher mortality risk. 
Furthermore, this study supports that Māori were more likely to present 
with ruptured AAA than present with an intact abdominal aneurysm (120), 
corresponding to a higher aneurysm-related mortality.  
The average life expectancy of Māori and Pacific island people is lower than 
that of NZ Europeans (127). However, after AAA repair and excluding 30-day 
mortality, Māori had a 40% higher risk of death compared to NZ Europeans 
while the survival of Pacific Island people was very similar to that of NZ 
Europeans. 
Another novel finding was observed in the over representation of females 
undergoing aneurysm repair (41%) compared to the ~20% female 
proportion that is consistently reported in the literature (105). This might 
be due to the known high smoking rates of Māori women (257) and the lower 
life expectancy of Māori men causing an under representation in those with 
an AAA (127). 
These findings highlight the disparity in outcomes following AAA repair in 
Māori and should stimulate further work to understand association of AAA 
in different ethnic groups and therefore potentially reduce health 
inequalities. 
7.2.5 Prognostic decision-making tools 
The vascular surgery community might benefit from a decision-making 
model that can better inform surgeons and patients of the individualised 
risks of those undergoing aneurysm repair or surveillance as part of a shared 
decision-making process. Ideally, this practice should be tailored to the 
individual patient risk rather that based on results published from national 
reports or clinical trials. Surgeons can vary with their perception of risk-
benefit analysis (325) and this may therefore result in discrepancies in 
treatment choices.  
In this thesis, one of the primary aims was to develop and externally validate 
a clinical decision tool that could aid in the management of AAA. There are a 
few developed prognostic models that can predict long-term outcomes after 
AAA repair reported in the literature. Three models have been validated, 
with discrimination for 5-year survival resulting in c-statistics of 0.68-0.69 
(230, 302, 306). Despite the smaller number of patients available for 
validation in this study, the c-statistic was 0.71, indicating sufficient accuracy 
for predicting 5-year survival (309). 
The decision to treat AAA with either OAR or EVAR remains a complex one. 
Long-term outcomes of EVAR and OAR (>15 years) have shown no difference 
in overall survival between the two modalities in controlled and 
observational studies (317, 326), but aneurysm-related mortality was 
higher in the EVAR group (64, 326). The decision-aid tool developed in this 
thesis might assist in this selection process by estimating individualised life 
expectancies.  
As the developed model provides an estimate of the background mortality of 
patients based on their comorbidities, the potential for using such tools 
might be a useful public health initiative. For example, if a form of an AAA 
detection program is to be developed, a pre-screening test by using the AAA 
model might determine if a patient would benefit from screening based on 
existing comorbidities and therefore utilising health resources efficiently.  
7.3 Topical questions related to potential AAA screening in 
New Zealand 
7.3.1 Should AAA screening be introduced to NZ? 
In Sweden nearly ten years after introducing a national aneurysm screening 
program, the overall annual number of intact AAA repairs increased while 
the number of ruptures decreased by 50%, as expected from such a program 
(327).  In NZ, where aneurysm detection still relies on incidental radiological 
findings and physician-led referral systems, the number of aneurysm repairs 
remained fairly constant for both scheduled and rupture presentations 
during the last decade. 
In Sweden, there was a gradual uptake by counties for AAA screening, and 
there was a significant reduction in both AAA-related and cardiovascular 
mortality when comparing those screened with those not screened (321). 
Similarly, in the UK, a decline of aneurysm rupture was observed in 65-74 
year old men at a higher rate that those older than 75 years old, which could 
be due to the national screening programme (328).  
The information from this thesis has highlighted that the prevalence of AAA 
was high in a selected population undergoing CTC in the South Island of NZ. 
This population had a lower expected survival than an age-and-sex-matched 
population, but after adjusting for age and sex, the presence of AAA was not 
associated with any statistical difference in overall survival. 
Given the impact of screening in other countries, the prevalence of AAA and 
the number of deaths related to AAA in NZ, it seems that national population 
screening for AAA will likely result in a reduction of premature deaths in 
men. The barrier to such a programme remains to be the costs in 
implementation. 
7.3.2 Who and how to screen for an AAA? 
In New Zealand, the viability of screening for AAA is being investigated and 
it is of big importance to be able to provide an accurate estimate of local 
figures. The change of AAA epidemiology and the relatively lower early 
mortality achieved nowadays with elective repair can alter the clinical 
decision-making for AAA management in comparison to evidence-based 
norms established two decades ago (329). 
In this study, patients living in higher deprived areas where more likely to 
have an AAA and they also had a higher representation in those undergoing 
aneurysm repair. Lower income and SES have been associated with a higher 
AAA prevalence (145). It is therefore of some concern that geographical 
regions with low average incomes and SES appear to have lower attendance 
rates to national AAA screening (112, 114). A more targeted approach that 
aims to improve the capture of higher-risk individuals might decrease AAA-
related mortality rates through earlier detection and enabling greater 
cardiovascular risk-factor management opportunities.  
Other methods for increasing the detection rate of AAA would be to utilize 
other radiological modalities for aortic assessments in those undergoing 
abdominal imaging, then linking the information regarding abdominal aortic 
size to a central database were people over the age of 50 get their aorta 
measured.  This might be the most cost-effective strategy and “smartest” 
method to ensure that the majority of people who undergo incidental 
imaging are screened, hence reserving screening to those with less access to 
healthcare. 
One issue which might arise is that patients would not have directly 
consented to have their aorta measured, which might potentially be 
associated with a psychological burden for some of them (330). Data from 
screening trials suggest that there was a small impact on health status after 
detecting aneurysms in men compared to those who did not have an 
aneurysm detected, but this association was no longer evident after 1 year 
(331). It remains the patient’s choice if an incidental AAA was discovered 
whether they wished to have this treated or monitored after being 
appropriately counselled. The rates of incidental findings will continue to 
mirror the use of radiological modalities used for diagnostic and therapeutic 
purposes, therefore understanding the implication of an aneurysm diagnosis 
on the patient’s quality of life is an important area and requires further work 
(332). 
7.4 Limitations  
There were some limitations discussed at the end of each chapter relating to 
the study design, data collection and assumptions where applicable. This 
section will discuss the overall limitations of this thesis.   
7.4.1 CTC study 
The biggest limitation in using the CT colonography cohort as a surrogate for 
an ultrasound screening population was the selection process for patient 
inclusion, which might have created a bias towards those with higher 
comorbidities and gastrointestinal symptoms. Another weakness was the 
retrospective nature of the study design, which has resulted in some missing 
data points. However, using this approach had an advantage of including 
individuals from all socioeconomic groups who sought medical attention. An 
alternative prospective approach may have resulted in avoidance from some 
(low socioeconomic group) individuals as observed in other studies (112, 
115).  
Longitudinal population-based studies have provided most of the data on the 
natural history of AAA. Such studies can take a considerable amount of time 
to complete and can be associated with high costs due to the necessity to 
collect long-term follow-up. Indeed, this was apparent in the CTC data 
examined in this thesis, in which it was apparent that at least 5 years of 
follow-up were required to provide meaningful observations that could be 
translated to the clinical setting. In NZ, a general population longitudinal 
study has not been performed and is unlikely to be undertaken in the near 
future, therefore using this large CTC cohort provided some information at 
little additional costs or risks to the patients.  
In order for more reliable information on AAA to be gathered from different 
ethnic groups in NZ, collaboration with other existing cardiovascular 
research groups to provide further information in this field is required, as it 
was noted that the absolute numbers included in this study were small. 
7.4.2 New Zealand AAA data 
To provide information on national AAA trends and outcomes, all available 
datasets were used. From 2010 to 2014, the Australasian Vascular Audit 
(AVA) was used to supplement the National Minimum Data Set. For the 2000 
to 2009 period, the previous Otago Surgical Audit was not accessible and the 
information was not consistently recorded. This might correspond to 150 to 
200 patients that could be missing from the pre-2010 period, and more likely 
to present patients undergoing aortic repair at a private institution. 
Fortunately, it has become mandatory that private hospitals report 
operative cases to the NMDS with a lag time in data of 2 years. 
Another limitation of this study was that it was not possible to gather further 
information and validate the quality of data provided in the mortality 
collection database to a similar standard as that to which the administrative 
and clinical datasets were scrutinised. It appears that there is significant 
under-reporting as pre-hospital deaths only contributed to a small 
proportion (21%) of ruptured AAA presentations compared to the estimated 
32% figure that was previously reported (6).   
7.4.3 Systematic review and meta-analysis 
The systematic review had some inherent weaknesses mostly due to 
information and publication bias, which might have limited the 
understanding of some of the impacts on survival. There was some 
inconsistency in defining the risk factors studied, which was reflected by a 
high heterogeneity in some instances. The comorbidities were considered in 
a binary (yes/no) manner and information such as the duration and severity 
of each comorbidity could not always be quantified. In addition, duration and 
doses of the medications used were not reported, therefore limiting the 
translational knowledge to patient care. These hazard risk estimates might 
have led to the model’s over-prediction of mortality. 
7.4.4 Model development  
As with any model development, there is susceptibility to simulating ‘real 
world’ environment and therefore some assumptions had to be made. Some 
of the risk factors were collected retrospectively, which might have resulted 
in inaccurate sample representation. With regards to testing the 
performance of this tool, there was limited available data to use for external 
validation of the discrete event-simulation AAA-management model. This 
was partly attributed to requiring a minimum of five years follow-up to avoid 
right censor biases in the validation process. Despite this, the model’s 
predictability performance was considered sufficiently accurate.   
7.4.5 Future research & direction  
This work has laid some foundation for further research into this field. The 
advantage of conducting population research in NZ is the ability to link some 
databases to improve the quality and accuracy of the data. In addition, the 
survival status can also be updated, which would increase the duration of 
follow-up.  
The model developed in this thesis is still in its infancy and requires further 
external validation and refinement. Further work has begun to test the 
validation of the model in different clinical settings, such as those of 
Australia, Netherlands and Hong Kong.  
Another example where model inputs can be adjusted would be in the AAA 
expansion rates. In the DES model, the growth rates of AAA were assumed to 
be similar in all age groups, as age was not found to be an independent 
predictor of AAA growth (32). However, the meta-analyses have not 
included any octogenarians, as historically this group of patients was not 
routinely offered repair. Work has begun to explore the expansion rate of 
AAA in the octogenarian population. If a substantial difference in growth is 
found, the DES AAA management tool can be updated to represent this and 
therefore simulate a more accurate representation of patients with an AAA. 
Potentially the DES AAA model can be used for selecting patients for 
aneurysm detection, surveillance and for repair consideration.  
While the model has been shown to be relatively accurate at predicting 5-
year survival, the influence of the DES AAA model on clinician and patient 
decision- making is an area that warrants further exploration. As the model 
generates 10 year survival curves adjusted to individual patient 
comorbidities, these can be presented to patients and their families, the 
decision surrounding the management options could potentially be 
improved and hence steer the outcome towards the strategy that is more 
likely to achieve the agreed desired patient outcome.     
Some of the data generated in this thesis has been used in developing a 
National Health Committee document on Models of Care for AAA. 
Furthermore, I have collaborated with the Burden of Disease, Epidemiology, 
Equity and Cost Effectiveness Programme (BODE3) in developing a cost-
effective screening model for screening AAA in New Zealand. There were 
several inputs into the model that used the data presented in this thesis.  
The development of a robust national AAA preoperative and outcome 
database used in this thesis allowed the collaboration with some 
international vascular registries such as the VASCUNET. This is likely to 
generate future international work and shed some light into AAA 
management across different areas. 
7.5 Conclusions 
In conclusion, based on the prevalence, trends of presentations and 
mortality, AAA remains a significant burden on the NZ population and their 
health care system. The prognostic factors that reduce survival may help in 
decision-making when managing patients with AAA, and cardiovascular 
risk-factor modifications with antiplatelet and statin use appear to improve 
the overall survival.  Ethnic and social deprivation inequality still occurs in a 
universal health-care system and therefore requires further targeted 
attempts to reduce this apparent disparity. The discrete event-simulation 
tool developed was a useful predictor of 5-year survival for patients who 
underwent AAA repair and might have other uses in management of small 
aneurysms and selecting treatment strategies. Understanding the limitations 
of the existing datasets and what information is already available might help 
future-reporting of AAA outcome data. Also, the findings from this study may 
provide information that could assist in decision-making related to the 
prospect of a national AAA screening programme. The work generated in 
this thesis has not only informed our contemporary understanding of AAA 
on New Zealand society but, given the effect of our aging population, will 
likely play an important role in the necessary future work to be conducted in 







“Are you saying there is no basis for doing a trial or for introducing a 
screening programme and including a control group?” 
“There would be if there was an important question that such trial 
would answer but I’m not aware that there is.” 
Law et al. responding to R A P Scott (principal investigator of Chichester AAA 
screening study) in one of the earliest articles promoting and arguing the case 
for AAA screening (84) 
 
8.1 Triaging Patients with Gastrointestinal Symptoms  


























Symptoms (>6 weeks) 
Rectal bleeding: 
  - Sinister 
  - Outlet 
Change in bowel habit: 
  - Loose 
















Unexplained Iron deficiency Anemia 
Faecal occult blood positive 







8.1.2 Pathway of undergoing investigation depending on The 
Canterbury Colorectal System Pathway scoring tool 
 
 
Adapted from Sanders el al. A novel pathway for investigation of colorectal symptoms 
with colonoscopy or computed tomography colonography N Z Med J 2013 (123)  
8.2 Search History for Systematic Review 
EMBASE 
1. exp abdominal aortic aneurysm/ 
2. abdominal aortic aneurysm.tw.  
3. infrarenal aortic aneurysm.mp.  
4. aneurysm surgery/ or Endovascular aneurysm repair/  
5. elective surgery/ or abdominal aorta aneurysm/ or aneurysm surgery/ 
6. exp risk reduction/  
7. exp long term survival/ 
8. exp survival prediction/ 
9. exp predictor variable/ 
10. exp survival/ 
11. 1 or 2 or 3 
12. 4 or 5 
13. 6 or 7 or 8 or 9 or 10 




1. Abdominal aortic Aneurysm.mp. 
2. Abdominal aortic Aneurysm/ 
3. Aortic Aneurysm, Abdominal/su [Surgery] 
4. Risk Factors/ or Risk Adjustment/ or Risk/ or Risk Management/ or Risk 
assessment.mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier] 
5. Survival Rate/ 
6. time factors/ 
7. time factors.mp. 
8. risk factors.mp. 
9. postoperative complication/ 
10. 4 or 5 or 6 or 7 or 8 
11. 1 or 2 or 3 









8.3 Codes Extracted from the International Classification of 
diseases (ICD-10) 
8.3.1  Diagnosis and Procedural Codes Extracted from 
Administrative Databases 
I71.3 Abdominal aortic aneurysm, ruptured  
I71.4 Abdominal aortic aneurysm, without mention of rupture  
9022800 Endoluminal repair of aneurysm  
9020902 Direct closure of wound of aorta  
9021302 Repair of wound of aorta by interposition graft  
3308000 Repair of intra-abdominal aneurysm  
3318100 Repair of ruptured intra-abdominal aneurysm  
3310900 Replacement of thoraco-abdominal aneurysm with graft  
3311200 Replacement of suprarenal abdominal aorta aneurysm with 
graft  
3311500 Replacement of infrarenal abdominal aortic aneurysm with 
tube graft  
3311800 Replacement of infrarenal abdominal aortic aneurysm with 
bifurcation graft to iliac arteries  
3312100 Replacement of infrarenal abdominal aortic aneursym with 
bifurcation graft to femoral arteries  
3312400 Replacement of iliac artery aneurysm with graft, unilateral  
3312700 Replacement of iliac artery aneurysm with graft, bilateral  
3314800 Replacement of ruptured thoraco-abdominal aneurysm with 
graft  
3315100 Replacement of ruptured suprarenal abdominal aortic 
aneurysm with graft  
3315400 Replacement of ruptured infrarenal abdominal aortic 
aneurysm with tube graft  
3315700 Replacement of ruptured infrarenal aortic aneurysm with 
bifurcation graft to iliac arteries  
3316000 Replacement of ruptured infrarenal abdominal aortic 
aneurysm with bifurcation graft to femoral arteries  
3316300 Replacement of ruptured iliac artery aneurysm with graft  
3416000 Repair of aorto-enteric fistula with direct closure of aorta  
3416300 Repair of aorto-enteric fistula with insertion of aorta graft  
3416600 Repair of aorto-enteric fistula with oversewing of abdominal 
aorta and axillo- femoral bypass graft 
 
8.3.2 Codes Used to Identify Comorbidities and Risk Factors  
 
Comorbidities ICD-10 
Ischaemic heart disease  
 
I200, I201, I208, I209-I214, I219, I221, I229, 
I234, I240, I248-9, I2510-I2512, I252-3, I255, 
I258-9 
Hypertension I10, I110, I130 
Atrial fibrillation I48 
Diabetes E1120, E1130, E1140, E1150, E1160, E1170, 
E1180, E1190, E1450, E1490 
Respiratory disease J40, J410, J42, J438-J441, J448-J449, J459, J47 
Cerebrovascular disease I602, I608, 1611, I615, I620, I632, I634-5, 
I638-9, I64, I652-3, I658, I661, I664, I671-2, 
I678-9, I690, I692-4, I698 
Ex-smoker/personal history 
of tobacco use 
Z8643 
Current smoker/tobacco use Z720 
Peripheral artery disease I700, I7020-4, I708-9 
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8.6.1 Prevalence of abdominal aortic aneurysm (AAA) in a 
population undergoing computed tomography 



















8.6.2 Abdominal aortic aneurysm repair in New Zealand: a 












8.6.3 Systematic Review and Meta-analysis of Factors 
































8.6.4 Does the diameter of abdominal aortic aneurysm influence 
late survival following abdominal aortic aneurysm repair? 























8.6.5 Management of Modifiable Vascular Risk Factors Improves 
Late Survival following Abdominal Aortic Aneurysm 
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